WO2007044026A2 - Compositions comprising modified collagen and uses therefore - Google Patents
Compositions comprising modified collagen and uses therefore Download PDFInfo
- Publication number
- WO2007044026A2 WO2007044026A2 PCT/US2005/042813 US2005042813W WO2007044026A2 WO 2007044026 A2 WO2007044026 A2 WO 2007044026A2 US 2005042813 W US2005042813 W US 2005042813W WO 2007044026 A2 WO2007044026 A2 WO 2007044026A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cmp
- collagen
- group
- conjugate
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 469
- 108010035532 Collagen Proteins 0.000 title claims abstract description 468
- 229920001436 collagen Polymers 0.000 title claims abstract description 468
- 239000000203 mixture Substances 0.000 title claims description 136
- 238000000034 method Methods 0.000 claims description 227
- 210000004027 cell Anatomy 0.000 claims description 221
- 239000000562 conjugate Substances 0.000 claims description 185
- 229920001223 polyethylene glycol Polymers 0.000 claims description 179
- -1 poly(ethylene oxide) Polymers 0.000 claims description 168
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 157
- 239000011159 matrix material Substances 0.000 claims description 139
- 229920000642 polymer Polymers 0.000 claims description 109
- 210000001519 tissue Anatomy 0.000 claims description 108
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 74
- 239000002105 nanoparticle Substances 0.000 claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 67
- 239000000017 hydrogel Substances 0.000 claims description 57
- 239000003550 marker Substances 0.000 claims description 54
- 201000010099 disease Diseases 0.000 claims description 50
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- 238000002844 melting Methods 0.000 claims description 43
- 230000008018 melting Effects 0.000 claims description 43
- 239000003102 growth factor Substances 0.000 claims description 41
- 239000000863 peptide conjugate Substances 0.000 claims description 41
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 36
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 36
- 210000000845 cartilage Anatomy 0.000 claims description 36
- 210000002744 extracellular matrix Anatomy 0.000 claims description 36
- 208000007536 Thrombosis Diseases 0.000 claims description 35
- 210000002889 endothelial cell Anatomy 0.000 claims description 34
- 150000003384 small molecules Chemical class 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 32
- 230000003115 biocidal effect Effects 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 32
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 31
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 31
- 210000000988 bone and bone Anatomy 0.000 claims description 31
- 239000003242 anti bacterial agent Substances 0.000 claims description 30
- 230000008439 repair process Effects 0.000 claims description 28
- 210000001612 chondrocyte Anatomy 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 26
- 210000004927 skin cell Anatomy 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 26
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 24
- 210000000481 breast Anatomy 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 22
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 22
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 22
- 230000029663 wound healing Effects 0.000 claims description 22
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 20
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 230000002439 hemostatic effect Effects 0.000 claims description 19
- 230000004083 survival effect Effects 0.000 claims description 19
- 230000007704 transition Effects 0.000 claims description 19
- 230000002785 anti-thrombosis Effects 0.000 claims description 18
- 230000010261 cell growth Effects 0.000 claims description 18
- 210000002784 stomach Anatomy 0.000 claims description 18
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 17
- 210000002919 epithelial cell Anatomy 0.000 claims description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 16
- 230000002496 gastric effect Effects 0.000 claims description 16
- 238000013268 sustained release Methods 0.000 claims description 16
- 239000012730 sustained-release form Substances 0.000 claims description 16
- 108010067306 Fibronectins Proteins 0.000 claims description 15
- 102000016359 Fibronectins Human genes 0.000 claims description 15
- 102000007547 Laminin Human genes 0.000 claims description 15
- 108010085895 Laminin Proteins 0.000 claims description 15
- 230000004075 alteration Effects 0.000 claims description 15
- 125000004386 diacrylate group Chemical group 0.000 claims description 15
- 230000035755 proliferation Effects 0.000 claims description 15
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 14
- 210000002449 bone cell Anatomy 0.000 claims description 14
- 210000003321 cartilage cell Anatomy 0.000 claims description 14
- 239000002872 contrast media Substances 0.000 claims description 14
- 210000003494 hepatocyte Anatomy 0.000 claims description 14
- 230000009545 invasion Effects 0.000 claims description 14
- 210000002510 keratinocyte Anatomy 0.000 claims description 14
- 239000004098 Tetracycline Substances 0.000 claims description 13
- 210000003443 bladder cell Anatomy 0.000 claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims description 13
- 210000002064 heart cell Anatomy 0.000 claims description 13
- 229920002674 hyaluronan Polymers 0.000 claims description 13
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 210000003292 kidney cell Anatomy 0.000 claims description 13
- 210000005229 liver cell Anatomy 0.000 claims description 13
- 210000005265 lung cell Anatomy 0.000 claims description 13
- 210000004216 mammary stem cell Anatomy 0.000 claims description 13
- 210000002997 osteoclast Anatomy 0.000 claims description 13
- 210000004738 parenchymal cell Anatomy 0.000 claims description 13
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 13
- 235000019364 tetracycline Nutrition 0.000 claims description 13
- 150000003522 tetracyclines Chemical class 0.000 claims description 13
- 238000004627 transmission electron microscopy Methods 0.000 claims description 13
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 12
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 12
- 108700023160 Thymidine phosphorylases Proteins 0.000 claims description 12
- 230000021164 cell adhesion Effects 0.000 claims description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 12
- 210000003491 skin Anatomy 0.000 claims description 12
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 11
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 11
- 102000003951 Erythropoietin Human genes 0.000 claims description 11
- 108090000394 Erythropoietin Proteins 0.000 claims description 11
- 229930182555 Penicillin Natural products 0.000 claims description 11
- 102100031372 Thymidine phosphorylase Human genes 0.000 claims description 11
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 11
- 229940105423 erythropoietin Drugs 0.000 claims description 11
- 210000003714 granulocyte Anatomy 0.000 claims description 11
- 210000002216 heart Anatomy 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 11
- 229960002180 tetracycline Drugs 0.000 claims description 11
- 229930101283 tetracycline Natural products 0.000 claims description 11
- 102100022987 Angiogenin Human genes 0.000 claims description 10
- 102000000905 Cadherin Human genes 0.000 claims description 10
- 108050007957 Cadherin Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 10
- 230000001070 adhesive effect Effects 0.000 claims description 10
- 108010072788 angiogenin Proteins 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 10
- 210000004204 blood vessel Anatomy 0.000 claims description 10
- 238000004132 cross linking Methods 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 229940049954 penicillin Drugs 0.000 claims description 10
- 108010078656 plectasin Proteins 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003431 cross linking reagent Substances 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 102000006495 integrins Human genes 0.000 claims description 9
- 108010044426 integrins Proteins 0.000 claims description 9
- 150000003147 proline derivatives Chemical group 0.000 claims description 9
- 229920001059 synthetic polymer Polymers 0.000 claims description 9
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 claims description 8
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 claims description 8
- 108090000184 Selectins Proteins 0.000 claims description 8
- 102000003800 Selectins Human genes 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 8
- 229940088710 antibiotic agent Drugs 0.000 claims description 8
- 229960004676 antithrombotic agent Drugs 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000000921 morphogenic effect Effects 0.000 claims description 8
- 230000010399 physical interaction Effects 0.000 claims description 8
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 208000001667 Achondrogenesis type 2 Diseases 0.000 claims description 7
- 102000016284 Aggrecans Human genes 0.000 claims description 7
- 108010067219 Aggrecans Proteins 0.000 claims description 7
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 7
- 102000016942 Elastin Human genes 0.000 claims description 7
- 108010014258 Elastin Proteins 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 229920002971 Heparan sulfate Polymers 0.000 claims description 7
- 229920000288 Keratan sulfate Polymers 0.000 claims description 7
- 208000001182 Kniest dysplasia Diseases 0.000 claims description 7
- 201000010810 Otospondylomegaepiphyseal dysplasia Diseases 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 7
- 102000016611 Proteoglycans Human genes 0.000 claims description 7
- 108010067787 Proteoglycans Proteins 0.000 claims description 7
- 208000027077 Stickler syndrome Diseases 0.000 claims description 7
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 7
- 229940051593 dermatan sulfate Drugs 0.000 claims description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 7
- 229920002549 elastin Polymers 0.000 claims description 7
- 102000013370 fibrillin Human genes 0.000 claims description 7
- 108060002895 fibrillin Proteins 0.000 claims description 7
- 229940099552 hyaluronan Drugs 0.000 claims description 7
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 7
- 229960002591 hydroxyproline Drugs 0.000 claims description 7
- 208000003074 hypochondrogenesis Diseases 0.000 claims description 7
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 230000004766 neurogenesis Effects 0.000 claims description 7
- 230000011164 ossification Effects 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 230000001846 repelling effect Effects 0.000 claims description 7
- 201000010812 spondyloepimetaphyseal dysplasia, Strudwick type Diseases 0.000 claims description 7
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 claims description 7
- 208000022350 spondyloperipheral dysplasia Diseases 0.000 claims description 7
- 230000024642 stem cell division Effects 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 206010053567 Coagulopathies Diseases 0.000 claims description 6
- 230000003416 augmentation Effects 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 230000035602 clotting Effects 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims description 6
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 229960004642 ferric ammonium citrate Drugs 0.000 claims description 5
- HZHFFEYYPYZMNU-UHFFFAOYSA-K gadodiamide Chemical class [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC HZHFFEYYPYZMNU-UHFFFAOYSA-K 0.000 claims description 5
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical group [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 5
- 239000004313 iron ammonium citrate Substances 0.000 claims description 5
- 235000000011 iron ammonium citrate Nutrition 0.000 claims description 5
- 239000013610 patient sample Substances 0.000 claims description 5
- 210000000278 spinal cord Anatomy 0.000 claims description 5
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 4
- 210000003238 esophagus Anatomy 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 229920005615 natural polymer Polymers 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000003101 oviduct Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 229960004072 thrombin Drugs 0.000 claims description 4
- 210000001541 thymus gland Anatomy 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 210000003437 trachea Anatomy 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 210000000626 ureter Anatomy 0.000 claims description 4
- 210000003708 urethra Anatomy 0.000 claims description 4
- 210000004291 uterus Anatomy 0.000 claims description 4
- FGMPLJWBKKVCDB-BYPYZUCNSA-N (2s)-1-hydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@H]1C(O)=O FGMPLJWBKKVCDB-BYPYZUCNSA-N 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 238000002316 cosmetic surgery Methods 0.000 claims description 3
- 230000002518 glial effect Effects 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 2
- 101800003265 Beta-thromboglobulin Proteins 0.000 claims description 2
- 102000001187 Collagen Type III Human genes 0.000 claims description 2
- 108010069502 Collagen Type III Proteins 0.000 claims description 2
- 102100036154 Platelet basic protein Human genes 0.000 claims description 2
- 239000004019 antithrombin Substances 0.000 claims description 2
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 230000002797 proteolythic effect Effects 0.000 claims description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims 6
- ZIWHMENIDGOELV-BKLSDQPFSA-N (2s)-4-fluoropyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(F)CN1 ZIWHMENIDGOELV-BKLSDQPFSA-N 0.000 claims 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 3
- 229960002442 glucosamine Drugs 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000002870 angiogenesis inducing agent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 49
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 238000002405 diagnostic procedure Methods 0.000 abstract description 7
- 239000013317 conjugated microporous polymer Substances 0.000 description 53
- 210000000056 organ Anatomy 0.000 description 41
- 239000000835 fiber Substances 0.000 description 38
- 239000000463 material Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 239000003814 drug Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000009472 formulation Methods 0.000 description 23
- 238000013270 controlled release Methods 0.000 description 22
- 238000000576 coating method Methods 0.000 description 21
- 239000000499 gel Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000012384 transportation and delivery Methods 0.000 description 18
- 102000012422 Collagen Type I Human genes 0.000 description 15
- 108010022452 Collagen Type I Proteins 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 238000002983 circular dichroism Methods 0.000 description 14
- 238000012377 drug delivery Methods 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 13
- 239000010931 gold Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 239000000512 collagen gel Substances 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 11
- 229910052737 gold Inorganic materials 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000008827 biological function Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 229940014259 gelatin Drugs 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 7
- 210000004872 soft tissue Anatomy 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 229920000954 Polyglycolide Polymers 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229940068984 polyvinyl alcohol Drugs 0.000 description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 108010050297 hydroxyprolyl-glycine Proteins 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 210000000069 breast epithelial cell Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 4
- 208000018631 connective tissue disease Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920001432 poly(L-lactide) Polymers 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000004584 polyacrylic acid Substances 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- 239000002407 tissue scaffold Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000012490 blank solution Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000000879 optical micrograph Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 230000008467 tissue growth Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-BKLSDQPFSA-N 4-hydroxy-L-proline Chemical compound OC1C[NH2+][C@H](C([O-])=O)C1 PMMYEEVYMWASQN-BKLSDQPFSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000009842 Fibril-Associated Collagens Human genes 0.000 description 2
- 108010020305 Fibril-Associated Collagens Proteins 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 208000005137 Joint instability Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015916 branching morphogenesis of a tube Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 229940082483 carnauba wax Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 208000025645 collagenopathy Diseases 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940074045 glyceryl distearate Drugs 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 230000000887 hydrating effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000010324 immunological assay Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940127554 medical product Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- OLTAWOVKGWWERU-UHFFFAOYSA-N proxazole Chemical compound C=1C=CC=CC=1C(CC)C1=NOC(CCN(CC)CC)=N1 OLTAWOVKGWWERU-UHFFFAOYSA-N 0.000 description 2
- 229960001801 proxazole Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- AUDFHJLSHQWFQQ-SFHVURJKSA-N (2s)-2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]-3-hydroxypropanoic acid Chemical compound CC1=C(CC(=O)N[C@@H](CO)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AUDFHJLSHQWFQQ-SFHVURJKSA-N 0.000 description 1
- XYRIRLDHOQSNLW-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC2C3=CC=CC=C3C(=O)O2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XYRIRLDHOQSNLW-UHFFFAOYSA-N 0.000 description 1
- SHCYQUDTKWHARF-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1C2=CC=CC=C2C(=O)O1 SHCYQUDTKWHARF-UHFFFAOYSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- BVNJBATUHVXZKP-QXMHVHEDSA-N (3z)-6-chloro-5-fluoro-3-[hydroxy(thiophen-2-yl)methylidene]-2-oxoindole-1-carboxamide Chemical compound C12=CC(F)=C(Cl)C=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 BVNJBATUHVXZKP-QXMHVHEDSA-N 0.000 description 1
- ZDHHGGFQZRPUSN-UHFFFAOYSA-N (4-chlorophenyl)-[3-(2h-tetrazol-5-ylmethyl)indol-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C(CC2=NNN=N2)=C1 ZDHHGGFQZRPUSN-UHFFFAOYSA-N 0.000 description 1
- PPQZABOURJVKNI-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-fluorophenyl)-4-hydroxy-1-methylpiperidin-3-yl]methanone Chemical compound C1N(C)CCC(O)(C=2C=CC(F)=CC=2)C1C(=O)C1=CC=C(F)C=C1 PPQZABOURJVKNI-UHFFFAOYSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- JFTOCKFCHJCDDX-UVTDQMKNSA-N (4z)-4-benzylidene-5,6,7,8-tetrahydroisoquinoline-1,3-dione Chemical compound C1CCCC2=C1C(=O)NC(=O)\C2=C/C1=CC=CC=C1 JFTOCKFCHJCDDX-UVTDQMKNSA-N 0.000 description 1
- VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 1
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 1
- YETULFFXNIHQLK-UHFFFAOYSA-N 1-ethynyl-4-(2-fluorophenyl)benzene Chemical compound FC1=CC=CC=C1C1=CC=C(C#C)C=C1 YETULFFXNIHQLK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ULIDRMKBVYYVIQ-UHFFFAOYSA-N 1-phenyltetrazol-5-amine Chemical compound NC1=NN=NN1C1=CC=CC=C1 ULIDRMKBVYYVIQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
- IZGMROSLQHXRDZ-UHFFFAOYSA-N 2-(1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid Chemical compound N1C2=CC=CC=C2C2=C1C(CCC)(CC(O)=O)OCC2 IZGMROSLQHXRDZ-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- IDCAZKFFVIMCCS-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-imino-2-oxoimidazolidin-1-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)N(CC#N)CC1=N IDCAZKFFVIMCCS-UHFFFAOYSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- NLGUJWNOGYWZBI-UHFFFAOYSA-N 2-[3-chloro-4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 NLGUJWNOGYWZBI-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- QKKLKGVIECOSRM-CODXZCKSSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 QKKLKGVIECOSRM-CODXZCKSSA-N 0.000 description 1
- LNXXSBRGLBOASF-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid Chemical compound O1C(COC(C)(C)C(O)=O)=C(C)N=C1C1=CC=C(Cl)C=C1 LNXXSBRGLBOASF-UHFFFAOYSA-N 0.000 description 1
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- PLZMRGRLCWCLFW-UHFFFAOYSA-N 3-[5-(3-bromophenyl)tetrazol-2-yl]-1-piperidin-1-ylpropan-1-one Chemical compound BrC1=CC=CC(C2=NN(CCC(=O)N3CCCCC3)N=N2)=C1 PLZMRGRLCWCLFW-UHFFFAOYSA-N 0.000 description 1
- YLJRTDTWWRXOFG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)furan-2-yl]-3-hydroxypropanoic acid Chemical compound O1C(C(CC(O)=O)O)=CC=C1C1=CC=C(Cl)C=C1 YLJRTDTWWRXOFG-UHFFFAOYSA-N 0.000 description 1
- YUORBURTMIUPMW-UHFFFAOYSA-N 3-methyl-5-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C)CC1CCN1CC=C(C=2C=CC=CC=2)CC1 YUORBURTMIUPMW-UHFFFAOYSA-N 0.000 description 1
- PIAMNHTVFPWVHG-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.N1C=NC(C=2C=CC(Cl)=CC=2)=C1C PIAMNHTVFPWVHG-UHFFFAOYSA-N 0.000 description 1
- INDZCVYWKNWKIQ-UHFFFAOYSA-N 4-(fluoren-9-ylidenemethyl)benzenecarboximidamide;hydrochloride Chemical compound Cl.C1=CC(C(=N)N)=CC=C1C=C1C2=CC=CC=C2C2=CC=CC=C21 INDZCVYWKNWKIQ-UHFFFAOYSA-N 0.000 description 1
- LQVMQEYROPXMQH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CCC(=O)O)=CC=C3OC2=C1 LQVMQEYROPXMQH-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- CXSJGNHRBWJXEA-UHFFFAOYSA-N 5,12-dihydrophthalazino[3,2-b]phthalazine-7,14-dione Chemical compound C1C2=CC=CC=C2C(=O)N2N1C(=O)C1=CC=CC=C1C2 CXSJGNHRBWJXEA-UHFFFAOYSA-N 0.000 description 1
- HEOZYYOUKGGSBJ-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C2N1CCC2C(O)=O HEOZYYOUKGGSBJ-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 description 1
- XWXVKXXKKLBDDJ-UHFFFAOYSA-N 7-chloro-3,3a-dihydro-2h-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one Chemical compound O1C2CCON2C(=O)C2=CC(Cl)=CC=C21 XWXVKXXKKLBDDJ-UHFFFAOYSA-N 0.000 description 1
- MFFDXDZDAJXSJX-UHFFFAOYSA-N 9-(2-hydroxyethoxy)-2-(methylamino)-3h-purin-6-one Chemical compound O=C1NC(NC)=NC2=C1N=CN2OCCO MFFDXDZDAJXSJX-UHFFFAOYSA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- KATBVKFXGKGUFE-UHFFFAOYSA-N Cintazone Chemical compound C12=CC=CC=C2N2C(=O)C(CCCCC)C(=O)N2C=C1C1=CC=CC=C1 KATBVKFXGKGUFE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241001574013 Collogenes Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 206010070874 Joint laxity Diseases 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024452 Ligament laxity Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HUXCOHMTWUSXGY-GAPIFECDSA-N Meclorisone dibutyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2Cl HUXCOHMTWUSXGY-GAPIFECDSA-N 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 description 1
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- SBVPYBFMIGDIDX-SRVKXCTJSA-N Pro-Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1N(C(=O)[C@H]2NCCC2)CCC1 SBVPYBFMIGDIDX-SRVKXCTJSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 1
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000000875 Spinal Curvatures Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- WKDDRNSBRWANNC-ATRFCDNQSA-N Thienamycin Chemical class C1C(SCCN)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 WKDDRNSBRWANNC-ATRFCDNQSA-N 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000133063 Trixis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- MVLBCBPGBUAVJQ-CENSZEJFSA-N [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-17-(chloromethylsulfanylcarbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O MVLBCBPGBUAVJQ-CENSZEJFSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- LSWBQIAZNGURQV-WTBIUSKOSA-N algestone acetonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)C)[C@@]1(C)CC2 LSWBQIAZNGURQV-WTBIUSKOSA-N 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229950004699 anirolac Drugs 0.000 description 1
- HDNJXZZJFPCFHG-UHFFFAOYSA-N anitrazafen Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C)N=C1C1=CC=C(OC)C=C1 HDNJXZZJFPCFHG-UHFFFAOYSA-N 0.000 description 1
- 229950002412 anitrazafen Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- UIDLJTHRRPMIQP-UHFFFAOYSA-L bis[2-[4-(2-methylpropyl)phenyl]propanoyloxy]aluminum;hydrate Chemical compound O.C1=CC(CC(C)C)=CC=C1C(C)C(=O)O[Al]OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 UIDLJTHRRPMIQP-UHFFFAOYSA-L 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 208000024668 brittle bone disease Diseases 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 229950011622 broperamole Drugs 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- 229950002545 cicloprofen Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229950005384 cliprofen Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- SJCRQMUYEQHNTC-UHFFFAOYSA-N clopirac Chemical compound CC1=CC(CC(O)=O)=C(C)N1C1=CC=C(Cl)C=C1 SJCRQMUYEQHNTC-UHFFFAOYSA-N 0.000 description 1
- 229950009185 clopirac Drugs 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229950007956 diftalone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- GZBONOYGBJSTHF-QLRNAMTQSA-N drocinonide Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O GZBONOYGBJSTHF-QLRNAMTQSA-N 0.000 description 1
- 229950006082 drocinonide Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- ULANGSAJTINEBA-UHFFFAOYSA-N ethyl n-(3-benzoylphenyl)-n-(trifluoromethylsulfonyl)carbamate Chemical compound CCOC(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ULANGSAJTINEBA-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229950003579 fenamole Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- 229950002296 fenpipalone Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229950004322 flazalone Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- OPYFPDBMMYUPME-UHFFFAOYSA-N flumizole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)NC(C(F)(F)F)=N1 OPYFPDBMMYUPME-UHFFFAOYSA-N 0.000 description 1
- 229950005288 flumizole Drugs 0.000 description 1
- WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical class FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229950007253 fluquazone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229950003750 fluretofen Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229950008156 furaprofen Drugs 0.000 description 1
- 229950006099 furobufen Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 229950011445 ilonidap Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004260 indomethacin sodium Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229950008443 indoxole Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229950004204 intrazole Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003317 isoflupredone acetate Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- GQVWFGYYMWLERN-UHFFFAOYSA-J magnesium;2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;sulfate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQVWFGYYMWLERN-UHFFFAOYSA-J 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001011 medrysone Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- OJGJQQNLRVNIKE-UHFFFAOYSA-N meseclazone Chemical compound O1C2=CC=C(Cl)C=C2C(=O)N2C1CC(C)O2 OJGJQQNLRVNIKE-UHFFFAOYSA-N 0.000 description 1
- 229950000701 meseclazone Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- CDMLLMOLWUKNEK-AOHDELFNSA-M methylprednisolone suleptanate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS([O-])(=O)=O)CC[C@H]21 CDMLLMOLWUKNEK-AOHDELFNSA-M 0.000 description 1
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960003251 morniflumate Drugs 0.000 description 1
- LDXSPUSKBDTEKA-UHFFFAOYSA-N morniflumate Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OCCN2CCOCC2)=C1 LDXSPUSKBDTEKA-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 description 1
- HWCORKBTTGTRDY-UHFFFAOYSA-N n-(4-chlorophenyl)-1,3-dioxo-4h-isoquinoline-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)NC1=O HWCORKBTTGTRDY-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 229950006890 naproxol Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229950006046 nimazone Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 229950003655 orpanoxin Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 229950008421 prednazate Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- WAAVMZLJRXYRMA-UHFFFAOYSA-N prifelone Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)C=2SC=CC=2)=C1 WAAVMZLJRXYRMA-UHFFFAOYSA-N 0.000 description 1
- 229950004465 prifelone Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229950003795 prodolic acid Drugs 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229950001166 romazarit Drugs 0.000 description 1
- 229950000125 salcolex Drugs 0.000 description 1
- 229950009768 salnacedin Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- GIZKAXHWLRYMLE-UHFFFAOYSA-M sanguinarium chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 GIZKAXHWLRYMLE-UHFFFAOYSA-M 0.000 description 1
- 229950011197 sanguinarium chloride Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229950002093 seclazone Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229950006250 sermetacin Drugs 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- HVBBVDWXAWJQSV-UHFFFAOYSA-N sodium;(3-benzoylphenyl)-(difluoromethylsulfonyl)azanide Chemical compound [Na+].FC(F)S(=O)(=O)[N-]C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HVBBVDWXAWJQSV-UHFFFAOYSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
- SEEXPXUCHVGZGU-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate Chemical compound [Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C SEEXPXUCHVGZGU-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- NNFXVGOLTQESMQ-UHFFFAOYSA-M sodium;4-butyl-5-oxo-1,2-diphenylpyrazol-3-olate Chemical compound [Na+].C=1C=CC=CC=1N1C(=O)C(CCCC)=C([O-])N1C1=CC=CC=C1 NNFXVGOLTQESMQ-UHFFFAOYSA-M 0.000 description 1
- AVERBMQHYOZACV-UHFFFAOYSA-M sodium;7-chloro-4-[(3,4-dichlorophenyl)carbamoyl]-1,1-dioxo-2,3-dihydro-1$l^{6}-benzothiepin-5-olate;hydrate Chemical compound O.[Na+].C1CS(=O)(=O)C2=CC=C(Cl)C=C2C([O-])=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 AVERBMQHYOZACV-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950005100 talmetacin Drugs 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 229950005400 talosalate Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229950003441 tebufelone Drugs 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 229950007324 tesicam Drugs 0.000 description 1
- 229950000997 tesimide Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003803 thymidine kinase inhibitor Substances 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 1
- 229960003114 tixocortol pivalate Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- VSVSLEMVVAYTQW-VSXGLTOVSA-N triclonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]2(C)C[C@@H]1Cl VSVSLEMVVAYTQW-VSXGLTOVSA-N 0.000 description 1
- 229950008073 triclonide Drugs 0.000 description 1
- 229950000451 triflumidate Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229960003516 zomepirac sodium Drugs 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Definitions
- Collagen is used in a variety of medical applications ranging from hemostatic materials and biocompatible coatings to drug delivery and tissue engineering.
- Collagen- based biomaterials are presently used for soft-tissue engineering and repair, and medical products composed of collagen have been approved by the FDA, and are commercially available. These include collagen-based corneal shields, anti-infectious catheters, tissue sealants, hemostatic sponges, and topical wound dressing products.
- Collagen is also used for tissue engineering substrates targeted for skin, bone, and blood vessel replacement.
- biocompatible and biofunctional materials that feature collagen as a scaffold to support tissue growth, to promote healing, and to develop engineered tissues for organ replacement therapies.
- collagen is used as a passive biomaterial that protects injured sites and supports healing processes.
- Methods for modifying collagen would be useful for the development of materials that can participate in tissue regeneration by actively regulating cell differentiation, proliferation, and tissue organization.
- Methods for producing modified collagens have focused on chemical modification, that include coupling modifying groups to collagen' s amino acid side chains; however, the chemical reactions between exogenous components and collagen molecules are toxic and difficult to control because collagen molecules are large and complex biopolymers.
- Progress in the area of tissue repair and regeneration requires better methods for conjugating exogenous functionalities to collagen. Desirably, such methods should overcome challenges associated with controlling chemical reactions and chemical toxicity.
- compositions comprising modified collagen and therapeutic and diagnostic methods related to the use of such compositions.
- the invention features a method for modifying collagen, the method involving contacting collagen with a collagen mimetic peptide, under conditions that provide for a physical interaction between the collagen and the collagen mimetic peptide.
- the invention provides a modified collagen made by the process of the above aspect.
- the invention features a collagen mimetic peptide conjugate, where the conjugate is selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
- the collagen mimetic peptide contains a Z-[X-Y-GIy] n repeat unit, where Z is any amino acid, X is proline or modified proline, Y is proline or modified proline, and n is an integer between 1 and 20, inclusive.
- the invention provides collagen mimetic peptide that contains amino acid sequences Gly n -(ProHypGly)n', (ProHypGly) n'-Tyr n , or Cys n -(Pro-Hyp-Gly) n ' where n is an integer between 1 and 5, and n' is any integer between 1 and 15, and the peptide further comprises a modifier selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, an anti-inflammatory, a component of the extracellular matrix, a polymer, PEG, and a small molecule.
- n' is 5, 6, 7, or 8.
- the invention provides a modified collagen containing a CMP mimetic peptide of any previous aspect or made by the process of a previous aspect.
- the invention provides a method of modifying the adhesiveness of a composition, the method involving contacting the composition with a CMP conjugate.
- the composition comprises collagen, for example, in a three-dimensional matrix or in a collagen film, hi other embodiments, the collagen is modified in a micropattern.
- the CMP conjugate is a poly(ethyleneglycol)/CMP conjugate.
- modification increases or decreases adhesiveness.
- the invention provides a nanoparticle containing a collagen mimetic peptide fixed to the nanoparticle.
- the collagen mimetic peptide contains the following sequence CyS n -(PrO-HVp-GIy) n ', where n is any integer between 1 and 5, and n' is any integer between 1 and 10. In another embodiment, n is 1 and n' is 3. In another embodiment, n' is 5, 6, 7, or 8. In yet another embodiment, the collagen mimetic peptide is fixed to the surface of the nanoparticle. In another embodiment, the nanoparticle is between 5 and 20 run (e.g., between 10 and 15 nm in diameter). In another embodiment, the nanoparticle is a metal, such as gold (AU).
- the transmission electron microscopy marker contains the nanoparticle of any previous aspect.
- the nanoparticle comprises AU.
- the invention provides a diagnostic marker containing a detectable CMP conjugate, where the marker binds collagen and detects a disease.
- CMP is conjugated to a nanoparticle, a detectable label, or a contrast reagent.
- the marker detects a disease characterized by disruption of collagen structure, hi another embodiment, the marker detects the disease by binding to a collagen selected from the group consisting of collagen type 1-type 29 (e.g., type I, II, III, IV, IX, X, or XI).
- the disease is selected from the group consisting of Ehlers-Danlos syndrome, osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweym ⁇ ller.
- the marker is detectable using transmission electron microscopy.
- the invention provides a method for diagnosing a subject as having or having a propensity to develop a disease characterized by disruption of a collagen structure, the method involving contacting a patient sample with a detectable CMP-conjugate; and detecting an alteration in a collagen structure present in the patient sample, where the alteration diagnoses the subject as having or having a propensity to develop a disease characterized by disruption of a collagen structure.
- the invention provides a method for diagnosing a subject as having or having a propensity to develop a thrombosis, the method involving contacting a blood vessel with a detectable CMP-conjugate; and detecting an alteration present in the blood vessel, where the alteration diagnoses the subject as having or having a propensity to develop a thrombosis, hi one embodiment, the detectable CMP-conjugate binds a collagen selected from the group consisting of collagen type 1-type 29 (e.g., type I, II, III, IV, IX, X, or XI).
- collagen type 1-type 29 e.g., type I, II, III, IV, IX, X, or XI
- the disease is selected from the group consisting of Ehlers-Danlos syndrome, Osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweym ⁇ ller.
- the marker binds a collagen present in a thombosis or a vessel wall.
- the invention provides diagnostic kit containing a detectable CMP conjugate and directions for the use of the conjugate in the diagnosis of a disease characterized by a disruption in collagen structure
- the detectable CMP- conjugate binds a collagen selected from the group consisting of collagen type 1-type 29 (e.g., type I, II, III, IX, X, or XI).
- the disease is selected from the group consisting of Ehlers-Danlos syndrome, Osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymuller.
- the invention provides a composition for repelling cell adhesion, the composition containing a CMP-poly(ethylene glycol) conjugate
- CMP- poly(ethylene glycol) conjugate comprises methoxy-PEG 2 ooo-Gly 3 -(Pro-Hyp-Gly) 7 or (Pro- Hyp-Gly) 9 -Gly 3 -PEG 5O oo.
- CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG or NHS activated star-shaped PEG.
- composition comprises star shaped PEG having the following formula:
- the composition comprises AcGly-Gly 2 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 .
- the CMP comprises -(Pro-Hyp-GlyV, where n is any integer between 1 and 3, and n' is any integer between 1 and 10.
- the invention provides matrix containing a CMP -polymer conjugate, where the CMP -polymer conjugate alters the adhesive properties of the matrix,
- the CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG 2000 - Gly 3 -(Pro-Hyp-Gly) 7 or (PrO-HyP-GIy) 9 -GIy 3 -PEG 5 O 00 .
- the CMP- poly(ethylene glycol) conjugate comprises grafted linear PEG.
- the composition comprises NHS activated star-shaped PEG.
- the composition comprises star shaped PEG star shaped PEG having the following formula:
- the composition comprises AcGly-Gly 2 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 .
- the matrix further contains a cell selected from the group consisting of chondrocytes, endothelial cells, dendritic cells, stem cells, multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, and osteoclasts.
- the CMP-poly(ethylene glycol) conjugate is present in a pattern.
- the CMP comprises -(Pro-Hyp- GIy) n ', where n is any integer between 1 and 3, and n' is any integer between 1 and 10.
- the invention provides method for repelling cell adhesion on a composition, the method involving fixing a CMP-PEG conjugate to a composition, where the CMP-PEG conjugate repels cell adhesion on the composition, hi one embodiment, the CMP- poly(ethylene glycol) conjugate comprises methoxy-PEG 2 o 0 o-Gly 3 -(Pro-Hyp-Gly) 7 or (Pro- Hyp-Gly) 9 -Gly 3 -PEG 5 Qoo- hi another embodiment, the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG or NHS activated star-shaped PEG.
- the method repels adhesion of a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
- a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells
- the invention provides composition containing a CMP- poly(ethylene glycol) conjugate that comprises a detectable marker.
- CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG 2 oo 0 -Gly3-(Pro-Hyp-Gly) 7 or (Pro-Hyp-Gly) 9 -Gly 3 -PEG 50 oo.
- the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG, NHS activated star-shaped PEG, or star shaped PEG having the formula shown above.
- the composition comprises AcGIy-GIy 2 -LyS-GIy 3 -(PrO- Hyp-Gly) 8.
- the invention provides a method of determining the presence of a CMP-poly( ethylene glycol) conjugate in a composition, the method involving contacting a composition with a CMP-poly(ethylene glycol) conjugate containing a detectable marker; and detecting binding of the CMP-poly(ethylene glycol) conjugate to the composition.
- the detecting quantifies the level of detectable marker.
- the detecting localizes the detectable marker in the composition.
- the invention provides a composition for crosslinking collagen, the composition containing a CMP-poly(ethylene glycol) conjugate.
- CMP is conjugated to a multi-armed PEG compound
- PEG comprises an amino group, a thiol group.
- the composition comprises star shaped PEG of a Formula shown above.
- the composition comprises AcGIy-GIy 2 - Lys-Gly 3 -(Pro-Hy ⁇ -Gly) 8 .
- the invention provides method for preventing or treating thrombosis in a subject, the method involving contacting a blood vessel having or having a propensity to develop a thrombosis with a CMP-anti-thrombosis conjugate; where the contacting prevents or treats a thrombosis.
- the propensity to develop a thrombosis is related to angioplasty
- the invention provides the vessel is contacted with a hydrogel containing a CMP-anti-thrombosis conjugate.
- the CMP- anti-thrombosis conjugate binds collagen present in the thrombosis
- the CMP-anti-thrombosis conjugate degrades the thrombosis
- the method further involves monitoring the efficacy of the method (e.g., by determining plasma level of ⁇ -thromboglobulin or thrombin-antithrombin complexes).
- the invention provides diagnostic marker that detects a vessel having or having an increased propensity to develop a thrombosis relative to a control vessel, the marker containing a detectable CMP conjugate that binds collagen, hi one embodiment, the marker detects the presence of a thrombosis in the vessel, hi another embodiment, the marker binds collagen type III. In yet another embodiment, the marker detects a vessel having a propensity to develop a thrombosis.
- the invention provides a diagnostic kit containing the diagnostic marker of any previous aspect and directions for the use of the conjugate in the diagnosis of a thromobosis or a propensity to develop a thrombosis.
- the invention provides an implantable, sustained release device containing a CMP conjugate fixed to a collagen matrix.
- the conjugate is selected from the group consisting of an antibiotic, a growth factor, an anti-inflammatory, a component of the extracellular matrix, and a small molecule.
- the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
- the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, and platelet-derived growth factor.
- the small molecule is selected from the group consisting of anti-thrombotics, anti-atherosclerosis agents, cartilage repair agent.
- the collagen matrix is a hydrogel. In another embodiment, the collagen matrix is a pellet or a film.
- the invention provides a kit containing an effective amount of an implantable, sustained release device of a previous aspect, and directions for the use of the device in the treatment of a disease or disorder.
- the invention provides a hemostatic sponge containing a collagen mimetic peptide and collagen.
- the collagen mimetic peptide physically associates with the collagen.
- the sponge further contains a natural or synthetic polymer.
- the collagen mimetic peptide further comprises a conjugate selected from the group consisting of clotting agents, growth factors, and antibiotics.
- the clotting agents is the group selected from the group consisting of thrombin and fibrin.
- the invention provides a corneal shield containing a collagen mimetic peptide conjugate and a polymer.
- the CMP conjugate comprises an antibiotic, an anti-inflammatory, or a small molecule.
- the invention provides a wound healing device containing a collagen mimetic peptide conjugate and a polymer.
- the CMP conjugate comprises an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, and a small molecule.
- the device is in the form of a plug, mesh, strip, suture, dressing, patch, threads, suture, or biological fastener.
- the device further contains a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
- a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells,
- the invention provides a kit containing the wound healing device of any previous aspect.
- the invention provides matrix containing a polymer in association with a collagen mimetic peptide, where the matrix promotes the survival, differentiation, or proliferation of a cell.
- the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable.
- the polymer is collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), polyvinyl alcohol, or polyacrylic acid.
- the physical interaction occurs by helical assembly or strand invasion.
- collagen mimetic peptide conjugate acts as a cross-linking agent.
- the matrix is susceptible to proteolytic breakdown.
- the matrix further comprises an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
- CMP is conjugated to an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
- PEG is star shaped PEG, a multi-armed PEG, a graft linear PEG, PEG 200O , or PEG 5000 .
- the matrix further contains a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
- the invention provides a method for synthesizing a matrix, the method involving contacting a collagen mimetic peptide to a polymer and cross-linking the polymer such that a molecular matrix is formed.
- the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable.
- the polymer is selected from the group consisting of poly(ethylene glycol), poly( ethylene oxide) diacrylate (PEODA), polyvinyl alcohol, or polyacrylic acid.
- the invention provides a method for promoting cell survival or proliferation, involving growing a cell in contact with a matrix containing a polymer and a collagen mimetic peptide.
- the collagen mimetic peptide is capable of retaining a cell-secreted collagen.
- the matrix further comprises an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
- the CMP is conjugated to an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
- the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable.
- the cell is selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
- the invention provides a method for replacing a damaged or absent tissue, the method involving growing a cell in a matrix of any one of a previous aspect; and contacting a damaged tissue or site of an absent tissue with the cell and matrix, such that the cell and matrix replaces the damaged or absent tissue.
- the invention provides a method for or for tissue augmentation, the method involving growing a cell in a matrix of a previous aspect; and contacting a tissue that requires augmentation with the cell and matrix, such that the cell and matrix augments the tissue.
- the cell is derived from or the tissue is selected from any one or more of muscle, cartilage, heart, bladder, brain, nervous tissue, glial tissue, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, ovaries, prostate, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, breast, skeletal muscle, skin, bone, and cartilage.
- the cell is any one or more of endothelial cells, dendritic cells, stem cells, multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, adipocytes, osteoclasts, and chondrocytes.
- the method is useful for cosmetic surgery.
- the method reconstructs a breast, a face, or a body part after cancer surgery or trauma.
- the invention provides a method for promoting cartilage repair, the method involving growing a chondrocyte in a matrix of a previous aspect; and contacting cartilage with the chondrocyte and matrix, where the contact promotes cartilage repair.
- the collagen mimetic peptide or collagen mimetic peptide conjugate comprises a Z-[X-Y-GIy] n repeat unit, where Z is any amino acid, X is proline or modified praline (e.g., 4-hydroxyl proline, 4-fluoro praline), Y is proline or modified proline (e.g., 4-hydroxyl proline, 4-fluoro praline), and n is an integer between 1 and 20.
- Z is any amino acid
- X is proline or modified praline (e.g., 4-hydroxyl proline, 4-fluoro praline)
- Y is proline or modified proline (e.g., 4-hydroxyl proline, 4-fluoro praline)
- n is an integer between 1 and 20.
- the collagen mimetic peptide comprises (ProHypGly) x , (ProProGly) x ,or (ProFlpGly) x , where Hyp is hydroxyl proline, FIp is 4-fiuoro proline, and x is any integer between 1 and 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 25, 30).
- the collagen mimetic peptide comprises at least 5, 10, 15, 20, 25, 30, 40, or 50 amino acids.
- the collagen mimetic peptide is conjugated to an antibiotic (e.g., penicillin, tetracycline, plectasin, LAH4), a cell adhesion molecule (e.g., cadherin, fibronectin, integrin, laminin, selectin), a contrast agent (e.g., a gadolinium complex, gadodiamide derivative, ferric ammonium citrate, and mangafodipar trisodium), a detectable label (e.g., a colloidal particle, an enzyme, an electron- dense reagent, a fluorescent dye, a hapten, an immunogen, a magnetic bead, a radiolabel, carboxy- fluorescein), a growth factor that promotes angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, or cell survival, such as angiogenin, erythropoietin, vascular endothelial growth factor (VEVE)
- an antibiotic e.g.
- collagen mimetic peptide binds to any one or more collagen selected from the group consisting of type 1-29 collagen, such as type I, II, III, rv, IX, X, or XL
- collagen mimetic peptide peptide comprises an amino acid sequence selected from the group consisting of Gly 3 -(ProHypGly) 6 , Gly 3 -(ProHypGly) 7; Gly 3 -(ProHypGly) 8 , Gly 3 -(ProHypGly) 9 , (PrOHyPGIy) 6 -TyT, (ProHypGly) 7 -Tyr, (ProHypGly) 8 -Tyr, Cys-(Pro-Hy ⁇ -Gly) 3 , Cys-(Pro- Hyp-Gly) 5 , and Cys-(Pro-Hyp-Gly) 7 , carbo ⁇ yfiuoresc
- the peptide has a melting transition temperature between 5 0 C and 95°C (e.g., between 10°C and 8O 0 C, 15°C and 40°C, 20°C and 37°C).
- CMP is conjugated to a multi-armed PEG compound.
- PEG comprises an amino group, a thiol group, is monoacrylated, or is diacrylated.
- CMP is conjugated to a clotting agent, such as thrombin or fibrin.
- the polymer is collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), polyvinyl alcohol, or polyacrylic acid.
- the CMP physically interacts or binds collagen.
- the physical interaction occurs by helical assembly or strand invasion.
- the collagen mimetic peptide conjugate e.g., a conjugate containing a reactive group, such as an acrylate group (e.g., PEG mono- or diacrylate)
- the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable
- collagen is meant a protein component of an extracellular matrix having a tertiary structure that includes polypeptide chains intertwining to form a collagen triple helix or having a characteristic amino acid composition comprising GIy-X-Y repeat units, or a fragment thereof.
- Collagens useful in the methods of the invention include any collagen known in the art (e.g., one of collagen type 1-29).
- CMP collagen mimetic peptide
- a CMP has an amino acid sequence comprising -[X-Y-GIy] n repeat units.
- a CMP binds collagen with high affinity.
- a "collagen mimetic peptide conjugate” is a CMP covalently bound to another molecule.
- Molecules capable of acting as CMP conjugates include, but are not limited to, polypeptides, or fragments thereof, nucleic acid molecules, small molecule compounds, detectable labels, nanoparticles, and polymers.
- ameliorate decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
- alteration is meant a change (increase or decrease) in the expression levels of a gene or polypeptide as detected by standard art known methods such as those described above.
- an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or greater change in expression levels.
- Bio sample refers to a sample obtained from a biological subject, including sample of biological tissue or fluid origin, obtained, reached, or collected in vivo or in situ, that contains or is suspected of containing nucleic acids or polypeptides.
- samples can be, but are not limited to, organs, tissues, fractions and cells isolated from mammals including, humans such as a patient, mice, and rats.
- Biological samples also may include sections of the biological sample including tissues, for example, frozen sections taken for histologic purposes.
- detectable label is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
- useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
- disease is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
- an effective amount is meant the amount required to ameliorate the symptoms of a disease relative in an untreated patient.
- the effective amount of active compound(s) used to practice the present invention for therapeutic treatment of a neurodegenerative disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.
- fragment is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
- a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
- immunological assay an assay that relies on an immunological reaction, for example, antibody binding to an antigen.
- immunological assays include ELISAs, Western blots, immunoprecipitations, and other assays known to the skilled artisan.
- polymer is meant a natural or synthetic organic molecule formed by combining smaller molecules in a regular pattern.
- small molecule any chemical compound.
- modulation is meant any alteration (e.g., increase or decrease) in a biological function or activity.
- nanoparticle an aggregate of anywhere from a few hundred to tens of thousands of atoms that have a diameter ranging from 3 -300 nanometers.
- matrix is meant a substance that fills the spaces between isolated cells in culture.
- a matrix is an adhesive substrate used to coat a glass or plastic surface prior to cell culture.
- repellent cell adhesion is meant decreasing an adhesive characteristic of a composition relative to an untreated composition.
- reference is meant a standard or control condition.
- subject is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
- a physical interaction is meant an association that does not require covalent bonding.
- a physical interaction includes incorporation into a helical structure.
- treat refers to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
- the terms "prevent,” “preventing,” “prevention,” “prophylactic treatment” and the like refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.
- the invention provides modified collagen and related therapeutic methods. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
- Figure 1 shows circular dichroism (CD) thermal melting curves of collagen mimetic peptide derivatives 1 ⁇ 3.
- Tm °C
- Figure 2 shows a CD thermal melting curve OfCF-GIy 3 -(PHG) 6 (peptide 4).
- Figure 3 shows a CD thermal melting curve of mPEG 2O oo-Gly 3 -(PHG) 7 (peptide 5).
- Figure 4 shows a CD measurement of collagen films after the treatment with peptide 2 or blank solution. Both solutions were pre-equilibrated at 80°C before addition to the collagen film. Treatment with blank solution (80 0 C) unfolded the native collagen and only 32% of collagen's original helical content remains after the treatment. However collagen film treated with peptide 2 retains 80% of its original helical content. The additional helical content is likely due to peptide 2 associating with partially unfolded collagen in the form of triple helix.
- Figures 5 A and 5B are graphs showing the fluorescence intensities of collagen films (type I, bovine) treated with 5CF labeled CMPs and other control samples.
- the X axis represents the temperature at which fluorescence solutions were equilibrated prior to addition to the collagen film (see support information).
- Figure 5A shows the binding of peptide 2 and control samples to collagen (groups a and b) and gelatin (group c) films. The gelatin film was prepared by subjecting the collagen film to heat (80 0 C) for 30 minutes.
- Figure 5B shows the binding of peptide 4 to collagen films.
- Figure 6 shows transmission electron and fluorescence (inset) micrographs of collagen fibers (type I) after the treatment with peptide 4 at 30 0 C.
- the collagen fibers exhibit native banding pattern suggesting that the modification process did not disrupt the native collagen structure.
- the presence of peptide 4 on the collagen fiber was confirmed by fluorescence microscopy (inset).
- Figures 7 A, 7B and 7C are optical micrographs of human fibroblasts ( Figures 7A and7B) and breast epithelial cells (Figure 7C) cultured on collagen films that were pre-treated with mPEG 2O oo ( Figure 7A), or peptide 5 ( Figures 7B and 7C). Areas of the picture to the right side of the dotted lines were treated with HiPEG 2 O 0 O or peptide 5.
- Figure 8 is a schematic diagram showing methods for altering the growth of epithelial cells on a collagen gel using modified CMP conjugated to PEG.
- Figures 9A-9C are optical micrographs of human breast epithelial cells cultured on collagen films that were treated with mPEG 2 ooo-Gly 3 -(Pro-Hyp-Gly) 7 3rd day ( Figure 9A), 5th day ( Figure 9B), and 7th day ( Figure 9C).
- the bar scales represent 100 ⁇ m.
- Figures 10A- 1OF are optical micrographs of human breast epithelial cells cultured on collagen films that were treated with (Pro-Hyp-Gly) 8 -Gly 3 -PEG 5 ooo-OH 3rd day (A), 5th day (B), and 7th day (C), or longer 10D- 1OF.
- the bar scales represent 250 ⁇ m.
- Figure 11 is a graph that quantitates the release of fluorescence-labeled CMP derivatives from collagen films incubated in PBS buffer solution of pH 7.4 at 37 0 C.
- Figure 12 is a schematic diagram showing the structure of star shaped, rigid and flexible linear PEG on substrate.
- the structure of star shaped or suitable linear PEG (PEG5000) explains its capacity for repelling approaching molecules or cells compared to flexible linear PEG (PEG20000).
- Figure 13 is a schematic diagram showing the structures of CMP-star shaped PEG.
- A) [AcGly-Gly 2 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 ] 4 -star shaped PEG.
- B) [CF-Gly 3 -Lys-Gly 3 -(Pro-Hyp- Gly) 8 ] 4 -star shaped PEG, fluorescence tagged star shaped PEG-CMP.
- Star shaped PEG NHS activated four-armed star shaped PEG, molecular weight is approximately 10,000 Da; CMP: AcGly-Gly 2 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 ; CF-CMP: carboxyfluorescein-Gly 3 -lys-(Pro-Hyp- GIy) 8 .
- Figure 14 shows the thermal melting transition curves for peptides l' ⁇ 4'.
- Figure 15 shows the Gaussian fit of the dynamic light scattering (DLS) data showing the hydrodynamic size of nanoparticle-peptide number (NP-Xs).
- DLS dynamic light scattering
- Figure 16 shows the determination of the number of peptides per Au NP.
- Figures 17A-17D are transmission electron microscope (TEM) micrographs of negatively stained NP-I ( Figure 17A), NP-2 ( Figure 17B), NP-3 ( Figure 17C) and unmodified NPs (Figure 17D).
- Scale bar 50 nm
- Figures 18A and 18B show the aggregation parameters of NP-3 at different NaCl concentration ( Figure 18A) and pH ( Figure 18B).
- Figure 20 shows a TEM micrograph of NP-3 incubated with reconstituted type I collagen fibers at 4O 0 C.
- FIG 21 is a schematic diagram showing the general approach used for collagen mimetic peptide (CMP) functionalized gold nanoparticle (NPs) use.
- CMP functionalized NPs are highly stable in aqueous solution and exhibit preferential affinity to the gap regions of intact type I collagen fibers.
- CMP functionalized NPs are used to identify structural abnormalities in collagen fibers that are related to many debilitating human diseases.
- FIG 22 is a schematic diagram showing a CMP/ poly(ethylene oxide) diacrylate (PEODA) hydrogel containing cells.
- the collagen secreted from the cell binds efficiently to the CMP present in the hydrogel matrix.
- Figure 23 A and 23B show the effects of CMP on collagen retention.
- Figure 23 A is a schematic diagram showing that cell-secreted collagen is more effectively retained by hydrogels that include CMP (right panel) than by hydrogels lacking CMP (left panel).
- Figure 24 is a fluorescence micrograph of chondrocytes encapsulated in 2% CMP/PEODA hydrogels after Live/Dead staining.
- Figure 25A-25F are micrographs of chondrocytes cultured in PEODA, 1% CMP/PEODA, and 2% CMP/PEODA matrices. Histological sections were evaluated after 2 weeks of culture. Safranine-0 staining for glycosaminoglycan ( Figure 25 A, 25B, and 25C) and Masson Trichrome staining for collagen ( Figure 25D, 26E, and 26F) were used.
- Figures 26A-26C are micrographs showing immunohistochemical staining of chondrocytes cultured in matrices containing PEODA control, 1 % CMP/PEODA, and 2% CMP/PEODA. Antibody for collagen type II was used. Controls showed no staining for antigen.
- Figure 28 provides a schematic diagram showing monoacrylated PEG-CMP.
- Monoacrylated PEG-CMP is polymerized with difunctional PEG to form a hydrogel.
- the invention features compositions comprising modified collagen and related therapeutic and diagnostic methods.
- the methods described herein provide for the physical modification of collagen.
- This invention is based, in part, on the discovery that collagen mimetic peptides (CMPs) of sequence -(Pro-Hyp-Gly) x - exhibited strong affinity for collagen.
- CMPs collagen mimetic peptides
- the invention provides for the modulation of the cell adhesion characteristics of collagen by contacting a poly(ethyleneglycol)-CMP conjugate with collagen.
- Collagen is the most abundant structural protein in the body, existing as the foremost component of the extracellular matrix (ECM). Most types of collagen contain a unique tertiary structure that includes three individual right-handed helical polypeptide chains intertwining to form a left-handed helix. Collagen has a characteristic amino acid composition comprised of GIy-X-Y repeat units, where 28% of the X positions consist of proline (Pro) and 38% of the Y positions consist of post-translationally modified 4- hydroxyproline residues (Hyp). The triple-helical structure can be denatured upon heating above its melting temperature 1 . Collagen mimetic peptides (CMPs) with GIy-X-Y sequences have been used to analyze collagen.
- CMPs Collagen mimetic peptides
- CMPs based on Pro-Pro-Gly and Pro-Hyp-Gly trimers have been widely studied, and their collagen-like triple helical structure and melting behaviors have been charaterized 2"8 .
- CMPs exhibit reversible melting behavior due to their small size. When denatured collagen is cooled, it regains only about 5- 10% of its original triple helical content, and the remainder turns into gelatin. In contrast, CMP regains almost 100% of its original triple helical structure after denaturation.
- Collagen is used in a variety of medical applications including hemostatic materials, biocompatible coatings, drug delivery and tissue engineering.
- Collagen-based biomaterials are also used in soft-tissue engineering and repair, hi the past two decades, a multitude of medical products composed of collagen have been approved by the FDA, and many are available as commercial products 9 , including collagen-based corneal shields, anti-infectious catheters, tissue sealants, hemostatic sponges, and topical wound dressing products.
- Collagen is also used as a tissue engineering substrate for skin 10 , bone 11 , and blood vessel replacement 12 .
- Collagen has typically been used as a scaffold to support tissue growth and promote healing or for the development of engineered tissues in organ replacement therapies. In virtually any application, wherever collagen is used, CMP modified collogen maybe substituted.
- Collagens are complex molecules that provide structure, strength, and elasticity (the ability to stretch) to connective tissue. Mutations in I, II, III, IX, X, and XI collagens are associated with a variety of human connective tissue disorders affecting bone, cartilage, and blood vessels. Ehlers-Danlos syndrome (EDS) is most often associated with a genetic defect in type I collagen that is characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. Osteogenesis imperfecta or "brittle bone disease" arises from mutations in two genes encoding type I collagen.
- EDS Ehlers-Danlos syndrome
- OI osteogenesis imperfecta
- Type II and type XI collagens are components of the cartilage found in joints and the spinal column, the inner ear, and the vitreous humor of the eye.
- the type II and XI collagenopathies include achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweym ⁇ ller.
- the clinical features of the type II and XI collagenopathies typically include problems with bone development that results in short stature, enlarged joints, spinal curvature, and juvenile arthritis. Problems with vision and hearing, as well as a cleft palate with a small lower jaw, are common.
- compositions of the invention can be used to visualize the structure of collagen by binding a collagen mimetic peptide conjugate to collagen present in a patient sample.
- compositions of the invention are used for the diagnosis of a disease or disorder characterized by an alteration in the structure of collagen.
- a nanoparticle having a collagen mimetic peptide, or collagen mimetic peptide conjugate is used as a diagnostic. Such nanoparticles are used to examine the structure of collagen in biological samples derived from patients suspected of having a connective tissue disorder related to the disruption of collagen.
- the collagen mimetic peptide allows for the physical association of the nanoparticle with a collagen (e.g., type 1-29) present in the tissue sample.
- a collagen e.g., type 1-29
- the tissue sample is then analysed using a transmission electron microscopy. Under transmission electron microscopy, collagen fibers exhibit characteristic banding patterns.
- CMP-NPS bind to defined locations within the collagen fiber. This binding pattern provides an indication of the structural integrity of the collagen molecules and their assembly. Alterations in the structural integrity can be visualized with CMP-NP and correlated with particular connective tissue disease states. Thus, CMP-NP are useful as diagnostics for the identification of alterations in collagen types 1-29.
- compositions of the invention are used to identify the presence of a thrombosis comprising collagen in a vessel or to identify vessels having an increased risk of having a thrombosis. Vessels that have been subjected to angioplasty are particularly prone to the formation of a thrombosis.
- Collagen mimetic peptides may be conjugated to a variety of agents using methods known in the art and described herein. Typically, this conjugation is mediated by a covalent bond.
- Suitable agents include therapeutic and diagnostic agents. Such agents include, but are not limited to, antibiotics, anti-thrombotics, cell adhesion molecules, components of the extracellular matrix, contrast reagents, detectable labels, growth factors, polymers, PEG, and small compounds having biological activity.
- Antimicrobial agents include antibacterials, antifungals, and antivirals.
- Exemplary antibiotics include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin, and erythromycin), the fluoroquinolones (e.g., ciprofloxaci).
- a penicillin-CMP antibiotic has the following structure:
- a tetracycline-CMP antibiotic has the following structure:
- the antimicrobial is a plectasin-CMP or an LAH4-CMP having the following sequences, respectively:
- Antiviral agents are substances capable of inhibiting the replication of viruses.
- anti-viral agents include l,-D-ribofuranosyl-l,2,4-triazole-3 carboxamide, 9-2- hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine arabinoside, protease inhibitors, thymidine kinase inhibitors, sugar or glycoprotein synthesis inhibitors, structural protein synthesis inhibitors, attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, and ganciclovir.
- Antifungal agents include both fungicidal and fungistatic agents such as, for example, benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazoles, allylamine, thicarbamates, amphotericin B, butylparaben, clindamycin, econaxole, fluconazole, flucytosine, griseofulvin, nystatin, and ketoconazole.
- fungicidal and fungistatic agents such as, for example, benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazoles, allylamine, thicarbamates, amphotericin B, butylparaben, clindamycin, econaxole, fluconazole, flucytosine, griseofulvin, nystatin, and ketoconazole.
- a CMP conjugate is used for the treatment of atherosclerosis.
- a CMP is conjugated, for example to an anti-platelet medication (e.g., aspirin), anti-coagulants (e.g., as heparin, warfarin, aspirin, ticlopidine, and clopidogrel) or inhibitors of platelet clumping.
- anti-platelet medication e.g., aspirin
- anti-coagulants e.g., as heparin, warfarin, aspirin, ticlopidine, and clopidogrel
- Other atherosclerosis therapeutics include, but are not limited to, cholestyramine, colestipol, nicotinic acid, gemfibrozil, probucol, atorvastatin, lovastatin.
- the collagen mimetic peptides are also useful for the delivery of compounds having anti-thrombotic activity.
- Such compounds include heparin, hirudin, ReoProTM,Streptokinase, urokinase, and tissue plasminogen activator (t-PA).
- Other drugs include recombinant, or genetically engineered, t-PA (a newer version of t-PA) and TNK (Tenecteplase) or other antithrombotic compounds.
- the anti-thrombotic is PEG-CMP having the following structure:
- the anti-thrombotic is a saratin-CMP or a hirudin CMP conjugate having the following sequences, respectively:
- Hirudin-CMP (anti-platelet) LTYTDC(6)TESGQNLC(14)LC(16)EGSNVC(22)GQGNKC(28)ILGSDGEKNQC(39)VTG EGTPKPQSHNDGDFEEIPEEY(SCe)LQ-K-(CMP) 2 .
- Cell adhesion molecules suitable for CMP conjugation include components of the extracellular matrix that promote cell spreading or extension or fragments thereof.
- fragments of a cell adhesion molecule include the adhesion molecule binding domaing.
- binding domains include consensus sequences that mediate cell-cell interactions, including the RGD peptide.
- Integrins bind the RGD motif in cell attachment proteins (See, for example, Tosatti et al., J Biomed Mater Res. 68(3):458-72, 2004; and Reyes et al., J Biomed Mater Res 69:591-600, 2004, which are hereby incorporated by reference).
- Such molecules may be conjugated to a collagen mimetic peptide of the invention for use in the therapeutic compositions described herein.
- Exemplary cell adhesion molecules include cadherin (e.g., E-cadherin, N-cadherin), cell adhesion molecule (CAM) (e.g., vascular cell adhesion molecule (VCAM)-I and intracellular adhesion molecule (ICAM)-I neuronal cell adhesion molecule), fibronectin, integrin (e.g., ⁇ -integrin), laminin, and selectin.
- cadherin e.g., E-cadherin, N-cadherin
- CAM cell adhesion molecule
- VCAM vascular cell adhesion molecule
- IAM intracellular adhesion molecule
- fibronectin e.g., integrin, ⁇ -integrin
- laminin e.g., laminin, and selectin.
- Growth factors are typically polypeptides or fragments thereof that support the survival, growth, or differentiation of a cell.
- a collagen mimetic peptide described herein can be conjugated to virtually any growth factor known in the art.
- growth factors include angiopoietin, acidic fibroblast growth factors (aFGF) (GenBank Accession No. NP_149127) and basic FGF (GenBank Accession No. AAA52448), bone morphogenic protein (GenBank Accession No. BAD92827), vascular endothelial growth factor (VEGF) (GenBank Accession No. AAA35789 or NP_001020539), epidermal growth factor (EGF)(GenBank Accession No.
- aFGF acidic fibroblast growth factors
- VEGF vascular endothelial growth factor
- EGF epidermal growth factor
- NP_001954 transforming growth factor ⁇ (TGF- ⁇ ) (GenBank Accession No. NP_003227) and transforming growth factor ⁇ (TFG- ⁇ ) (GenBank Accession No. 1109243 A), platelet-derived endothelial cell growth factor (PD- ECGF)(GenBank Accession No. NPJ)Ol 944), platelet-derived growth factor (PDGF)( GenBank Accession No. 1109245 A), tumor necrosis factor ⁇ (TNF-cc)(GenBank Accession No. CAA26669), hepatocyte growth factor (HGF)(GenBank Accession No. BAA14348), insulin like growth factor (IGF)(GenBank Accession No.
- erythropoietin GenBank Accession No. POl 588
- colony stimulating factor CSF
- macrophage-CSF M- CSF
- GM-CSF granulocyte/macrophage CSF
- NOS nitric oxide synthase
- a CMP is conjugated to a component of the extracellular matrix (ECM).
- ECM components include structural proteins, such as collagen and elastin; proteins having specialized functions, such as fibrillin, f ⁇ bronectin, and laminin; and proteoglycans that include long chains of repeating disaccharide units termed of glycosaminoglycans (e.g., hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, aggrecan).
- glycosaminoglycans e.g., hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, aggrecan).
- a CMP is conjugated to an anti-inflammatory agent.
- anti-inflammatory agents include, but are not limited to, Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinaf ⁇ de; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Pot
- a CMP is conjugated to an agent having diagnostic applications.
- agents include contrast reagents and detectable labels.
- Magnetic resonance imaging is typically used for diagnostic purposes to visualized diseased organs or tissues.
- the utility of MRI is hampered by poor image quality.
- Collagen mimetic peptides can be conjugated to conventional MRI contrast reagents and then introduced to a desired tissue or tissue sample where the collagen-contrast reagent conjugate binds to collagens present in the tissue to enhance MRI image quality.
- Exemplary contrast reagents include gadolinium complex, gadodiamide derivative, ferric ammonium citrate, and mangafodipar trisodium.
- Detectable labels include compositions that when linked to a collagen mimetic peptide render the peptide detectable via spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
- Exemplary detectable labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, and haptens.
- a matrix is a substance that fills the spaces between isolated cells in culture.
- a matrix is an adhesive substrate used to coat a glass or plastic surface prior to cell culture.
- cells are embedded in a matrix, or injected into a matrix already implanted at a desired site.
- a matrix provides a physical support and an adhesive substrate for isolated cells during in vitro culturing and subsequent implantation.
- Preferred polymers for use in a matrix have mechanical and biochemical properties that enhance the viability and proliferation of transplanted cells, tissues, or organs.
- the matrix configuration is dependent on the tissue that is to be treated, repaired, or produced, but desirably, the matrix is a pliable, biocompatible, porous template that allows for cell and/or vascular growth.
- Preferred polymers for use in the methods of the invention include poly( ethylene glycol) (PEG), star shaped PEG, grafted linear PEG, poly(ethylene oxide) diacrylate (PEODA), polyacrylic acid, poly vinyl alcohol, collagen gels, poly (D, L-lactide-co-glycolide (PLGA) fiber matrices, polyglactin fibers, calcium alginate gels, polyglycolic acid (PGA) meshes, and other polyesters, such as poly- (L-lactic acid) (PLLA) and polyanhydrides.
- Matrices can include materials that are non-biodegradable or biodegradable. Desirably, biodegradable materials will degrade over a time period of less than a year, more preferably less than six months.
- a collagen mimetic peptide is conjugated to a polymer capable of forming a hydrogel.
- a hydrogel is formed when an organic polymer (natural or synthetic) is cross- linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure that entraps water molecules to form a gel.
- materials that can be used to form a hydrogel include poly(ethylene glycol), polysaccharides (e.g., alginate), polyphosphazenes, and polyacrylates (e.g., hydroxyethyl methacrylate).
- proteins e.g., fibrin, collagen, fibronectin
- polymers e.g., polyvinylpyrrolidone
- hyaluronic acid e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
- Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used.
- acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH groups.
- polymers with basic side groups that can be reacted with anions are poly (vinyl amines), poly (vinyl pyridine), poly (vinyl imidazole), and some imino substituted polyphosphazenes.
- the ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups.
- basic side groups are amino and imino groups.
- Alginate can be ionically cross-linked with divalent cations in water at room temperature to form a hydrogel matrix. Additional methods for the synthesis of the other polymers described above are known to those skilled in the art (see, for example, Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, E. Goethals, editor, Pergamen Press, Elmsford, NY 1980). Many polymers, such as poly (acrylic acid), are commercially available.
- a synthetic polymer capable of forming a matrix is used.
- synthetic polymers are preferred for reproducibility and controlled release kinetics.
- Synthetic polymers that can be used include biodegradable polymers, such as poly(lactide), poly(glycolic acid), poly(lactide-co-glycolide), poly (caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly (vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, Teflon and nylon.
- One preferred non-degradable material for implantation of a matrix is a polyvinyl alcohol sponge, or alkylation or acylation derivatives thereof (e. g., ester derivatives), including esters.
- the invention provides a simple means for delivering biologically active compounds (including nucleic acids, peptides, small molecule inhibitors, and mimetics) conjugated to a collagen mimetic peptide (CMP).
- CMP collagen mimetic peptide
- the CMP conjugate is incorporated into a polymer matrix containing natural or synthetic polymers.
- the CMP conjugate is incorporated in a collagen matrix.
- the collagen matrix comprising the CMP conjugate is delivered to a subject and the CMP conjugate is released from the collagen matrix.
- the CMP conjugate is capable of acting as a therapeutic for the treatment of a disease or disorder that requires controlled and/or localized drug delivery over some period of time (e.g., 1, 3, 5, 7 days; 2, 3, 4 weeks; 1, 2, 3, 6, 12 months).
- a biologic agent conjugated to a collagen mimetic peptide and found to have medicinal value using the methods described herein is useful as a drug or as information for structural modification of existing compounds, e.g., by rational drug design.
- the conjugates include antibiotics (e.g., penicillin, tetracycline, plectasin, LAH4), cell adhesion molecules (e.g., cadherin, fibronectin, integrin, laminin, selectin), growth factors that promote angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, or cell survival (e.g., angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, and platelet-derived growth factor), or small molecules, such as antithrombotics (e.g., heparin-CMP, Hirud
- the polymers including the collagen mimetic peptide conjugates are administered either as liquids or solids. Where the polymers are administered as a liquid, they are typically converted to a solid in vivo by cross-linking. Such crosslinking may be accomplished using any method known in the art, such as photopolymerization.
- collagen mimetic peptide conjugates are incorporated into hydrogel- forming polymeric materials that are useful as drug delivery devices.
- Hydrogel-forming polymers are polymers that are capable of absorbing a substantial amount of water to form elastic or inelastic gels. Medical devices incorporating hydrogel-forming polymers are capable of being implanted in liquid or gelled form. Once implanted, the hydrogel forming polymer absorbs water and swells. The release of a pharmacologically active agent incorporated into the device using a collagen mimetic peptide takes place through this gelled matrix via a diffusion mechanism.
- Many hydrogels, although biocompatible, are not biodegradable or are not capable of being remodeled and incorporated into a host tissue.
- compositions or agents identified using the methods disclosed herein may be administered systemically.
- a matrix comprising a CMP conjegate is formulated in a pharmaceutically-acceptable buffer such as physiological saline.
- routes of administration include, for example, subcutaneous, intravenous, interperitoneally, intramuscular, or intradermal injections that provide continuous, sustained levels of the drug in the subject.
- Treatment of subjects e.g., human patients or other animals
- a therapeutically effective amount of a CMP therapeutic conjugate in a physiologically-acceptable carrier such as a collagen matrix that includes the CMP therapeutic conjugate.
- Suitable carriers and their formulation are described, for example, in Remington's Pharmaceutical Sciences by E. W. Martin.
- the amount of the therapeutic agent to be administered varies depending upon the manner of administration, the age and body weight of the subject, and with the clinical symptoms of the subject. Generally, amounts will be in the range of those used for other agents used in the treatment of similar diseases (e.g., thrombosis, atherosclerosis).
- a compound is administered at a dosage that controls the clinical or physiological symptoms of the disease as determined by a diagnostic method known to one skilled in the art.
- the administration of a compound for the treatment of a disease may be by any suitable means that results in a concentration of the therapeutic that, combined with other components, is effective in ameliorating, reducing, or stabilizing the disease.
- the compound may be contained in any appropriate amount in a any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition.
- the composition may be provided in a dosage form that is suitable for parenteral (e.g., subcutaneously, intravenously, intramuscularly, or intraperitoneally) administration route.
- the pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
- compositions according to the invention may be formulated to release the active compound substantially immediately upon administration or at any predetermined time or time period after administration.
- controlled release formulations which include (i) formulations that create a substantially constant concentration of the drug within the body over an extended period of time; (ii) formulations that after a predetermined lag time create a substantially constant concentration of the drug within the body over an extended period of time; (iii) formulations that sustain action during a predetermined time period by maintaining a relatively, constant, effective level in the body with concomitant minimization of undesirable side effects associated with fluctuations in the plasma level of the active substance (sawtooth kinetic pattern); (iv) formulations that localize action by, e.g., spatial placement of a controlled release composition adjacent to or in proximity to the tissue or organ that requires treatment; (v) formulations that allow for convenient dosing, such that doses are administered, for example, once every one or two weeks; and (vi) formulations that target an disease by using carriers or chemical derivatives
- controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings.
- the therapeutic is formulated with appropriate excipients into a pharmaceutical composition that, upon administration, releases the therapeutic in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes that include the CMP therapeutic conjugate.
- a polymer comprising the CMP therapeutic conjugate is delivered to the subject identified as in need of such treatment.
- a large number of polymers can be used to construct the delivery devices of the present invention. The only requirements are that they are inert, non-immunogenic and of the desired permeability.
- the rate of passage of the drug through the material by diffusion is generally dependent on the solubility of the drug therein, as well as on the thickness of the wall. This means that selection of appropriate materials for fabricating the wall will be dependent on the particular drug to be used.
- the rate of diffusion of the effective agent through a polymeric layer(s) of the present invention may be determined via diffusion studies using, for example, a CMP therapeutic conjugate comprising a detectable label as described herein.
- the CMP therapeutic conjugate is contained within a collagen matrix, such that the CMP therapeutic conjugate physically associates with the collagen.
- the drug delivery devices of the invention may be made in a wide variety of ways, such as by obtaining an effective amount of a CMP therapeutic conjugate in a collagen matrix and compressing the matrix to a desired shape. Once shaped, one or more coating layers is applied. Such coatings are used to delay release of the CMP therapeutic conjugate.
- the drug delivery system of the invention is administered to subject via any route of administration known in the art. Such routes of administration include intraocular, oral, subcutaneous, intramuscular, intraperitoneal, intranasal, dermal, and the like.
- the drug delivery system of the invention is particularly suitable for direct implantation.
- Controlled release delivery systems include those systems capable of site specific delivery, extended release, sustained release, delayed release, repeat action, prolonged release, bimodal release, pulsitile release, modified delivery, pH sensitive delivery, and/or target specific delivery, among others.
- the system may include agents added to aid in gastric bypass or to modify the release profile due to pH-specif ⁇ c swelling characteristics or site- specific enzyme degradation within the gastrointestinal tract.
- agents may include, but are not limited to, at least one of alginate, polysaccharides such as such as gelatin or collagen, guar gum, xanthan gum, pectin, heterogeneous protein mixtures, and polypeptides.
- the polysaccharides may be pectin and/or an alginate salt, among others.
- the galactomannan gums may be guar gum, xanthan gum and/or locust bean gum, among others.
- the polyethylene derivatives may be polyethylene oxide (PEO) and/or polyethylene glycol (PEG), among others.
- the hydrolyzed proteins may be gelatin and/or collagen, among others.
- Release of the CMP conjugate into the surrounding environment may be accomplished through a rate-controlled hydration and subsequent swelling of hydrophilic agents.
- the release of the CMP conjugate is determined by the erosion rate and polymeric disentanglement of the swollen hydrophilic matrix.
- the swelling of the hydrophilic matrix allows for a highly reproducible, programmable release pattern.
- the programmability of the system allows for nearly any physiologically relevant release pattern to be accomplished.
- Formulation specific to the physical characteristics of a CMP therapeutic conjugate and the desired release profile can be accomplished through both theoretical and empirical means, allowing dissolution of the system and CMP therapeutic conjugate release to occur in a specific physiologic region.
- the pharmaceutical composition may be administered parenterally by injection, infusion or implantation (subcutaneous, intravenous, intramuscular, intraperitoneal, or the like) in dosage forms, formulations, or via suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants.
- injection, infusion or implantation subcutaneous, intravenous, intramuscular, intraperitoneal, or the like
- suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants.
- compositions for parenteral use may be provided in unit dosage forms (e.g., in single- dose ampoules), or in vials containing several doses and in which a suitable preservative may be added (see below).
- the composition may be in the form of a solution, a suspension, an emulsion, an infusion device, or a delivery device for implantation, or it may be presented as a dry powder to be reconstituted with water or another suitable vehicle before use.
- the composition may include suitable parenterally acceptable carriers and/or excipients.
- the active inflammatory bowel disorder therapeutic (s) may be incorporated into microspheres, microcapsules, nanoparticles, liposomes, or the like for controlled release.
- the composition may include suspending, solubilizing, stabilizing, pH-adjusting agents, tonicity adjusting agents, and/or dispersing, agents.
- the pharmaceutical compositions according to the invention may be in the form suitable for sterile injection.
- the suitable active CMP therapeutic conjugate(s) are dissolved or suspended in a parenterally acceptable liquid vehicle.
- acceptable vehicles and solvents that may be employed are water, water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution and dextrose solution.
- the aqueous formulation may also contain one or more preservatives (e.g., methyl, ethyl or n-propyl p-hydroxybenzoate).
- a dissolution enhancing or solubilizing agent can be added, or the solvent may include 10-60% w/w of propylene glycol or the like.
- Controlled release parenteral compositions may be in form of aqueous suspensions, microspheres, microcapsules, magnetic microspheres, oil solutions, oil suspensions, or emulsions.
- the active drug may be incorporated in biocompatible carriers, liposomes, nanoparticles, implants, or infusion devices.
- Biodegradable/bioerodible polymers such as polygalactia poly-(isobutyl cyanoacrylate), poly(2-hydroxyethyl-L-glutam- nine) and, poly(lactic acid).
- Biocompatible carriers that may be used when formulating a controlled release parenteral formulation are carbohydrates (e.g., dextrans), proteins (e.g., albumin), lipoproteins, or antibodies.
- Materials for use in implants can be non-biodegradable (e.g., polydimethyl siloxane) or biodegradable (e.g., poly(caprolactone), poly(lactic acid), poly(glycolic acid) or poly(ortho esters) or combinations thereof).
- biodegradable e.g., poly(caprolactone), poly(lactic acid), poly(glycolic acid) or poly(ortho esters) or combinations thereof.
- Formulations for oral use include tablets containing the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients.
- Excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates, or alginic acid); binding agents (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, carboxymethylcellulose sodium, methylcellulose, hydroxypropyl methyl
- the tablets may be uncoated or they may be coated by known techniques, optionally to delay disintegration and absorption in the gastrointestinal tract and thereby providing a sustained action over a longer period.
- the coating may be adapted to release the active drug in a predetermined pattern (e.g., in order to achieve a controlled release formulation) or it may be adapted not to release the active drug until after passage of the stomach (enteric coating).
- the coating may be a sugar coating, a film coating (e.g., based on hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, acrylate copolymers, polyethylene glycols and/or polyvinylpyrrolidone), or an enteric coating (e.g., based on methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and/or ethylcellulose).
- a time delay material such as, e.g., glyceryl monostearate or glyceryl distearate may be employed.
- the solid tablet compositions may include a coating adapted to protect the composition from unwanted chemical changes, (e.g., chemical degradation prior to the release of the active active inflammatory bowel disease therapeutic substance).
- the coating may be applied on the solid dosage form in a similar manner as that described in Encyclopedia of Pharmaceutical Technology, supra.
- At least two active therapeutics may be mixed together in the tablet, or may be partitioned.
- the first active therapeutic is contained on the inside of the tablet, and the second active therapeutic is on the outside, such that a substantial portion of the second therapeutic is released prior to the release of the first active therapeutic.
- Formulations for oral use may also be presented as chewable tablets, or as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example, peanut oil, liquid paraffin, or olive oil.
- Powders and granulates may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g., a mixer, a fluid bed apparatus or a spray drying equipment.
- Controlled release compositions for oral use may, e.g., be constructed to release the active therapeutic by controlling the dissolution and/or the diffusion of the active substance.
- Dissolution or diffusion controlled release can be achieved by appropriate coating of a tablet, capsule, pellet, or granulate formulation of compounds, or by incorporating the compound into an appropriate matrix.
- a controlled release coating may include one or more of the coating substances mentioned above and/or, e.g., shellac, beeswax, glycowax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glycerol palmitostearate, ethylcellulose, acrylic resins, dl-polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinyl pyrrolidone, polyethylene, polymethacrylate, methylmethacrylate, 2-hydroxymethacrylate, methacrylate hydrogels, 1,3 butylene glycol, ethylene glycol methacrylate, and/or polyethylene glycols.
- shellac beeswax, glycowax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glyce
- the matrix material may also include, e.g., hydrated metylcellulose, carnauba wax and stearyl alcohol, carbopol 934, silicone, glyceryl tristearate, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene, and/or halogenated fluorocarbon.
- a controlled release composition containing one or more therapeutic compounds may also be in the form of a buoyant tablet or capsule (i.e., a tablet or capsule that, upon oral administration, floats on top of the gastric content for a certain period of time).
- a buoyant tablet formulation of the compound(s) can be prepared by granulating a mixture of the compound(s) with excipients and 20-75% w/w of hydrocolloids, such as hydroxyethylcellulose, hydroxypropylcellulose, or hydroxypropylmethylcellulose. The obtained granules can then be compressed into tablets. On contact with the gastric juice, the tablet forms a substantially water-impermeable gel barrier around its surface. This gel barrier takes part in maintaining a density of less than one, thereby allowing the tablet to remain buoyant in the gastric juice.
- a CMP conjugate may be included in a coating material that is used to coat a medical device (e.g., drug delivery or other medical device).
- a coating material that is used to coat a medical device (e.g., drug delivery or other medical device).
- Such coatings are used, for example, for altering the adehesive properties of the device or for drug delivery.
- a polymeric coating such as collagen, polyethylene glycol, polyurethane, polytetrafluoroethylene, polyalkylmethacrylates, polyarylmethacrylates, poly(ethylene-co-vinyl acetate), or any other polymer or combination of polymers, may be combined with a CMP of the present invention, such that the CMP is fixed to or physically associates with the polymer, and the CMP conjugate polymer combination is applied to a medical device.
- the CMP conjugate thereby modulates the cell adhesive properties of the medical device or provides for release of a therapeutic from the device.
- Such coatings can be applied to any medical device known in the art, including, but not limited to, drug-delivering vascular stents (e.g., a balloon-expanded stents); other vascular devices (e.g., grafts, catheters, valves, artificial hearts, heart assist devices); implantable defibrillators; blood oxygenator devices (e.g., tubing, membranes); surgical devices (e.g., sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds); membranes; cell culture devices; chromatographic support materials; biosensors; shunts for hydrocephalus; wound management devices; endoscopic devices; infection control devices; orthopedic devices (e.g., for joint implants, fracture repairs); dental
- intraocular coils/screws glaucoma drain shunts
- synthetic prostheses e.g., breast
- intraocular lenses respiratory, peripheral cardiovascular, spinal, neurological, dental, ear/nose/throat (e.g., ear drainage tubes); renal devices; and dialysis (e.g., tubing, membranes, grafts), urinary catheters, intravenous catheters, small diameter grafts, vascular grafts, artificial lung catheters, atrial septal defect closures, electro-stimulation leads for cardiac rhythm management (e.g., pacer leads), glucose sensors (long-term and short-term), degradable coronary stents (e.g., degradable, non- degradable, peripheral), blood pressure and stent graft catheters, birth control devices, prostate cancer implants, bone repair/augmentation devices, breast implants, cartilage repair devices, dental implants, implanted drug infusion tubes, intravitreal drug delivery devices, nerve regeneration conduits, oncological implants, electrostimulation
- vena cava filters examples include, but are not limited to, vena cava filters, urinary dialators, endoscopic surgical tissue extractors, atherectomy catheters, clot extraction catheters, coronary guidewires, drug infusion catheters, esophageal stents, circulatory support systems, angiographic catheters, coronary and peripheral guidewires, hemodialysis catheters, neurovascular balloon catheters, tympanostomy vent tubes, cerebrospinal fluid shunts, defibrillator leads, percutaneous closure devices, drainage tubes, thoracic cavity suction drainage catheters, electrophysiology catheters, stroke therapy catheters, abscess drainage catheters, biliary drainage products, dialysis catheters, central venous access catheters, and parental feeding catheters.
- vena cava filters examples include, but are not limited to, vena cava filters, urinary dialators, endoscopic surgical tissue extractors, atherectomy catheters, clot extraction catheters, coronary guidewires
- medical devices suitable for the present invention include, but are not limited to implantable vascular access ports, blood storage bags, blood tubing, central venous catheters, arterial catheters, vascular grafts, intraaortic balloon pumps, cardiovascular sutures, total artificial hearts and ventricular assist pumps, extracorporeal devices such as blood oxygenators, blood filters, hemodialysis units, hemoperfusion units, plasmapheresis units, and artificial organs. It is noted that in other embodiments of the present invention, the CMP conjugates of the present invention may also be adhered to the medical device by means other than coating materials, such as adhesives or compression.
- a polymeric solution is applied to the surface of a device, and a CMP conjugate is applied subsequently.
- the polymeric solution comprising the CMP is allowed to dry, cure and/or polymerize thereby fixing the CMP conjugate to the polymeric material coating.
- the CMP is allowed to associate with the polymer prior to, during or following application of the CMP polymer conjugate to the device.
- the CMP conjugate includes a therapeutic agent suitable for delivery from a CMP polymer coating.
- the CMP conjugate may be administered to the surface by press rolling the polymer coated surface in the CMP conjugate, spraying the CMP conjugate onto the device, or gently heating (e.g., below the transition melting temperature) the polymer coating in the presence of a CMP conjugate, such that the heating facilitates the incorporation of the CMP conjugate into the polymer.
- heating is to a temperature sufficient to denature the CMP.
- the polymeric materials with biocompatible surfaces may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, including drug delivery patches, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices, including protein matrix suture material and meshes, skin/bone/tissue grafts, adhesion prevention barriers, cell scaffolding, medical device coatings/films and other biocompatible implants.
- drug delivery devices for the controlled release of pharmacologically active agents including drug delivery patches, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices, including protein matrix suture material and meshes, skin/bone/tissue grafts, adhesion prevention barriers, cell scaffolding, medical device coatings/films and other biocompatible implants.
- the present invention also provides wound healing compositions that utilize a polymeric material comprising a CMP conjugate.
- the wound healing devices may be configured by fixing a CMP conjugate to a polymer (e.g., a collagen film or PEODA) and forming the CMP conjugate containing polymer into a shape and size sufficient to accommodate the wound being treated.
- a polymer e.g., a collagen film or PEODA
- Such wound healing devices are desirably produced in whatever shape and size is necessary to provide optimum treatment to the wound.
- These devices can be produced in forms that include, but are not limited to, plugs, meshes, strips, sutures, or any other form able to accommodate and assist in the repair of a wound.
- the damaged portions of the patient that may be treated with a devices made of the particles of the present invention include, but are not limited to, skin, tissue (nerve, muscle, cartilage, brain, spinal cord, heart, lung, etc.) and bone. Other similar devices are administered to assist in the treatment repair and remodeling of a damaged tissue, bone, or cartilage.
- the wound healing device comprises a matrix containing one or more cells. For some applications, it is desirable for the device to be incorporated into an existing tissue to facilitate wound repair. For other applications, it is desirable for the device to degrade over the course of days, weeks, or months.
- the CMP is conjugated to a therapeutic agents and the CMP conjugate is delivered to a wound using a polymeric material to form a delivery system.
- the polymer contains an effective amount of a CMP conjugate that includes a dosage of the chemical or pharmaceutically active component.
- An adhesive or other adhering means may be applied to the outer edges of the polymeric material to hold the patch in position during the delivery of the chemical or pharmaceutically active component.
- wound-healing devices configured and produced as polymeric material biological fasteners, such as threads, sutures and woven sheets. Threads and sutures comprising various embodiments of the polymeric material provide a biocompatible fastening and suturing function for temporarily treating and sealing an open wound.
- the biological fasteners may include pharmacologically active agents that may assist in the healing and remodeling of the tissue within and around the wound.
- the CMP conjugate is administered directly to an injured area.
- the CMP conjugate is administered by sprinkling, packing, implanting, inserting or applying or by any other administration means to open wounds on the body.
- the invention further provides hemostatic matrices (e.g., hemostatic sponges) that contain a polymer, such as collagen, and a CMP or CMP conjugate capable of absorbing bodily fluids (e.g. blood).
- hemostatic matrices e.g., hemostatic sponges
- Such matrices generally comprise porous compositions formed from a suitable biocompatible matrix.
- suitable biocompatible matrix materials include naturally-occurring polymers, such as collagen, and/or synthetic polymers.
- sponge matrices can be formed by providing a liquid solution or suspension of a matrix- forming material, and causing the material to form a porous three-dimensionally stable structure.
- a collagen solution is prepared.
- Collagen is derived from a natural source (e.g., bovine, porcine, human) or is synthetically-derived.
- the collagen is typically digested to form a collagen solution. Such digestion is usually carried out under acidic conditions. Optionally, enzymatic digestion may be utilized using known enzymes for this purpose such as pepsin, trypsin, and/or papain. After digestion, the enzymes are removed using standard methods. Additional information relating to collagenous matrix materials and their preparation, is described in U.S. Patent Nos. 4,511,653, 4,902,508, 4,956,178, 5,554,389, and 6,099,567, and International Publication Nos. WO9825637 and WO9822158, each of which is hereby incorporated herein by reference in its entirety.
- a CMP or CMP conjugate is incubated with the collagen prior to, during, or after polymerization, such that the CMP or CMP conjugate is incorporated into the collagen.
- This incubation is typically carried out at a temperature that is above the melting point of the CMP as determined using methods described herein.
- the collagen solution is heated gently (e.g., at or below the transition melting temperature of the CMP) to destabilize the collagen and to facilitate incorporation of the CMP.
- the heating is below the level required to denature the collagen.
- the resulting collagen solution is crosslinked. Such crosslinking may be achieved using CMPs.
- crosslinking agents such as glutaraldehyde, formaldehyde, carbodiimides, UV irradiation, or other crosslinking agents.
- a polyepoxide crosslinker is used, such as polyglycidyl ether (e.g., ethylene glycol diglycidyl ether).
- polyglycidyl ethers or polyepoxide compounds impart polar groups and a hydrophilic character to the resulting matrix.
- the resulting matrix is wettable and provides for rapid hydration and expansion.
- Sponge matrix materials of the invention will advantageously be highly expandable when wetted.
- the sponge has the capacity to expand at least 100%, 200%, 300%, 500%, or 1000% by volume when wetted to saturation with deionized water.
- Preferred sponge materials achieve rapid volume expansions (e.g., maximum expansion in less than 10 seconds or 5 seconds, when immersed in deionized water) Hemostatic sponges are produced in any size required for application to a wound.
- the expanded sponge exerts compression on surrounding tissues when implanted or delivers an active agent to the implantation site and surrounding tissue.
- Compact, dense sponge matrices of the invention are prepared by first hydrating a porous sponge matrix, and then compressing and drying the matrix. Drying will be conducted to reduce the liquid (e.g. water) content of the matrix to less than about 5%, 10%, or 20% by weight.
- the sponge matrix is stabilized structurally and remains in a highly dense and compacted state until contacted with a liquid susceptible to absorption by the matrix, for example body fluids.
- the pores of the matrix are thereby stably retained at a volume substantially reduced from their maximum volume, but return to a partially or fully expanded state when the matrix material is wetted.
- the compacted or compressed sponge is sterilized using any suitable means (e.g., radiation).
- the device is packaged in sterile packaging for medical use.
- Sponge elements or other devices of the invention may also contain one or more active therapeutic agents.
- they include agents that promote clotting (e.g., thrombin and/or fibrinogen).
- sponge elements or other devices of the invention include growth factors that promote tissue growth and healing.
- Polymeric matrices that comprise a collagen mimetic peptide are useful for supporting the survival of a variety of cell types including, but not limited to, endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, or chondrocytes.
- These cell-types may be introduced prior to, during, or after gelation. This introduction may take place in vitro or in vivo. When the cells are introduced in vivo, the introduction may be at the site where implantation is desired or at a location removed from that site. Exemplary routes of administration of the cells include injection (e.g., by catheter) and surgical implantation.
- a polymeric matrix comprising a collagen mimetic peptide can be filled with cells from virtually any organ. Because many cell- types can be expanded in vitro, grafts can be made using a limited number of cells (e. g. , 100,500, 1000,10, 000,100, 000,1, 000,000, 10,000, 000, or 100,000, 000), which represent a small percentage (e. g. , 0.0001%, 0.001%, 0.005%, 0.01%, 0.05%, 0.10%, 1.0%, 2.0%, or 5.0%) of the cells present in a naturally-occurring tissue or organ. Exemplary cells for organogenesis include, hepatocytes, myocytes (e. g.
- cardiac or skeletal muscle myocytes cardiac or skeletal muscle myocytes
- keratinocytes osteocytes
- chondrocytes islet cells
- nerve cells astrocytes
- glial cells from the central or peripheral nervous system
- preadipocytes derived from fat or breast tissue preadipocytes derived from fat or breast tissue
- adipocytes derived from fat or breast tissue.
- Such cells might be obtained from the intended implant recipient (an autograft), from a donor (allogeneic graft), or from a cell line.
- autografts One particular advantage of autografts is that the grafted tissue does not induce an immune response because the grafted cells are recognized as self (Heath etal., Trends Biotechnol, 18 : 17-19,2000).
- such cells are obtained from a mammal of a different species (e. g., pig or primate).
- the implanted cells may be derived from the recipient's own tissue, derived from a different individual of the same species, or derived from a mammalian species that is different from the recipient (e. g. , pig or primate).
- Cells can be isolated from a number of sources, for example, from biopsies or autopsies using standard methods.
- the isolated cells are preferably autologous cells obtained by biopsy from the subject.
- the cells from a biopsy can be expanded in culture. Cells from relatives or other donors of the same species can also be used with appropriate immunosuppression. Methods for the isolation and culture of cells are discussed in Fauza et al. (J. Ped. Surg. 33,7- 12,1998).
- a selected tissue or organ can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage.
- Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with digestive enzymes (e. g. , trypsin, chymotrypsin, collagenase, elastase, hyaluronidase, DNase, pronase, and dispase).
- digestive enzymes e. g. , trypsin, chymotrypsin, collagenase, elastase, hyaluronidase, DNase, pronase, and dispase.
- tissue disruption can be accomplished by scraping the surface of the organ, the use of grinders, blenders, sieves, homogenizers, pressure cells, or sonicators.
- tissue disruption techniques see Freshney, (Culture of Animal Cells. A Manual of Basic Technique, 2d Ed. , A. R. Liss, Inc. , New York, Ch. 9, pp. 107-126, 1987)
- Preferred cell types include, without limitation, chondrocytes, endothelial cells, osteoblasts, and nerve cells.
- Selection techniques include separation based upon differential cell agglutination in a mixed cell population, freeze-thaw procedures, differential adherence properties of the cells in the mixed population, filtration, conventional and zonal centrifugation, unit gravity separation, countercurrent distribution, electrophoresis and fluorescence-activated cell sorting.
- Cell fractionation may be useful when the donor has a disease, such as cancer.
- Isolated cells can be cultured in vitro to increase the number of cells available for transplantation.
- the use of allogenic cells, and more preferably autologous cells, is preferred to prevent tissue rejection.
- the subject may be treated withimmunosuppressive agents, such as cyclosporin or FK506, to reduce the likelihood of rejection.
- Isolated cells may be transfected.
- Useful genetic material may be, for example, genetic sequences that are capable of reducing or eliminating an immune response in the host. For example, the expression of cell surface antigens such as class I and class II histocompatibility antigens may be suppressed. This may allow the transplanted cells to have reduced chance of rejection by the host. In addition, transfection could also be used for gene delivery.
- the cell-substrate construct can carry genetic information required for the long- term survival of the host or the artificial organ or for detecting or monitoring the cells.
- the implanted cell or cells are genetically modified to express a bioactive molecule that promotes cell growth or survival.
- the cell or cells are genetically modified to expresses a fluorescent protein marker.
- Exemplary markers include GFP, EGFP, BFP, CFP, YFP, and RFP.
- the cell- substrate construct can also carry genetic information required for promoting or maintaining angiogenesis. Transfection may be used for transient gene expression or stable gene expression by incorporation of the gene into the host cell.
- Isolated cells can be normal or genetically-engineered to provide additional or normal function.
- Methods for genetically engineering cells with viral vectors such as retroviral vectors or other methods known to those skilled in the art can be used. These include using expression vectors which transport and express nucleic acid molecules in the cells (see, for example, Goeddel etal., (Gene Expression Technology: Methods in Enzymology 185, AcademiPress, San Diego, Calif. , 1990).
- Vector DNA is introduced into prokaryotic oreukaryotic cells via conventional transformation or transfection techniques. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989) ), and other laboratory textbooks.
- the invention features methods of repairing diseased or damaged tissues and organs.
- Cells are administered to a damaged or diseased tissue or organ. These methods may stabilize a damaged tissue or organ in a patient on a transplantation waiting list; or the methods may repair a damaged or diseased tissue or organ, thereby obviating the need for transplantation. Methods for repairing damaged tissue or organs may be carried out either in vitro, in vivo, or ex vivo.
- the invention features methods of producing an engineered replacement tissue.
- Cells are preferably cultured in the presence of a matrix that contains a CMP or CMP conjugate.
- a CMP conjugate is used to modulate the adhesive properties of the matrix.
- the CMP is conjugated to a PEG, such that the CMP PEG conjugate is designed to repel the adhesion of a cell.
- the CMP conjugate is designed to promote cell adhesion, thereby promoting incorporation of the matrix (e.g., a synthetic polymer based matrix, decellularized skin or other tissue source; collagen or other extracellular matrix gel) into an existing tissue as described herein.
- the matrix e.g., a synthetic polymer based matrix, decellularized skin or other tissue source; collagen or other extracellular matrix gel
- Methods for producing an engineered tissue or organ may be carried out either in vitro, in vivo, or ex vivo. It is also contemplated that matrices of the invention comprising cells are administered to a mammal to treat damage or deficiency of cells in an organ, muscle, or other body structure, or to form an organ, muscle, or other body structure.
- Desirable organs include the bladder, brain, nervous tissue, glial tissue, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, ovaries, prostate, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, breast, skeletal muscle, skin, bone, and cartilage.
- Exemplary transplantation methods of the present invention include repairing or replacing bone or cartilaginous tissue, such as articular cartilage.
- Traditional bone or cartilage tissue engineering methods can be improved by administering chondrocytes in a matrix comprising collagen mimetic peptides to the damaged or diseased bone or cartilage in vivo or to a bone or cartilage transplant tissue before, during, or after the transplant tissue is administered to a mammal.
- Traditional bone and cartilaginous tissue reconstruction methods are described, for example, in U. S.patentNos. 6,197, 061; 6,197, 586; 6,228, 117; 6,419, 702;and 6, 451,060.
- Engineered bone is useful for the treatment of a variety of diseases or disorders, including arthritis, cancer, congenital defects of bone or cartilage such as worn or torn cartilage in joint linings (e.g., knee joint, hip joint, and temporomandibular joint) and trauma. It is known that connective-tissue cells, including fibroblasts, cartilage cells, and bone cells, can undergo radical changes of character. A great variety of materials are useful as matrices for this purpose.
- Matrices can include materials that are nonbiodegradable or biodegradable. Desirably, biodegradable materials will degrade over a time period of less than a year, more preferably less than six months.
- a donor organ, donor cell, engineered tissue, or engineered organ is transplanted into a patient (e.g.,, a human or mammal) for the treatment or stabilization of a condition, disease, or disorder using standard methods known to the skilled artisan.
- a patient e.g., a human or mammal
- Methods for three- dimensional skeletal muscle tissue-engineering are described by Saxena etal., (Biomed. Mater. Eng. 11 (4): 275-281,2001). Corneal Shields
- Corneal shields of the invention are ophthalmic lens that contain collagen in association with a collagen mimetic peptide Collagen is a major component of the white sclera and the clear cornea. Natural or synthetic collagens are shaped into a contact lens that can be placed on the surface of the eye. The collagen shield provides a protective environment that promotes the healing of surgical and traumatic wounds to the eye. Such shields are useful as ophthalmic dressings and as ophthalmic drug delivery devices.
- Drugs or diagnostic agents which can be administered include antibiotics, such as beta-lactam antibiotics, such as cefoxitin, n-formamidoylthienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides; antiinflammatories, such as cortisone, hydrocortisone, hydrocortisone acetate, betamethasone, dexamethasone, dexamethasone sodium phosphate, prednisone, methylprednisolone, medrysone, fiuorometholone, prednisolone, prednisolone sodium phosphate, triamcinolone, indainethacin, sulindac.
- antibiotics such as beta
- the corneal shield comprises a physiologically acceptable vehicle having a buffered pH and hypoosmotic, hyperosmotic, or isoosmotic characteristics.
- the pH and osmolality of the ophthalmic delivery device is matched to the pH and osmolality of the eye.
- the corneal shield is subject to degradation over time. Such degradation is typically accomplished via a naturally occurring enzyme present in tears.
- Collagen mimetic peptide therapeutics include cell containing matrices as well as collagen mimetic peptide conjugates. These therapeutics can be delivered by any method known to the skilled artisan.
- a CMP conjugate is administered via an intravenous catheter that is inserted into a blood vessel and guided through am artery or vein to a desired location.
- a CMP conjugate that includes an anti-thrombotic is administered via a catheter directly to a clot. The end of the catheter may be placed in the vessels leading to the brain, lung, heart, arm, or leg depending upon the location of the clot.
- a liquid solution containing cells and CMP-polymer conjugates is injected into a desired site or is surgically implanted.
- the liquid is then polymerized in vivo.
- the CMP-polymer conjugate is polymerized in vitro and subsequently administered.
- the present invention provides methods of treating diseases and/or disorders or symptoms thereof which comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a collagen mimetic peptide of a formulae herein to a subject (e.g., a mammal such as a human).
- a subject e.g., a mammal such as a human.
- the method includes the step of administering to the mammal a therapeutic amount of a compound herein sufficient to treat the disease or disorder or symptom thereof, under conditions such that the disease or disorder is treated.
- the methods herein include administering to the subject (including a subject identified as in need of such treatment) an effective amount of a compound described herein, or a composition described herein to produce such effect. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
- the therapeutic methods of the invention in general comprise administration of a therapeutically effective amount of the compounds herein, such as a compound of the formulae herein to a subject (e.g., animal, human) in need thereof, including a mammal, particularly a human.
- a subject e.g., animal, human
- Such treatment will be suitably administered to subjects, particularly humans, suffering from, having, susceptible to, or at risk for a disease, disorder, or symptom thereof. Determination of those subjects "at risk” can be made by any objective or subjective determination by a diagnostic test or opinion of a subject or health care provider (e.g., genetic test, enzyme or protein marker, Marker (as defined herein), family history, and the like).
- the compounds herein may be also used in the treatment of any other disorders in which it is desirable to target a tissue comprising collagen may be implicated.
- the invention provides a method of monitoring treatment progress.
- the method includes the step of determining a level of diagnostic marker (Marker) (e.g., any target delineated herein modulated by a compound herein, a protein or indicator thereof, etc.) or diagnostic measurement (e.g., screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof, in which the subject has been administered a therapeutic amount of a compound herein sufficient to treat the disease or symptoms thereof.
- the level of Marker determined in the method can be compared to known levels of Marker in either healthy normal controls or in other afflicted patients to establish the subject's disease status.
- a second level of Marker in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy, hi certain preferred embodiments, a pre- treatment level of Marker in the subject is determined prior to beginning treatment according to this invention; this pre- treatment level of Marker can then be compared to the level of Marker in the subject after the treatment commences, to determine the efficacy of the treatment.
- Methods of the invention are useful for treating or stabilizing in a patient (e.g., a human or mammal) a condition, disease, or disorder affecting a tissue or organ.
- Therapeutic efficacy is optionally assayed by measuring, for example, the biological function of the treated or transplanted organ (e.g.,, bladder, bone, brain, breast, cartilage, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, nervous tissue, ovaries, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, ureter, urethra, urogenital tract, and uterus).
- the biological function of the treated or transplanted organ e.g., bladder, bone, brain, breast, cartilage, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver,
- a transplantation method of the present invention increases the biological function of a tissue or organ by at least 5%, 10%, 20%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or even by as much as 300%, 400%, or 500%.
- the therapeutic efficacy of the methods of the invention can optionally be assayed by measuring an increase in cell number in the treated or transplanted tissue or organ as compared to a corresponding control tissue or organ (e.g.,, a tissue or organ that did not receive treatment).
- cell number in a tissue or organ is increased by at least 5%, 10%, 20%, 40%, 60%, 80%, 100%, 150%, or 200% relative to a corresponding tissue or organ.
- Methods for assaying cell proliferation are known to the skilled artisan and are described in (Bonifacino etal., Current Protocols in Cell Biology Loose-leaf, John Wiley and Sons, Inc. , San Francisco, CA).)
- the present invention provides for the delivery of therapeutic agents to cells, tissues, or organs in vitro or in vivo.
- the invention is based in part on the discovery that therapeutic agents can be conjugated to a collagen mimetic peptide. Collagen is then contacted with the collagen mimetic peptide conjugate, such that the collagen mimetic peptide conjugate physically associates with collagen.
- compositions of the invention are useful for the high-throughput low-cost screening of compounds conjugated to CMP. Desired CMP conjugates physically interact with collagen (e.g., bind with high affinity) without disrupting collagen structure. The CMP conjugate thereby modulates a biological function of a cell, tissue, or organ.
- Collagen, or tissues or cells comprising collagen are treated with a collagen mimetic peptide conjugate and are subsequently compared to untreated control samples to identify therapeutic CMP conjugates that bind collagen with high affinity without disrupting collagen structure and/or enhance a biological function of the cell, tissue, or organ. Any number of methods are available for carrying out screening assays to identify such compounds.
- candidate compounds are added at varying concentrations to the culture medium of cultured cells. Any desired biological function is then measured using standard methods. The biological function in the presence of the candidate compound is compared to the level measured in a control culture medium lacking the candidate molecule.
- a compound that enhances cell function is considered useful in the invention; such a candidate compound may be used, for example, as a therapeutic to prevent, delay, ameliorate, stabilize, or treat a disease described herein (e.g., atherosclerosis, thrombosis, inflammation, tissue damage).
- the candidate compound prevents, delays, ameliorates, stabilizes, or treats a disease or disorder described herein.
- Such therapeutic compounds are useful in vivo as well as ex vivo.
- CMP conjugates are screened for those that specifically bind to collagen.
- the efficacy of such a candidate compound is dependent upon its ability to interact with collagen, or with functional equivalents thereof. Such an interaction can be readily assayed using any number of standard binding techniques and functional assays (e.g., those described in herein).
- a CMP conjugate that binds to a collagen is identified using a chromatography-based technique. For example, collagen is immobilized on a column. A solution comprising a CMP conjugate is then passed through the column, and a CMP conjugate is identified on the basis of its ability to bind to the collagen and be immobilized on the column. To isolate the CMP conjugate, the column is washed to remove non-specifically bound molecules, and the CMP conjugate of interest is then released from the column and collected. Similar methods may be used to isolate a CMP conjugate bound to a collagen microarray comprising any collagen type desired (e.g., collagen types 1-29).
- collagen type desired e.g., collagen types 1-29
- a CMP conjugate identified using such methods is assayed for an effect on the biological function of a cell, tissue, or organ as described herein.
- the CMP conjugate e.g., the substrate
- the CMP conjugate is coupled to a radioisotope or enzymatic label such that binding of the compound, e.g., the substrate, to collagen can be determined by detecting the labeled compound, e.g., substrate, in a complex.
- compounds can be labeled with 125 1, 35 S, 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting.
- compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
- a cell-free assay in which a CMP conjugate or a biologically active portion thereof is contacted with a collagen and the ability of the CMP conjugate to bind to the collagen thereof is evaluated.
- the interaction between two molecules can also be detected, e.g., using fluorescence energy transfer (FET) (see, for example, Lakowicz et al, U.S. Patent No. 5,631,169; Stavrianopoulos et al, U.S. Patent No. 4,868,103).
- FET fluorescence energy transfer
- a fluorophore label on the first, 'donor' molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy.
- the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues.
- Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal.
- An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).
- determining the ability of a CMP conjugate to bind to a collagen can be accomplished using real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C, Anal. Chem. 63:2338-2345, 1991; and Szabo et al, Curr. Opin. Struct. Biol. 5:699-705, 1995).
- Biomolecular Interaction Analysis see, e.g., Sjolander, S. and Urbaniczky, C, Anal. Chem. 63:2338-2345, 1991; and Szabo et al, Curr. Opin. Struct. Biol. 5:699-705, 1995.
- BIA Biomolecular Interaction Analysis
- vessels examples include microtiter plates, test tubes, and micro-centrifuge tubes. Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above.
- cell free assays can be conducted in a liquid phase.
- the reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (see, for example, Rivas, G., and Minton, A.P., Trends Biochem Sd 18:284-7, 1993); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis and immunoprecipitation (see, for example, Ausubel, F. et al, eds. (1999) Current Protocols in Molecular Biology, J. Wiley: New York).
- the effects of a CMP conjugate on biological activity are typically compared to the biological activity in the absence of the CMP conjugate.
- the screening methods include comparing the value of a cell modulated by a candidate CMP conjugate to a reference value of an untreated control cell. Changes in tissue or organ morphology further comprise values and/or profiles that can be assayed by methods of the invention by any method known in the art.
- therapeutic compounds suitable for coupling to CMP are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries or from polypeptide or nucleic acid libraries, according to methods known in the art.
- Compounds used in screens may include known compounds (for example, known therapeutics used for other diseases or disorders).
- compounds for example, known therapeutics used for other diseases or disorders.
- compounds can be screened using the methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds.
- Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, N.H.) and Aldrich Chemical (Milwaukee, Wis.).
- chemical compounds to be used as candidate compounds can be synthesized from readily available starting materials using standard synthetic techniques and methodologies known to those of ordinary skill in the art.
- Synthetic chemistry transformations and protecting group methodologies useful in synthesizing the compounds identified by the methods described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
- libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FIa.), and PharmaMar, U.S.A. (Cambridge, Mass.).
- natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al, Proc. Natl. Acad. Sd. U.S.A.
- any library or compound is readily modified using standard chemical, physical, or biochemical methods.
- Libraries of compounds may be presented in solution (e.g., Houghten, Biotechniques 13:412-421, 1992), or on beads (Lam, Nature 354:82-84, 1991), chips (Fodor, Nature 364:555-556, 1993), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner U.S. Patent No. 5,223,409), plasmids (Cull et al, Proc Natl Acad Sd USA 89:1865-1869, 1992) or on phage (Scott and Smith, Science 249:386-390, 1990; Devlin, Science 249:404-406, 1990; Cwirla et al. Proc. Natl. Acad. Sci. 87:6378-6382, 1990; Felici, J. MoI. Biol. 222:301-310, 1991; Ladner supra.).
- Small molecules of the invention preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.
- kits that include CMP or CMP conjugates capable of interacting with collagen in vitro or in vivo.
- the kit includes a diagnostic composition containing a detectable CMP conjugate (e.g., CMP conjugated to a nanoparticle, a detectable label, or a contrast reagent).
- the kit contains a therapeutic device, such as a wound healing device, hemostatic sponge, or drug delivery device containing a CMP conjugate and a polymer.
- the kit comprises a sterile container which contains a CMP conjugate or a CMP conjugate and a polymer; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.
- a CMP conjugate of the invention is provided together with instructions for using it in a diagnostic or therapeutic method described herein.
- the instructions will generally include information about the use of the composition for the diagnosis or treatment of a disease in a subject in need thereof.
- the instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.
- Example 1 Methods of characterizing a CMP or CMP conjugate
- CMP and 5-carboxy fluorescein (5CF) labeled CMP derivatives were prepared as shown in Table 1 (Table 1 : 1 and 2, respectively), which provides the sequence and transition melting temperature (T m ) of peptides 1-5, as determined by circular dichroism spectroscopy ( Figures 1-3).
- Table 1 Transition Temperatures of Collagen Mimetic Peptide Derivatives Determined by Circular Dichroism Spectroscopy 8 .
- peptide 3 was synthesized having the same amino acid composition as peptide 2, but the Pro, Hyp, GIy sequence was scrambled, rendering peptide 3 non- helicogenic.
- Three consecutive glycines were inserted as a spacer between the fluorescence tag and the CMP. Attaching 5CF and three glycines to 1 elevated its melting temperature from 69°C to 75°C (Table 1). This is due in part to the hydrophobic nature of the fluorescence tag. Attachment of a hydrophobic fatty acid to the CMP was previously shown to stabilize the triple helix elevating its melting temperature. 5 As expected, no melting behavior was observed for compound 3.
- FACITs Fibril Associated Collagens with Interrupted Triple-helices
- poly(ethyleneglycol) 2 ooo-CMP conjugate polymer 25 ' 26 (Table 1 : 5) was prepared. This modified collagen was designed to reduce the adhesiveness of collagen to cells.
- the melting temperature of 5 was determined to be 29°C which is 7°C lower than the melting temperature of (ProHypGly) 7 (Table I). 27 Here, the hydrophilic and bulky PEG group seems to destabilize the triple helix in water.
- a solution containing 5 at 45 °C was added to the collagen coated culture plate (prepared as above) and human fibroblasts or breast epithelial cells were seeded and incubated for three days at 37°C. Homogenous distribution of fibroblasts is seen on the collagen film that was treated with mPEG 2O oo (Control sample, Figure 7A). In contrast, areas of collagen films treated with 5 are almost devoid of fibroblasts ( Figure 7B) and epithelial cells ( Figure7C). This experiment demonstrates that the adhesive properties of prefabricated collagen film can be readily modified by the simple action of delivering CMP conjugate solutions to the target area.
- fluorescence labeled PEG-CMPs FL-PEG 2000 -Gly 3 -(Pro-Hyp-Gly) 7 and 5CF-Gly 3 -(Pro-Hyp-Gly) 8 -Gly 3 - PEG 50O0 -OH, were prepared.
- the CF-GIy-(PrO-HyP-GIy) 10 derivatives bound collagen film with high affinity.
- Figure 11 shows a quantitation of the release of fluorescence-labeled CMP derivatives from culture dish and collagen film at 37 °C in PBS solution (pH 7.4).
- linear PEG of suitable lengths or star-shaped PEG are also useful in such methods.
- Such molecules have increased surface-shielding effects, and are more effective in protecting the conjugates from cell adhesion and protein adsorption (see Figure 12).
- a comparison of protein and cell repellent properties of grafted linear PEG and star shaped PEG has been described 13"16 , hi particular, star shaped PEG-coated glass, titanium and silicon samples inhibit cell adhesion 17 .
- CMP is conjugated to multi-armed PEG or to star shaped PEG (MW: 10,000 Da). These molecules provide for an increase in the number of collagen binding sites.
- [AcGly-Gly 2 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 ] 4 -star shaped PEG (MW: 10,000 Da) will be synthesized by conjugation of four NHS activated sites on 4-armed star PEG with AcGly-Gly 2 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 ( Figurel2 ). The amount of PEG-CMP immobilized in the collagen scaffold will be empirically determined. [Carboxyfiuorescein- Gly 3 -Lys-Gly 3 -(Pro-Hyp-Gly) 8 ] 4 -star shaped PEG will be prepared ( Figure 13).
- Fluorescence tagged star shaped PEG-CMP that can be quantified and visualized by fluorescence techniques will also be prepared to facilitate detection of star shaped PEG-CMP release.
- HPLC will be used to purify the CMP-star shaped PEGs and MALDI-TOF will be used to identify the target products and check for purity.
- the ability to control the organization of cells in collagen matrix provides a new pathway for engineered tissues. Furthermore, the affinity between the CMP and collagen could issued to immobilize therapeutic drugs to collagens in the living tissues, and to biomaterials that incorporate natural collagens.
- results using PEG-CMP to repel fibrobast cell growth suggest that PEG-CMP can be used to direct the growth and organization of endothelial cell growth as well, given the similarities that exist between the two cell types.
- endothelial cells rely on integrin-ECM interaction for initial binding to the scaffolds.
- PEG-CMP collagen gels on proliferation tubulogenesis, and capillary sprouting collagen (type I) films are treated with PEG-CMP of varying concentrations.
- the amount and pattern of immobilized PEG-CMP present in the collagen film is determined using fluororescien labeled-PEG.
- Endothelial cells are then plated on PEG-CMP modified collagen and cell attachment, morphology, and cytoskeletal organization is assessed to determine the effect of CMP-PEG modified collagen on cell attachment pattern and cell proliferation.
- Methods of characterizing cytoskeletal organization include staining with Oregon-Green conjugated phalloidin.
- endothelial cells are cultured in PEG-CMP modified three dimensional collagen gels.
- PEG-CMP inhibits fibroblast attachment. Without wishing to be bound by theory, this effect is likely due to the PEG blocking the ECM-integrin interaction.
- a three dimensional collagen gel containing varying concentrations of PEG-CMP is prepared by adding PEG-CMP to a collagen solution prior to gelation.
- Cell morphology is analysed to assess the efficacy of PEG-CMP in regulating cell growth, proliferation, tubulogenesis, and capillary sprouting in a three dimensional collagen gel.
- Samples of the gel are easily fixed and fluorescently labeled using actin and nuclear immunostaining.
- One end of the collagen gel is immersed in fluorescein labeled PEG -CMP solution to create a detectable PEG gradient along the length of the collagen gel.
- Cell morphology is visualized by actin and nuclear immunostaining, and evaluated using fluorescence microscope, which also provides for visualization of the PEG gradient.
- CMP-PEG is injected into the collagen gel via microsyringe. This injection is performed at the final stage of gel formation thus minimizing damage to the collagen matrix.
- the distribution of immobilized fluororescein labeled PEG-CMP is visualized and quantified by fluorescence microscope and the morphology of endothelial cells and capillary distribution is evaluated with respect to the local concentration of PEG- CMP.
- Example 3 Tissue fixation using (CMP) n conjugated- homo multifunctional PEG as a cross-linker
- present methods for tissue fixation use crosslinking reagents, such as formaldehyde, glutaraldehyde (GA), expoxy compounds, carbodiimide, proanthocyanidin and reactive multifunctional PEGs 18 ' 19 .
- crosslinking reagents such as formaldehyde, glutaraldehyde (GA), expoxy compounds, carbodiimide, proanthocyanidin and reactive multifunctional PEGs 18 ' 19 .
- the use of such reagents reduces the antigenicity of many proteins and increases their resistance to enzymatic degradation when tissues treated with these reagents are implanted 20 ' 21 ]. Additional drawbacks to the use of such agents includes their toxicity, unmanageable crosslinking rates, and instability.
- the present invention provides a a collagen crosslinking reagent that exhibits low cytotoxicity and can form biocompatible crosslinked products.
- CMPs conjugated onto multi-armed PEG compounds mediate physical binding to collagen and can serve as crosslinking reagents.
- CMP conjugated with homo- bifunctional or homo-tetrafunctional PEG which are commercially available from NEKTAR (San Carlos, CA) (such as NHS or thiol) are prepared and purified by HPLC.
- the reaction products are characterized using MALDI-TOF and CD measurements and rheometry, tensile gel swelling analyses and gel degradation analyses using collagenase are carried out on CMPs-multi armed PEG conjugate cross-linked collagen gels and fixed tissues.
- Example 4 CMP functionalized gold nanoparticles
- NPs CMP functionalized gold nanoparticles
- the triple helical structure of collagen and CMP bears similarity in structure to the DNA double helix.
- Both collagen and DNA are composed of long coaxial multiplex helices that are held together by inter-chain hydrogen bonds. They exhibit reversible melting transitions that reflect the stability and strength of the helix assembly.
- strand invasion by short DNAs or peptide nucleic acids is well documented in the literature. 28 Although collagens are known to incorporate thermally unstable domains where small segments of the triple helix are thought to be partially unraveled, strand invasion by other collagen molecules or collagen analogs have not been previously reported.
- collagen fibers Under transmission electron microscopy, collagen fibers exhibit characteristic banding patterns that indicate the structural integrity of the collagen molecules and their assembly. 30 The banding patterns also provide approximate position markers along the length of collagen molecules.
- the binding event between type I collagen fibers and CMP conjugated gold NPs was investigated to see if strand invasion occurs without destroying the native structure of collagen fibers. Antibody passivated gold NPs have been used successfully to identify specific types of collagen fibers in tissue samples. 31
- a fourth peptide, peptide 4', with an amino acid composition identical to that of peptide 3' but with a scrambled amino acid sequence that is unable to support a triple helical structure was also prepared.
- NP-2 20.5 ⁇ 3.3 nm 3.65 nm 4.3 (4.7) 444 ⁇ 18 nm
- the melting temperatures of CMPs bound to the NP surfaces could not be determined because circular dichroism measurements were hampered by light scattering from the NPs; calorimetric analysis was unsuccessful due to a trace amount of CMPs present on the NP surfaces.
- Thermal melting curves as determined by ellipicity of CMPs is shown in Figure 14.
- the thickness of the peptide layer on the gold NP surface was determined by dynamic light scattering (DLS) ( Figure 15).
- the peptide layer thicknesses of NP-I, NP-2 and NP-3 were 2.0 run, 3.65 run and 6.85 run, respectively (Table 3). These values were commensurate with the estimated lengths of the corresponding CMPs in helical conformation. 35
- the peptide layer thickness of NP -4 was only 1.5 nm, indicating that this peptide was either a random coil or had a distinctively different secondary structure that tended to lie flat on the particle surface.
- the average number of CMPs on the NPs was determined by measuring the concentrations of free CMPs remaining in solution after the removal of the NPs from a series of incubation mixtures with varying CMP/NP ratios ( Figure 16 and Table 3). 36
- the numbers of CMPs immobilized on the NP surfaces were 582, 444, and 399 for NP-I, NP-2, and NP-3, respectively. These values correspond to the effective footprint areas (per single chain) of 94 A 2 , 123 A 2 , and 137 A 2 , which are comparable to the cross-sectional area of the CMP triple helix, 80 A 2 .
- the peptide layer is likely composed of laterally packed single stranded CMPs. This may have been caused by surface anchoring of the chain ends that prohibited the staggered arrangement of the peptide chains required for the formation of triple helix.
- the DLS and average number of peptides per NP data are in agreement with CMPs standing upright on the NP surfaces in an extended conformation that resembles the poly(proline)-II helix.
- the peptides appear as a dense white layer covering the NP surface ( Figures 17A- 17D). All CMP functionalized NPs were able to assemble into a pseudo-hexagonal lattice, indicating that the CMPs fully passivated the NP surfaces and prevented the NPs from aggregating.
- the CMP conjugated NPs were highly stable in aqueous solution. No sign of aggregation was detected in buffer solutions of up to 5 M NaCl or within a pH range from 0 to 14 ( Figures 18A and 18B). All NPs can be freeze-dried and resuspended without aggregation of the particles. Peptides usually make poor passivating layers for NPs and even peptides that are carefully designed to disperse NPs did not protect NPs under such wide range of conditions. 36 CMP triple helices consist of three parallel peptide chains; hence the association of peptides with anti-parallel alignment from two different NPs is unlikely. It is likely that the high Hyp content and extended conformation of the peptides, as shown by DLS, caused the CMPs to mimic the behavior of poly(ethylene glycol) brushes on surfaces and prevent the NPs from aggregating in aqueous solution.
- Type I collagen fibers were prepared by adjusting the pH and ionic strength of an acid soluble type I collagen solution. 37 hi forming a fiber, collagen molecules aligned head to tail in the direction of the long axis in overlapping rows with a gap between the molecules within each row. Accumulation of staining agents (uranyl acetate) in these gap regions produced dark bands that repeated every 67 ran along the length of the fiber. Compound 3 had the highest melting temperature among the three CMPs, suggesting that it likely makes the most stable adduct with the collagen fiber. Therefore, NP-3 binding to reconstituted collagen fibers was characterized.
- the NP labeling technique may be used to identify structural abnormalities in collagen fibers that are related to debilitating human diseases. 15 Strand invasion or similar forms of strand association by collagen and collagen derivatives may uncover the behaviors of fibril-associated collagens (type IX and XII) and other proteins that incorporate collagen- like sequences.
- Example 5 CMP-containing hydrogels are useful for cartilage repair
- collagen mimetic peptides can be used to modified collagen compositions provides for the development of a variety of therapeutic compositions featuring such peptides.
- collagen mimetic peptides may be used to produce improved biocompatible tissue scaffolds that contain CMP conjugated to biochemically inert polymers. Such scaffolds retain collagens and other extraceullular matrix components secreted by the cells cultured within them.
- tissue scaffolds containing CMP reproduce a microenvironment that more closely resembles the cell's natural environment than conventional scaffolds ( Figure 22).
- the CMP (PrO-HyP-GIy) 7 -TyT, was synthesized at greater than 99 % purity. Purity was analyzed using MALDI-TOF spectrometry. (ProHypGly) 7 -Tyr was selected because the (ProHypGly) 7 - CMP unit was shown, as described above, to bind to collagen fiber at physiological temperatures. Tyr was added to the peptide to facilitate the accurate measurement of CMP concentration by UV- Vis spectrophotometer. The peptide was synthesized on a solid support (Wang resin), cleaved, and purified by reverse phase HPLC. The peptide's ability to form a collagen triple helix was confirmed using circular dichroism. The CD trace included a positive peak near 225 nm, a crossover around 215 nm, and a minimum at around 180 nm.
- the CD melting temperature (midpoint of CD melting curve) of the (ProHypGly) 7 - Tyr CMP was determined to be 38.5°C. This melting temperature is slightly higher than that of the (Pro-Hyp-Gly) 7 CMP, which had a melting temperature of 37 0 C. A similar change in melting temperature was observed when a hydrophobic fluorescence tag was attached to the N-termini of a CMP.
- a CMP/ poly( ethylene oxide) diacrylate (PEODA) hydrogel was prepared by photopolymerizing an aqueous solution containing the acryloyl-PEG-CMP and PEODA monomers (combined weight percent: 10%) as well as a photo reactive initiator (0.05%). Unconjugated reactants were removed using ultrafiltration and gel permeation chromatography. Purity of the final peptide-polymer conjugate was 80% as determined using MALDI-TOF.
- Example 7 A CMP /PEODA hydrogel retained added collagen
- the amount of collagen retained by the CMP/PEODA hydrogel reached saturation when the gel was incubated with 0.2 mg/mL of collagen.
- the amount of collagen retained did not increase when 0.5 mg/mL of collagen was added to the CMP/PEODA hydrogels.
- Example 8 CMP containing hydrogels have increased water content
- Water content of a hydrogel is closely correlated to crosslinking density and mesh size of the scaffold.
- the water content of hydrogels with and without CMP was determined following a twenty- four hour equilibration in chondrocyte medium.
- the wet and dry weights of gels crosslinked with various concentrations of collagen mimetic peptides was measured and the water content of each hydrogel was determined.
- Hydrogels crosslinked to CMP contained 10% more water than hydrogels that did not contain CMP (Table 4).
- Example 9 A CMP /PEODA hydrogel supported cell survival
- chondrocytes were harvested and encapsulated in control, 1 %, and 2% CMP/PEODA hydrogels.
- the CMP containing hydrogel successfully supported cell survival as shown by a cell viability assay ( Figure 24).
- cell viability was homogenous throughout the CMP/PEODA gels ( Figure 24).
- Example 10 A CMP /PEODA hydrogel retained cell-secreted collagen
- Cartilage is mainly comprised of collagen and proteoglycans.
- Collagen is a good marker of the cultured chondrocyte's biosynthetic capability because collagen is the most abundant extracellular matrix component in cartilage.
- the collagen produced by chondrocytes is mostly type II collagen.
- Type II collagen is also expected to physically interact with CMP.
- collagen content present in the hydrogel was assayed following one week of chondrocyte culture. Collagen content was 37% higher in the 2% CMP/PEODA hydrogel than in the 1% CMP/PEODA hydrogel.
- GAG glycosaminoglycan
- GAG synthesis in the 2% CMP/PEODA hydrogel was significantly greater than that in thel% CMP/PEODA hydrogel and control PEG gel, by 105% and 87%, respectively. However, there was no significant difference in GAG production between the control and 1% CMP/PEODA hydrogel.
- the total GAG assay indicated that the GAG production was not influenced by the presence of 1% PEODA-CMP in the hydrogel, even though the PEODA-CMP hydrogel had significantly higher water content than PEODA.
- increasing the water content of a hydrogel increases the tissue remodeling ability at the expense of mechanical properties.
- the mechanical strength of the hydrogel is weakened but due to higher water content, cell can take up nutrients easily and produce high levels of ECM. This was not observed in the CMP/PEODA hydrogel.
- 1% and 2% CMP/PEODA had similar water content, the GAG content of 2% CMP/PEODA was 1.9 times higher than that of the 1% CMP/PEODA. This indicates that the increase in GAG production was not the result of an increase in water content.
- Proteoglycan deposition was also examined using safranin-0 staining.
- the intensity of safranin-0 staining was highest in the 2% CMP/PEODA gels, and was next highest in the 1% CMP/PEODA hydrogel.
- Total collagen staining in the CMP/PEODA hydrogel was also examined using Masson's Trichrome stain.
- the CMP/PEODA hydrogel was more intensely stained than the PEODA gel. No difference in staining intensity was observed in hydrogel's containing varying CMP concentrations. No staining was observed in a control acellular CMP/PEODA hydrogel.
- Immunohistochemical staining for collagen type II also showed strong positive staining in 1% and 2% CMP/PEODA hydrogels ( Figure 26).
- Chondrocytes produce the matrix material and the collagen fibers present in bone. As the chondrocytes secrete matrix material around them, they become walled off into small chambers or lacunae. The chondrocytes embedded in the hydrogel had a spherical morphology and were present in isolated pockets resembling lacunae. Immediately surrounding the lacunae was a territorial matrix where newly synthesized ECM products were present. Heavy staining for collagen (both total collagen staining and type II collagen immunostaining) was observed in the territorial regions of the CMP/PEODA hydrogel indicating that the cell-secreted collagen remains in the chondrocytes microenvironment.
- Collagen synthesis in the 1% and 2% CMP/PEODA hydrogels was 47% and 103% respectively.
- Chondrocytes in CMP-containing hydrogels synthesized more collagen than chondrocytes in control hydrogels lacking CMP. Tissue formation was greater in CMP/PEODA hydrogels.
- Results of the biochemical assays of chondrocyte-encapsulated hydrogel were consistent with the histological findings ( Figure 27). DNA contents were similar in all samples. The high initial density of chondrocytes prevented their proliferation in the hydrogel.
- the results reported herein indicate that CMP/PEODA hydrogel provides an effective scaffold for cartilage regeneration that is superior to existing tissue scaffolds. Given these results, CMP/PEODA hydrogels are useful for the repair of damaged cartilage, and are particularly useful for applications involving the repair of articular cartilage.
- Example 12 Reduction of thrombus deposition by applying CMP derivatives
- Angioplasty denudes the vessel wall of the endothelial layer. Vessel healing is often accompanied by the overproliferation of smooth muscle under the endothelial layer. This process can narrow or even block blood vessels causing thrombosis formation 40 . Methods for preventing intimal hyperplasia and thrombosis subsequent to angioplasty are urgently required.
- the present invention provides a method of treating blood vessel injury using CMP to deliver anti-thrombotics.
- CMP may be conjugated to virtually any anti-thrombotic agent known in the art.
- Such agents include aspirin, thienopyridine, heparin, saratin (a 12,000 Da recombinant protein isolated from the saliva of the medicinal leech Hirudo medicinalis), hirudin (a 65 amino-acid polypeptide), pegylated hirudin, and unfractionated heparin (UH).
- CMP-anti-thrombotic conjugates bind collagen (type III) 49 and repel cell attachment.
- Saratin-CMPs, hirudin-CMPs, and PEG-CMPs are produced using standard methods and purified using HPLC. Purified conjugates are then characterized using MALDI- TOF and CD analysis as described herein.
- the activity of the CMP conjugates will be assessed in anti-platelet activation and anti-thrombin formation assays. Specifically, plasma levels of ⁇ -thromboglobulin ( ⁇ -TG) and thrombin-antithrombin complexes (T-AT) will be determined using immunoenzymoassays 50 .
- the activity of CMP-anti-thrombotic conjugates are assessed in animal experiments.
- CMP conjugates are employed as antithrombotics.
- Cys-Cys 6,14 Cys-Cys: 16,28 Cys-Cys: 22,39
- Fmoc-amino acids were purchased from Advanced ChemTech (Louisville, KY) and Fmoc-Gly-Wang resin was purchased from Novabiochem (La Jolla, CA).
- Acid soluble, type I bovine collagen was purchased from Sigma (St. Louis, MO) and mPEG 2OO o-Gly 3 - (ProHypGly) 7 (peptide 5) was purchased from Genscript Corporation (Piscataway, NJ).
- AU other chemicals were purchased from Sigma- Aldrich and used without further purification.
- Fibroblast (CRL- 1502) cells and breast epithelial cells (MCF-7) were from ATCC (Manassas, VA).
- Dulbecco's modified eagle's medium (DMEM) and Iscove's modified Dulbecco's medium (IMDM) were purchased from Invitrogen Corporation (Carlsbad, CA).
- TEM images were acquired on a Philips 420 EM using holey carbon grids from Ted Pella Inc (Redding, CA).
- UV- Vis spectra were measured in a Cary 50 Bio spectrophotometer.
- Thermal melting transition measurements were performed in a Jasco 710 spectropolarimeter.
- DLS data was acquired on a Malvern Zetasizer 3000.
- CMPs collagen mimetic peptides
- the peptides were synthesized by condensation of the corresponding Fmoc-amino acids (Fmoc-Gly-OH, Fmoc-Hyp-OH, and Fmoc-Pro-OH) and 5-carboxyfluorescein (5CF) on a solid support (Wang resin). Both manual and automated systems (Applied Biosystems 43 IA Peptide Synthesizer) were used to prepare peptides 1-4. Four- fold molar excess of the above amino acids was used in a typical coupling reaction. Fmoc-deprotection was accomplished by treatment with 20% (v/v) piperidine in dimethyl formamide (DMF) for 1 hour.
- DMF dimethyl formamide
- the coupling was achieved by treatment with 2-(lH-benzo-triazole-l-yl)-l,l,3,3- tetramethyluronium hexafluorophosphate (HBTU) in N, N-diisopropylethylamine (DIPEA). All the coupling reactions were completed within 3 ⁇ 4 hours and were monitored by ninhydrin or chloranil tests.
- HBTU 2-(lH-benzo-triazole-l-yl)-l,l,3,3- tetramethyluronium hexafluorophosphate
- DIPEA N, N-diisopropylethylamine
- the CMPs were cleaved from the resins by treatment with water/triisopropylsilane/trifluoroacetic acid (2.5:2.5:95) for 3 hours.
- the crude CMPs were precipitated with cold ether and dried.
- Reverse-phase HPLC purification was performed on a Varian Polaris 210 series Liquid Chromatograph with a Vydac C- 18 reversed-phase column at a flow rate of 1 ml/min.
- the purified peptides were analyzed by a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer (Kompact SEQ, KRATOS or Voyager DE-STR, Applied Biosystems).
- MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight
- Circular dichroism (CD) spectra were recorded on JASCO 710 spectrometer equipped with JASCO PTC-348 WI temperature controller and Hellma cell (400 ⁇ L, 0.1 mm pathlength). The thermal melting curves were obtained by measuring the molar ellipticity at 225 nm with l°C/min heating rate. All samples (57 ⁇ M in 50 mM acetic acid) were stored at 4°C for 24 hours before the CD measurement.
- Collagen (type I, bovine) film was treated with either peptide 2 solution or blank buffer solution as described before. After 3 hr of incubation at room temperature, the wells were washed with 0.01 M potassium phosphate buffer solution (pH 7.4) and deionized water. All samples were dissolved in 50 mM acetic acid to a concentration of 1.80 ⁇ M or 3.60 ⁇ M and stored at 4 0 C for 24 hours before the CD measurement. Average values of four independent experiments are reported ( Figure 4).
- Collagen fibers were prepared by dialysis of collagen in 0.0 IM acetic acid solution against dilute NaCl solution. Peptide 4 in potassium phosphate buffer (400 ⁇ l, 500 ⁇ M, pH 7.4) was added to the collagen fibers in the PBS buffer (1 ml, 1 mg/ml, pH 7.4). The mixture was incubated for 3 hours and excess peptide 4 was removed by repeated centrifugation. The collagen fibers were resuspended in deionized water and transferred to a TEM grid. Uranyl acetate was used to stain the collagen fiber. ( Figure 6) Cell (human fibroblasts and breast epithelial cells) adhesion study
- Gold nanoparticles were synthesized by citrate reduction method according using standard methods. 41 Briefly, tri-sodium citrate solution (25 mL, 38.8 mM) was quickly added to a refluxing aqueous solution OfHAuCl 4 (250 mL, 1 mM) with vigorous stirring. The color of the solution changed from pale yellow to deep red after adding the citrate solution. The solution was refluxed for an additional 15 minutes, cooled, and filtered through a glass filter.
- Collagen fibers were regenerated by mixing 0.5 mL of acid soluble type I collagen (1 mg/mL) in 50 mM acetic acid solution with 1 mL of sodium phosphate buffer (10 mM, pH 8.25). The mixture was incubated at room temperature for 12 hours.
- a drop (8 ⁇ L) of type I collagen solution (0.3 mg/mL in PBS containing 1% BSA) was added to a holey carbon TEM grid.
- NP-3 solution (3 nM in PBS containing 1% BSA) was added to the grid and incubated for 5 minutes at room temperature or at 4O 0 C, followed by washing with deionized water.
- the collagen fibers were stained with uranyl acetate (1%).
- the dried powder was dissolved in deionized water and run through a size exclusion column Sephadex® G-25 (Pharmacia, motive phase: deionized water) to remove small molecule impurities. Elution fractions containing the target product were combined and lyophilized.
- MALDI-TOF was used to confirm the molecular weight of the target product.
- Product was stored at -20 °C and used within a week.
- Type I collagen in 0.1 N acetic acid was neutralized and resuspended in macromer solutions (0.05 wt% initiator (D-2959, Ciba), 8 wt% PEODA (molecular weight: 3400, Nektar) and 2% of ACRL-PEG-(Pro-Hyp-Gly) 7 -Tyr) at a concentration of 0.2 or 0.5 mg/ml. Control samples composed of 10 wt% PEODA were also prepared.
- Ultraviolet lamp EXFO Acticure 4000; wavelength: 365 nm; intensity 5 mW/cm 2 ; 5 min. exposure time
- the polymerized gel constructs were transferred to 12 well tissue culture plates with each well containing 2 ml PBS buffer. The culture plate was incubated at 37°C in 5 % CO 2 atmosphere, and PBS buffer was replaced every 2-3 days for one-week period.
- the wet weight and dry weight of collagen-encapsulated hydrogel was determined by measurement of the hydrogel before and after 48 hours of lyophilization, respectively.
- a dry construct was digested in 900 ml of papain solution (250 ⁇ g/ml papain type II (Worthington Biomedical Corporation, Lakewood, NJ), 100 niM phosphate buffer, 10 mM EDTA, 10 mM cysteine at pH 6.3) for overnight at 60°C. The digests were then centrifuged at 10,000 rpm for 5 minutes, and supernatants were taken.
- Total collagen content of the gel was estimated from the hydroxyproline assay conducted with papain-digested solution after overnight hydrolysis reaction with 6N hydrochloric acid at 115°C 45 . Hydrolyzed samples were reacted with/7-dimethylamino benzaldehyde and chloramines-T hydrate 46 . Absorbance was measured at 550 nm on a UV- Vis spectrophotometer. Standard curve was generated using pure trans-4-hydroxy-L-proline (Sigma- Aldrich). Collagen content of the blank gel (no collagen) was determined and subtracted in the calculation of the total collagen content.
- Chondrocytes were isolated from the femoral patellar groove and femoral condyles of three 5- to 8-week-old calves.
- the articular cartilage was excised under aseptic conditions and digested overnight at 37°C in 0.2 % Collagenase type II (Gibco) and 5 % fetal bovine serum (FBS, Gibco, Carlsbad, California) in Dulbecco's modified Eagle medium (DMEM, Gibco).
- the digested suspension was filtered through a cell strainer (Fisher Scientific Co.) and centrifuged at 1500 rpm for 10 minutes.
- the supernatant was removed and the pellet was washed and resuspended in PBS buffer (Gibco) supplemented with 1 % penicillin- streptomycin (Gibco). The pellet was washed twice and resuspended in medium.
- the medium was composed of 10 mM HEPES (Gibco, Carlsbad, California), 0.1 mM NEAA (Gibco, Carlsbad, California), 0.4 mM proline (Sigma), 50 mg/L Vitamin C (Sigma), 10% FBS, and 1% penicillin-streptomycin in high glucose DMEM. Constructs were cultured at 37°C in 5% CO 2 atmosphere and medium was replaced every 2-3 days.
- hydrogel encapsulated cells The viability of hydrogel encapsulated cells was determined after 2 weeks of culture. The medium was discarded and the hydrogel matrices were washed twice with phosphate buffer solution (PBS, Gibco, Carlsbad, California). Cell viability was assessed based on the integrity of cellular membrane using Live/Dead Viability/Cytotoxicity Kit (Molecular Probes, Eugene, OR) that contains calcein-AM ("Live”) dye and ethidium homodimer-1 (“Dead”) dye. Dye solution was made with 0.5 ⁇ L of calcein-AM dye and 2 ⁇ L of ethidium homodimer-1 dye in 1 mL DMEM.
- Live calcein-AM
- Dead ethidium homodimer-1
- a slice of the cell containing matrix was incubated in 500 ⁇ L of the "Live/Dead” dye solution for 30 minutes. Fluorescence microscopy was performed using a fluorescein optical filter (485 ⁇ 10 nm) for calcein-AM and a rhodamine optical filter (530 ⁇ 12.5 nm) for ethidium homodimer-1.
- cell containing and control matrices were fixed overnight in 10% formalin solution and stored in 70% ethanol.
- the fixed cell containing matrix was embedded in paraffin, sectioned and stained with Safranin-O/fast green or with Masson's trichrome stain.
- Acellular controls of the CMP/PEODA hydro gel were also stained following the same procedure to measure any background signals. Immunohistochemistry was performed using rabbit polyclonal antibody to collagen type II (Research Diagnostics) and a Histostain-SP kit (Zymed).
- Water content (%) [(W w - W d ) / W w ] x 100 ( 1 ) where W w is wet weight of the hydro gel after one day equilibration in water, and Wd, dry weight of the hydrogel.
- Cell containing and control matrices were digested with Papain overnight. The digested samples were used for both DNA and glucosaminoglycan (GAG) measurements. Hoechst 33258 dye from Molecular Probes (Eugene, OR) was used for the DNA assay 47 . The solution (0.1 ⁇ g/ml) was prepared in 1 x TNE buffer (10 mM Tris, 1 mM EDTA, 0.2 M NaCl, pH 7.4). Calf Thymus DNA standards were prepared with 0 to 100 ⁇ g/ml DNA. Papain-digested samples (30 or 60 ⁇ L) or standards were mixed with the prepared dye solution.
- DNA content was measured with a fluorometer (365 nm excitation and 458 nm emission) and calculated from the calf thymus DNA standard curve.
- the GAG was measured using the dimethylmethlene blue (DMMB) dye 48 .
- a standard curve was created with chondroitin sulfate C (shark cartilage extract, Sigma). Absorbance was measured at 525 run on a UV-Vis spectrophotometer.
- Collagen assays were also performed as described above. Collagen contents in the acellular CMP hydrogels were also measured for the purpose of background subtraction. GAG and collagen contents from the biochemical assays were normalized by the DNA content. The value is presented as mean ⁇ standard deviation. Statistical significance was determined by unpaired Student t test and set as/? ⁇ 0.05.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides modified collagen and related therapeutic and diagnostic methods.
Description
COMPOSITIONS COMPRISING MODIFIED COLLAGEN AND USES
THEREFORE
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Provisional Application No. 60/630,271, which was filed on November 23, 2004, and U.S. Provisional Application No. 60/722,079, which was filed on September 29, 2005, each of which is hereby incorporated by reference in its entirety.
STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY
SPONSORED RESEARCH
This work was supported in part by the National Institutes of Health (Grant No. GM- 74812) and the National Science Foundation (CTS-0210220). The government may have certain rights in the invention.
BACKGROUND OF THE INVENTION
Collagen is used in a variety of medical applications ranging from hemostatic materials and biocompatible coatings to drug delivery and tissue engineering. Collagen- based biomaterials are presently used for soft-tissue engineering and repair, and medical products composed of collagen have been approved by the FDA, and are commercially available. These include collagen-based corneal shields, anti-infectious catheters, tissue sealants, hemostatic sponges, and topical wound dressing products. Collagen is also used for tissue engineering substrates targeted for skin, bone, and blood vessel replacement. There is increasing demand for biocompatible and biofunctional materials that feature collagen as a scaffold to support tissue growth, to promote healing, and to develop engineered tissues for organ replacement therapies.
Traditionally, collagen is used as a passive biomaterial that protects injured sites and supports healing processes. Methods for modifying collagen would be useful for the development of materials that can participate in tissue regeneration by actively regulating cell differentiation, proliferation, and tissue organization. Methods for producing modified collagens have focused on chemical modification, that include coupling modifying groups to collagen' s amino acid side chains; however, the chemical reactions between exogenous components and collagen molecules are toxic and difficult to control because collagen molecules are large and complex biopolymers. Progress in the area of tissue repair and
regeneration requires better methods for conjugating exogenous functionalities to collagen. Desirably, such methods should overcome challenges associated with controlling chemical reactions and chemical toxicity.
SUMMARY OF THE INVENTION
As described below, the present invention features compositions comprising modified collagen and therapeutic and diagnostic methods related to the use of such compositions.
In one aspect, the invention features a method for modifying collagen, the method involving contacting collagen with a collagen mimetic peptide, under conditions that provide for a physical interaction between the collagen and the collagen mimetic peptide.
In another aspect, the invention provides a modified collagen made by the process of the above aspect.
In another aspect, the invention features a collagen mimetic peptide conjugate, where the conjugate is selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule. In one embodiment, the collagen mimetic peptide contains a Z-[X-Y-GIy]n repeat unit, where Z is any amino acid, X is proline or modified proline, Y is proline or modified proline, and n is an integer between 1 and 20, inclusive. hi a related aspect, the invention provides collagen mimetic peptide that contains amino acid sequences Glyn-(ProHypGly)n', (ProHypGly) n'-Tyrn, or Cysn-(Pro-Hyp-Gly) n' where n is an integer between 1 and 5, and n' is any integer between 1 and 15, and the peptide further comprises a modifier selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, an anti-inflammatory, a component of the extracellular matrix, a polymer, PEG, and a small molecule. In one embodiment, n' is 5, 6, 7, or 8.
In another aspect, the invention provides a modified collagen containing a CMP mimetic peptide of any previous aspect or made by the process of a previous aspect. In yet another aspect, the invention provides a method of modifying the adhesiveness of a composition, the method involving contacting the composition with a CMP conjugate. In one embodiment, the composition comprises collagen, for example, in a three-dimensional matrix or in a collagen film, hi other embodiments, the collagen is modified in a micropattern. In one embodiment, the CMP conjugate is a poly(ethyleneglycol)/CMP conjugate. In another embodiment, modification increases or decreases adhesiveness.
In another aspect, the invention provides a nanoparticle containing a collagen mimetic peptide fixed to the nanoparticle. In one embodiment, the collagen mimetic peptide contains the following sequence CySn-(PrO-HVp-GIy)n', where n is any integer between 1 and 5, and n' is any integer between 1 and 10. In another embodiment, n is 1 and n' is 3. In another embodiment, n' is 5, 6, 7, or 8. In yet another embodiment, the collagen mimetic peptide is fixed to the surface of the nanoparticle. In another embodiment, the nanoparticle is between 5 and 20 run (e.g., between 10 and 15 nm in diameter). In another embodiment, the nanoparticle is a metal, such as gold (AU).
In another aspect, the transmission electron microscopy marker contains the nanoparticle of any previous aspect. In another embodiment, the nanoparticle comprises AU.
In another aspect, the invention provides a diagnostic marker containing a detectable CMP conjugate, where the marker binds collagen and detects a disease. In one embodiment, CMP is conjugated to a nanoparticle, a detectable label, or a contrast reagent. In another embodiment, the marker detects a disease characterized by disruption of collagen structure, hi another embodiment, the marker detects the disease by binding to a collagen selected from the group consisting of collagen type 1-type 29 (e.g., type I, II, III, IV, IX, X, or XI). hi one embodiment, the disease is selected from the group consisting of Ehlers-Danlos syndrome, osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymϋller. In one embodiment, the marker is detectable using transmission electron microscopy. hi another aspect, the invention provides a method for diagnosing a subject as having or having a propensity to develop a disease characterized by disruption of a collagen structure, the method involving contacting a patient sample with a detectable CMP-conjugate; and detecting an alteration in a collagen structure present in the patient sample, where the alteration diagnoses the subject as having or having a propensity to develop a disease characterized by disruption of a collagen structure. hi another aspect, the invention provides a method for diagnosing a subject as having or having a propensity to develop a thrombosis, the method involving contacting a blood vessel with a detectable CMP-conjugate; and detecting an alteration present in the blood vessel, where the alteration diagnoses the subject as having or having a propensity to develop a thrombosis, hi one embodiment, the detectable CMP-conjugate binds a collagen selected from the group consisting of collagen type 1-type 29 (e.g., type I, II, III, IV, IX, X, or XI). hi
another embodiment, the disease is selected from the group consisting of Ehlers-Danlos syndrome, Osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymϋller. In another embodiment, the marker binds a collagen present in a thombosis or a vessel wall. hi another aspect, the invention provides diagnostic kit containing a detectable CMP conjugate and directions for the use of the conjugate in the diagnosis of a disease characterized by a disruption in collagen structure, hi one embodiment, the detectable CMP- conjugate binds a collagen selected from the group consisting of collagen type 1-type 29 (e.g., type I, II, III, IX, X, or XI). hi another embodiment, the disease is selected from the group consisting of Ehlers-Danlos syndrome, Osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymuller.
In another aspect, the invention provides a composition for repelling cell adhesion, the composition containing a CMP-poly(ethylene glycol) conjugate, hi one embodiment, CMP- poly(ethylene glycol) conjugate comprises methoxy-PEG2ooo-Gly3-(Pro-Hyp-Gly)7 or (Pro- Hyp-Gly)9-Gly3-PEG5Ooo. In another embodiment, CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG or NHS activated star-shaped PEG. hi another embodiment,
In another embodiment, the composition comprises AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8. hi another embodiment, the CMP comprises -(Pro-Hyp-GlyV, where n is any integer between 1 and 3, and n' is any integer between 1 and 10.
In another aspect, the invention provides matrix containing a CMP -polymer conjugate, where the CMP -polymer conjugate alters the adhesive properties of the matrix, hi one embodiment, the CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG2000-
Gly3-(Pro-Hyp-Gly)7 or (PrO-HyP-GIy)9-GIy3-PEG5O00. In another embodiment, the CMP- poly(ethylene glycol) conjugate comprises grafted linear PEG. In another embodiment, the composition comprises NHS activated star-shaped PEG. In another embodiment, the composition comprises star shaped PEG star shaped PEG having the following formula:
In another embodiment, the composition comprises AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8. In another embodiment, the matrix further contains a cell selected from the group consisting of chondrocytes, endothelial cells, dendritic cells, stem cells, multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, and osteoclasts. In another embodiment, the CMP-poly(ethylene glycol) conjugate is present in a pattern. In yet another embodiment, the CMP comprises -(Pro-Hyp- GIy)n', where n is any integer between 1 and 3, and n' is any integer between 1 and 10. hi another aspect, the invention provides method for repelling cell adhesion on a composition, the method involving fixing a CMP-PEG conjugate to a composition, where the CMP-PEG conjugate repels cell adhesion on the composition, hi one embodiment, the CMP- poly(ethylene glycol) conjugate comprises methoxy-PEG2o0o-Gly3-(Pro-Hyp-Gly)7 or (Pro- Hyp-Gly)9-Gly3-PEG5Qoo- hi another embodiment, the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG or NHS activated star-shaped PEG. In another embodiment, the method repels adhesion of a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
In another aspect, the invention provides composition containing a CMP- poly(ethylene glycol) conjugate that comprises a detectable marker. In one embodiment, CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG2oo0-Gly3-(Pro-Hyp-Gly)7 or (Pro-Hyp-Gly)9-Gly3-PEG50oo. In another embodiment, the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG, NHS activated star-shaped PEG, or star shaped PEG having the formula shown above.
In yet another embodiment, the composition comprises AcGIy-GIy2-LyS-GIy3-(PrO- Hyp-Gly)8.
In another aspect, the invention provides a method of determining the presence of a CMP-poly( ethylene glycol) conjugate in a composition, the method involving contacting a composition with a CMP-poly(ethylene glycol) conjugate containing a detectable marker; and detecting binding of the CMP-poly(ethylene glycol) conjugate to the composition. In one embodiment, the detecting quantifies the level of detectable marker. In another embodiment, the detecting localizes the detectable marker in the composition.
In another aspect, the invention provides a composition for crosslinking collagen, the composition containing a CMP-poly(ethylene glycol) conjugate. In one embodiment, CMP is conjugated to a multi-armed PEG compound, hi another embodiment, PEG comprises an amino group, a thiol group. In one embodiment, the composition comprises star shaped PEG of a Formula shown above. In another embodiment, the composition comprises AcGIy-GIy2- Lys-Gly3-(Pro-Hyρ-Gly)8. hi another aspect, the invention provides method for preventing or treating thrombosis in a subject, the method involving contacting a blood vessel having or having a propensity to develop a thrombosis with a CMP-anti-thrombosis conjugate; where the contacting prevents or treats a thrombosis. In one embodiment, the propensity to develop a thrombosis is related to angioplasty, hi another aspect, the invention provides the vessel is contacted with a hydrogel containing a CMP-anti-thrombosis conjugate. In another embodiment, the CMP- anti-thrombosis conjugate binds collagen present in the thrombosis, hi another embodiment, the CMP-anti-thrombosis conjugate degrades the thrombosis, hi another embodiment, the method further involves monitoring the efficacy of the method (e.g., by determining plasma level of β-thromboglobulin or thrombin-antithrombin complexes).
In yet another aspect, the invention provides diagnostic marker that detects a vessel having or having an increased propensity to develop a thrombosis relative to a control vessel, the marker containing a detectable CMP conjugate that binds collagen, hi one embodiment, the marker detects the presence of a thrombosis in the vessel, hi another embodiment, the
marker binds collagen type III. In yet another embodiment, the marker detects a vessel having a propensity to develop a thrombosis.
In another aspect, the invention provides a diagnostic kit containing the diagnostic marker of any previous aspect and directions for the use of the conjugate in the diagnosis of a thromobosis or a propensity to develop a thrombosis.
In another aspect, the invention provides an implantable, sustained release device containing a CMP conjugate fixed to a collagen matrix. In one embodiment, the conjugate is selected from the group consisting of an antibiotic, a growth factor, an anti-inflammatory, a component of the extracellular matrix, and a small molecule. In another embodiment, the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4. In another embodiment, the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, and platelet-derived growth factor. In another embodiment, the small molecule is selected from the group consisting of anti-thrombotics, anti-atherosclerosis agents, cartilage repair agent. In one embodiment, the collagen matrix is a hydrogel. In another embodiment, the collagen matrix is a pellet or a film.
In another aspect, the invention provides a kit containing an effective amount of an implantable, sustained release device of a previous aspect, and directions for the use of the device in the treatment of a disease or disorder.
In another aspect, the invention provides a hemostatic sponge containing a collagen mimetic peptide and collagen. In one embodiment, the collagen mimetic peptide physically associates with the collagen. In another embodiment, the sponge further contains a natural or synthetic polymer. In another embodiment, the collagen mimetic peptide further comprises a conjugate selected from the group consisting of clotting agents, growth factors, and antibiotics. In another embodiment, the clotting agents is the group selected from the group consisting of thrombin and fibrin.
In another aspect, the invention provides a corneal shield containing a collagen mimetic peptide conjugate and a polymer. In one embodiment, the CMP conjugate comprises an antibiotic, an anti-inflammatory, or a small molecule.
In another aspect, the invention provides a wound healing device containing a collagen mimetic peptide conjugate and a polymer. In one embodiment, the CMP conjugate comprises an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, and a small molecule. In another embodiment, the
device is in the form of a plug, mesh, strip, suture, dressing, patch, threads, suture, or biological fastener. In other embodiments, the device further contains a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
In another aspect, the invention provides a kit containing the wound healing device of any previous aspect.
In another aspect, the invention provides matrix containing a polymer in association with a collagen mimetic peptide, where the matrix promotes the survival, differentiation, or proliferation of a cell. In one embodiment, the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable. In another embodiment, the polymer is collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), polyvinyl alcohol, or polyacrylic acid. In one embodiment, the physical interaction occurs by helical assembly or strand invasion. In another embodiment, collagen mimetic peptide conjugate (e.g., a conjugate containing a reactive group, such as an acrylate group (e.g., PEG mono- or diacrylate)) acts as a cross-linking agent. In another embodiment, the matrix is susceptible to proteolytic breakdown. In another embodiment, the matrix further comprises an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule. In another embodiment, CMP is conjugated to an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
In other embodiment of the above aspects, PEG is star shaped PEG, a multi-armed PEG, a graft linear PEG, PEG200O, or PEG5000. In still other embodiments of the above aspects, the matrix further contains a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
In another aspect, the invention provides a method for synthesizing a matrix, the method involving contacting a collagen mimetic peptide to a polymer and cross-linking the polymer such that a molecular matrix is formed. In one embodiment, the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable. In another embodiment, the polymer is selected from the group consisting of poly(ethylene glycol), poly( ethylene oxide) diacrylate (PEODA), polyvinyl alcohol, or polyacrylic acid.
In another aspect, the invention provides a method for promoting cell survival or proliferation, involving growing a cell in contact with a matrix containing a polymer and a collagen mimetic peptide. In one embodiment, the collagen mimetic peptide is capable of retaining a cell-secreted collagen. In another embodiment, the matrix further comprises an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule. In another embodiment, the CMP is conjugated to an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule. In another embodiment, the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable. In another embodiment, the cell is selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
In yet another aspect, the invention provides a method for replacing a damaged or absent tissue, the method involving growing a cell in a matrix of any one of a previous aspect; and contacting a damaged tissue or site of an absent tissue with the cell and matrix, such that the cell and matrix replaces the damaged or absent tissue.
In yet another aspect, the invention provides a method for or for tissue augmentation, the method involving growing a cell in a matrix of a previous aspect; and contacting a tissue that requires augmentation with the cell and matrix, such that the cell and matrix augments the tissue.
In various embodiments of the above aspects, the cell is derived from or the tissue is selected from any one or more of muscle, cartilage, heart, bladder, brain, nervous tissue, glial tissue, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, ovaries, prostate, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital
tract, ureter, urethra, uterus, breast, skeletal muscle, skin, bone, and cartilage. In still other embodiments of the above aspects, the cell is any one or more of endothelial cells, dendritic cells, stem cells, multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, adipocytes, osteoclasts, and chondrocytes. In another embodiment, the method is useful for cosmetic surgery. In another embodiment, the method reconstructs a breast, a face, or a body part after cancer surgery or trauma.
In yet another aspect, the invention provides a method for promoting cartilage repair, the method involving growing a chondrocyte in a matrix of a previous aspect; and contacting cartilage with the chondrocyte and matrix, where the contact promotes cartilage repair.
In various embodiments of any of the above aspects, the collagen mimetic peptide or collagen mimetic peptide conjugate comprises a Z-[X-Y-GIy]n repeat unit, where Z is any amino acid, X is proline or modified praline (e.g., 4-hydroxyl proline, 4-fluoro praline), Y is proline or modified proline (e.g., 4-hydroxyl proline, 4-fluoro praline), and n is an integer between 1 and 20. In other embodiments of any of the above aspects, the collagen mimetic peptide comprises (ProHypGly)x, (ProProGly)x ,or (ProFlpGly)x, where Hyp is hydroxyl proline, FIp is 4-fiuoro proline, and x is any integer between 1 and 30 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 20, 25, 30). In yet other embodiments of any of the above aspects, the collagen mimetic peptide comprises at least 5, 10, 15, 20, 25, 30, 40, or 50 amino acids. In still other embodiments of any of the above aspects, the collagen mimetic peptide is conjugated to an antibiotic (e.g., penicillin, tetracycline, plectasin, LAH4), a cell adhesion molecule (e.g., cadherin, fibronectin, integrin, laminin, selectin), a contrast agent (e.g., a gadolinium complex, gadodiamide derivative, ferric ammonium citrate, and mangafodipar trisodium), a detectable label (e.g., a colloidal particle, an enzyme, an electron- dense reagent, a fluorescent dye, a hapten, an immunogen, a magnetic bead, a radiolabel, carboxy- fluorescein), a growth factor that promotes angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, or cell survival, such as angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, or platelet-derived growth factor , a component of the extracellular matrix (e.g., collagen, elastin, fibrillin, fibronectin, laminin;
proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and aggrecan), an anti-inflammatory (e.g., corticosteroids, NSAE)S), a polymer (e.g., collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol) (PEG) (e.g., a star shaped PEG, a multi-armed PEG, a graft linear PEG, PEG2000, and PEG5OO0), and a small molecule, such as an anti-thrombotics (e.g., heparin-CMP, Hirudin- CMP, Saratin-CMP), atherosclerosis therapeutic (e.g., cholestyramine, colestipol, nicotinic acid, gemfibrozil, probucol, atorvastatin, lovastatin), a cartilage repair agent (e.g., chondroitan sulfate). In various embodiments, the collagen mimetic peptide binds to any one or more collagen selected from the group consisting of type 1-29 collagen, such as type I, II, III, rv, IX, X, or XL In yet other embodiments of the above aspects, collagen mimetic peptide peptide comprises an amino acid sequence selected from the group consisting of Gly3-(ProHypGly)6, Gly3-(ProHypGly)7; Gly3-(ProHypGly)8, Gly3-(ProHypGly)9, (PrOHyPGIy)6-TyT, (ProHypGly)7-Tyr, (ProHypGly)8-Tyr, Cys-(Pro-Hyρ-Gly)3, Cys-(Pro- Hyp-Gly)5, and Cys-(Pro-Hyp-Gly)7, carboχyfiuorescein-Gly3-(Pro-Hyp-Gly)6, carboxyfluorescein- Gly3-lys-(Pro-Hyp-Gly) 8, PEG2oo0-Gly3-(Pro-Hyp-Gly)7) Methoxy PEG20oo-Gly3-(Pro-Hyρ- GIy)7, (PrO-HyP-GIy)8-GIy3-PEG5000-OH, [AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG, [CF-Gly3-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG, AcGIy-GIy2-LyS-GIy3- (Pro-Hyp-Gly)8, FL-PEG20o0-Gly3-(Pro-Hyp-Gly)7, and 5 carboxyfluorescein -Gly3-(Pro-Hyp- GIy)8-GIy3-PEG500O-OH. In various embodiments of the above aspects, the peptide has a melting transition temperature between 50C and 95°C (e.g., between 10°C and 8O0C, 15°C and 40°C, 20°C and 37°C). In various embodiments of the above aspects, CMP is conjugated to a multi-armed PEG compound. In other embodiment, PEG comprises an amino group, a thiol group, is monoacrylated, or is diacrylated. In yet other embodiments of any of the above aspects, CMP is conjugated to a clotting agent, such as thrombin or fibrin. In yet other embodiments of the above aspects, the polymer is collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), polyvinyl alcohol, or polyacrylic acid. In still other embodiments of the above aspects, the CMP physically interacts or binds collagen. In other embodiments, the physical interaction occurs by helical assembly or strand invasion. In still other embodiments of the above aspects the collagen mimetic peptide conjugate (e.g., a conjugate containing a reactive group, such as an acrylate group (e.g., PEG mono- or diacrylate)) acts as a cross-linking agent. In still other embodiments of any of the above aspects, the polymer is in a hydrogel, is biochemically inert, or is photopolymerizable
By "collagen" is meant a protein component of an extracellular matrix having a tertiary structure that includes polypeptide chains intertwining to form a collagen triple helix
or having a characteristic amino acid composition comprising GIy-X-Y repeat units, or a fragment thereof. Collagens useful in the methods of the invention include any collagen known in the art (e.g., one of collagen type 1-29).
By "collagen mimetic peptide" (CMP) is meant a peptide that is able to form a collagen triple helical structure and physically interacts with a collagen polypeptide. In general a CMP has an amino acid sequence comprising -[X-Y-GIy]n repeat units. In general a CMP binds collagen with high affinity.
A "collagen mimetic peptide conjugate" is a CMP covalently bound to another molecule. Molecules capable of acting as CMP conjugates include, but are not limited to, polypeptides, or fragments thereof, nucleic acid molecules, small molecule compounds, detectable labels, nanoparticles, and polymers.
By "ameliorate" is meant decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease.
By "alteration" is meant a change (increase or decrease) in the expression levels of a gene or polypeptide as detected by standard art known methods such as those described above. As used herein, an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or greater change in expression levels. "
"Biological sample" as used herein refers to a sample obtained from a biological subject, including sample of biological tissue or fluid origin, obtained, reached, or collected in vivo or in situ, that contains or is suspected of containing nucleic acids or polypeptides. Such samples can be, but are not limited to, organs, tissues, fractions and cells isolated from mammals including, humans such as a patient, mice, and rats. Biological samples also may include sections of the biological sample including tissues, for example, frozen sections taken for histologic purposes.
By "detectable label" is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
By "disease" is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
By "an effective amount" is meant the amount required to ameliorate the symptoms of a disease relative in an untreated patient. The effective amount of active compound(s) used to practice the present invention for therapeutic treatment of a neurodegenerative disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an "effective" amount.
By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide. A fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
By "immunological assay" is meant an assay that relies on an immunological reaction, for example, antibody binding to an antigen. Examples of immunological assays include ELISAs, Western blots, immunoprecipitations, and other assays known to the skilled artisan.
By "polymer" is meant a natural or synthetic organic molecule formed by combining smaller molecules in a regular pattern.
By "small molecule" is meant any chemical compound.
By "modulation" is meant any alteration (e.g., increase or decrease) in a biological function or activity.
By "nanoparticle" is meant an aggregate of anywhere from a few hundred to tens of thousands of atoms that have a diameter ranging from 3 -300 nanometers.
By "matrix" is meant a substance that fills the spaces between isolated cells in culture. For some applications, a matrix is an adhesive substrate used to coat a glass or plastic surface prior to cell culture.
By "repelling cell adhesion" is meant decreasing an adhesive characteristic of a composition relative to an untreated composition.
By "reference" is meant a standard or control condition.
By "subject" is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
By "physical interaction" is meant an association that does not require covalent bonding. In one embodiment, a physical interaction includes incorporation into a helical structure.
As used herein, the terms "treat," treating," "treatment," and the like refer to reducing or ameliorating a disorder and/or symptoms associated therewith. It will be appreciated that,
although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated.
As used herein, the terms "prevent," "preventing," "prevention," "prophylactic treatment" and the like refer to reducing the probability of developing a disorder or condition in a subject, who does not have, but is at risk of or susceptible to developing a disorder or condition.
The invention provides modified collagen and related therapeutic methods. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows circular dichroism (CD) thermal melting curves of collagen mimetic peptide derivatives 1~3. The values of Tm (°C) are determined from the temperature at the midpoint of the thermal transition curves.
Figure 2 shows a CD thermal melting curve OfCF-GIy3-(PHG)6 (peptide 4).
Figure 3 shows a CD thermal melting curve of mPEG2Ooo-Gly3-(PHG)7 (peptide 5).
Figure 4 shows a CD measurement of collagen films after the treatment with peptide 2 or blank solution. Both solutions were pre-equilibrated at 80°C before addition to the collagen film. Treatment with blank solution (800C) unfolded the native collagen and only 32% of collagen's original helical content remains after the treatment. However collagen film treated with peptide 2 retains 80% of its original helical content. The additional helical content is likely due to peptide 2 associating with partially unfolded collagen in the form of triple helix.
Figures 5 A and 5B are graphs showing the fluorescence intensities of collagen films (type I, bovine) treated with 5CF labeled CMPs and other control samples. The X axis represents the temperature at which fluorescence solutions were equilibrated prior to addition to the collagen film (see support information). Figure 5A shows the binding of peptide 2 and control samples to collagen (groups a and b) and gelatin (group c) films. The gelatin film was prepared by subjecting the collagen film to heat (800C) for 30 minutes. Figure 5B shows the binding of peptide 4 to collagen films.
Figure 6 shows transmission electron and fluorescence (inset) micrographs of collagen fibers (type I) after the treatment with peptide 4 at 300C. The collagen fibers exhibit native banding pattern suggesting that the modification process did not disrupt the native
collagen structure. The presence of peptide 4 on the collagen fiber was confirmed by fluorescence microscopy (inset).
Figures 7 A, 7B and 7C are optical micrographs of human fibroblasts (Figures 7A and7B) and breast epithelial cells (Figure 7C) cultured on collagen films that were pre-treated with mPEG2Ooo (Figure 7A), or peptide 5 (Figures 7B and 7C). Areas of the picture to the right side of the dotted lines were treated with HiPEG2O0O or peptide 5.
Figure 8 is a schematic diagram showing methods for altering the growth of epithelial cells on a collagen gel using modified CMP conjugated to PEG.
Figures 9A-9C are optical micrographs of human breast epithelial cells cultured on collagen films that were treated with mPEG2ooo-Gly3-(Pro-Hyp-Gly)7 3rd day (Figure 9A), 5th day (Figure 9B), and 7th day (Figure 9C). The bar scales represent 100 μm.
Figures 10A- 1OF are optical micrographs of human breast epithelial cells cultured on collagen films that were treated with (Pro-Hyp-Gly)8-Gly3-PEG5ooo-OH 3rd day (A), 5th day (B), and 7th day (C), or longer 10D- 1OF. The bar scales represent 250 μm.
Figure 11 is a graph that quantitates the release of fluorescence-labeled CMP derivatives from collagen films incubated in PBS buffer solution of pH 7.4 at 37 0C.
Figure 12 is a schematic diagram showing the structure of star shaped, rigid and flexible linear PEG on substrate. The structure of star shaped or suitable linear PEG (PEG5000) explains its capacity for repelling approaching molecules or cells compared to flexible linear PEG (PEG20000).
Figure 13 is a schematic diagram showing the structures of CMP-star shaped PEG. A) [AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG. B) [CF-Gly3-Lys-Gly3-(Pro-Hyp- Gly)8]4-star shaped PEG, fluorescence tagged star shaped PEG-CMP. Star shaped PEG: NHS activated four-armed star shaped PEG, molecular weight is approximately 10,000 Da; CMP: AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8; CF-CMP: carboxyfluorescein-Gly3-lys-(Pro-Hyp- GIy) 8.
Figure 14 shows the thermal melting transition curves for peptides l'~4'.
Figure 15 shows the Gaussian fit of the dynamic light scattering (DLS) data showing the hydrodynamic size of nanoparticle-peptide number (NP-Xs).
Figure 16 shows the determination of the number of peptides per Au NP.
Figures 17A-17D are transmission electron microscope (TEM) micrographs of negatively stained NP-I (Figure 17A), NP-2 (Figure 17B), NP-3 (Figure 17C) and unmodified NPs (Figure 17D). Scale bar = 50 nm
Figures 18A and 18B show the aggregation parameters of NP-3 at different NaCl concentration (Figure 18A) and pH (Figure 18B).
Figures 19A-19C show TEM micrographs of reconstituted type I collagen fibers after incubation with NP-4 (Figure 19A) and NP-3 (Figure 19B) at 25°C. NP-3 shows preferential affinity to the dark bands of collagen fiber (Figure 19C). Scale bar = 500 nm.
Figure 20 shows a TEM micrograph of NP-3 incubated with reconstituted type I collagen fibers at 4O0C.
Figure 21 is a schematic diagram showing the general approach used for collagen mimetic peptide (CMP) functionalized gold nanoparticle (NPs) use. CMP functionalized NPs are highly stable in aqueous solution and exhibit preferential affinity to the gap regions of intact type I collagen fibers. CMP functionalized NPs are used to identify structural abnormalities in collagen fibers that are related to many debilitating human diseases.
Figure 22 is a schematic diagram showing a CMP/ poly(ethylene oxide) diacrylate (PEODA) hydrogel containing cells. The collagen secreted from the cell binds efficiently to the CMP present in the hydrogel matrix.
Figure 23 A and 23B show the effects of CMP on collagen retention. Figure 23 A is a schematic diagram showing that cell-secreted collagen is more effectively retained by hydrogels that include CMP (right panel) than by hydrogels lacking CMP (left panel). Figure 23B is a graph showing hydroxyproline content measured (n=3) in a hydrogel following one week of cell culture. Controls were as PEODA hydrogel alone without modified PEG-CMP.
Figure 24 is a fluorescence micrograph of chondrocytes encapsulated in 2% CMP/PEODA hydrogels after Live/Dead staining.
Figure 25A-25F are micrographs of chondrocytes cultured in PEODA, 1% CMP/PEODA, and 2% CMP/PEODA matrices. Histological sections were evaluated after 2 weeks of culture. Safranine-0 staining for glycosaminoglycan (Figure 25 A, 25B, and 25C) and Masson Trichrome staining for collagen (Figure 25D, 26E, and 26F) were used.
Figures 26A-26C are micrographs showing immunohistochemical staining of chondrocytes cultured in matrices containing PEODA control, 1 % CMP/PEODA, and 2% CMP/PEODA. Antibody for collagen type II was used. Controls showed no staining for antigen.
Figure 27A and 27B are graphs showing the quantitation of extracellular matrix secretions of chondrocytes as evaluated by biochemical assays (n=3, *: p<0.05, **:/K0.0005, ***:/7<0.0001): for glycosaminoglycan content (Figure 27A); or total collagen content
(Figure 27B). Background levels of collagen content present in the acellular CMP hydrogels was subtracted from these totals.
Figure 28 provides a schematic diagram showing monoacrylated PEG-CMP. Monoacrylated PEG-CMP is polymerized with difunctional PEG to form a hydrogel.
DETAILED DESCRIPTION OF THE INVENTION
The invention features compositions comprising modified collagen and related therapeutic and diagnostic methods. In contrast with previous methods, which typically rely on chemical modifications, particularly covalent modifications, the methods described herein provide for the physical modification of collagen. This invention is based, in part, on the discovery that collagen mimetic peptides (CMPs) of sequence -(Pro-Hyp-Gly)x- exhibited strong affinity for collagen. In addition, the invention provides for the modulation of the cell adhesion characteristics of collagen by contacting a poly(ethyleneglycol)-CMP conjugate with collagen.
Collagen
Collagen is the most abundant structural protein in the body, existing as the foremost component of the extracellular matrix (ECM). Most types of collagen contain a unique tertiary structure that includes three individual right-handed helical polypeptide chains intertwining to form a left-handed helix. Collagen has a characteristic amino acid composition comprised of GIy-X-Y repeat units, where 28% of the X positions consist of proline (Pro) and 38% of the Y positions consist of post-translationally modified 4- hydroxyproline residues (Hyp). The triple-helical structure can be denatured upon heating above its melting temperature1. Collagen mimetic peptides (CMPs) with GIy-X-Y sequences have been used to analyze collagen. CMPs based on Pro-Pro-Gly and Pro-Hyp-Gly trimers have been widely studied, and their collagen-like triple helical structure and melting behaviors have been charaterized 2"8. Unlike collagen, CMPs exhibit reversible melting behavior due to their small size. When denatured collagen is cooled, it regains only about 5- 10% of its original triple helical content, and the remainder turns into gelatin. In contrast, CMP regains almost 100% of its original triple helical structure after denaturation.
Collagen is used in a variety of medical applications including hemostatic materials, biocompatible coatings, drug delivery and tissue engineering. Collagen-based biomaterials are also used in soft-tissue engineering and repair, hi the past two decades, a multitude of medical products composed of collagen have been approved by the FDA, and many are
available as commercial products9, including collagen-based corneal shields, anti-infectious catheters, tissue sealants, hemostatic sponges, and topical wound dressing products. Collagen is also used as a tissue engineering substrate for skin10, bone11, and blood vessel replacement12. Collagen has typically been used as a scaffold to support tissue growth and promote healing or for the development of engineered tissues in organ replacement therapies. In virtually any application, wherever collagen is used, CMP modified collogen maybe substituted.
Collagen and Human Disease
Collagens are complex molecules that provide structure, strength, and elasticity (the ability to stretch) to connective tissue. Mutations in I, II, III, IX, X, and XI collagens are associated with a variety of human connective tissue disorders affecting bone, cartilage, and blood vessels. Ehlers-Danlos syndrome (EDS) is most often associated with a genetic defect in type I collagen that is characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. Osteogenesis imperfecta or "brittle bone disease" arises from mutations in two genes encoding type I collagen. People with osteogenesis imperfecta (OI) have bones that fracture easily, low muscle mass, and joint and ligament laxity. There are four major types of OI ranging in severity from mild to lethal. The appearance of people with OI varies considerably. Individuals may also have a blue or gray tint to the sclera (whites of the eyes), thin skin, growth deficiencies, and fragile teeth. They may develop scoliosis, respiratory problems, and hearing loss.
Type II and type XI collagens are components of the cartilage found in joints and the spinal column, the inner ear, and the vitreous humor of the eye. The type II and XI collagenopathies include achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymϋller. The clinical features of the type II and XI collagenopathies typically include problems with bone development that results in short stature, enlarged joints, spinal curvature, and juvenile arthritis. Problems with vision and hearing, as well as a cleft palate with a small lower jaw, are common.
Diagnostics
Given the propensity of collagen mimetic peptides to interact with collagen, compositions of the invention can be used to visualize the structure of collagen by binding a collagen mimetic peptide conjugate to collagen present in a patient sample. In one embodiment, compositions of the invention are used for the diagnosis of a disease or disorder characterized by an alteration in the structure of collagen. In one approach, a nanoparticle having a collagen mimetic peptide, or collagen mimetic peptide conjugate is used as a diagnostic. Such nanoparticles are used to examine the structure of collagen in biological samples derived from patients suspected of having a connective tissue disorder related to the disruption of collagen. The collagen mimetic peptide allows for the physical association of the nanoparticle with a collagen (e.g., type 1-29) present in the tissue sample. The tissue sample is then analysed using a transmission electron microscopy. Under transmission electron microscopy, collagen fibers exhibit characteristic banding patterns. CMP-NPS bind to defined locations within the collagen fiber. This binding pattern provides an indication of the structural integrity of the collagen molecules and their assembly. Alterations in the structural integrity can be visualized with CMP-NP and correlated with particular connective tissue disease states. Thus, CMP-NP are useful as diagnostics for the identification of alterations in collagen types 1-29.
In other embodiments, compositions of the invention are used to identify the presence of a thrombosis comprising collagen in a vessel or to identify vessels having an increased risk of having a thrombosis. Vessels that have been subjected to angioplasty are particularly prone to the formation of a thrombosis.
Collagen Mimetic Peptide Conjugates
Collagen mimetic peptides may be conjugated to a variety of agents using methods known in the art and described herein. Typically, this conjugation is mediated by a covalent bond. Suitable agents include therapeutic and diagnostic agents. Such agents include, but are not limited to, antibiotics, anti-thrombotics, cell adhesion molecules, components of the extracellular matrix, contrast reagents, detectable labels, growth factors, polymers, PEG, and small compounds having biological activity.
Antimicrobial Agents
Any antimicrobial agent known in the art can be used in the compositions of the invention at concentrations generally used for such agents. Antimicrobial agents include antibacterials, antifungals, and antivirals.
Exemplary antibiotics (i.e., antibacterial agents) include the penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), the cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), the tetracyclines (e.g., doxycycline, minocycline, and tetracycline), the aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, streptomycin, and tobramycin), the macrolides (e.g., azithromycin, clarithromycin, and erythromycin), the fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, and vancomycin.
In particular embodiments, a penicillin-CMP antibiotic has the following structure:
Penicillin-CMP (antimicrobial)
In another embodiment, a tetracycline-CMP antibiotic has the following structure:
Tetracycline-CMP (antimicrobial)
In still other embodiments, the antimicrobial is a plectasin-CMP or an LAH4-CMP having the following sequences, respectively:
Plectasin-CMP (antimicrobial)
GFGCNGPWDEDDMQCHNHCKSIKGYKGGYAKGGFVCKCY-CMP
LAH4-CMP
KKALLALALHHLAHLALHLALALKKA-CMP.
Antiviral agents are substances capable of inhibiting the replication of viruses. Examples of anti-viral agents include l,-D-ribofuranosyl-l,2,4-triazole-3 carboxamide, 9-2- hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2'-deoxyuridine, trifluorothymidine, interferon, adenine arabinoside, protease inhibitors, thymidine kinase
inhibitors, sugar or glycoprotein synthesis inhibitors, structural protein synthesis inhibitors, attachment and adsorption inhibitors, and nucleoside analogues such as acyclovir, penciclovir, valacyclovir, and ganciclovir.
Antifungal agents include both fungicidal and fungistatic agents such as, for example, benzoic acid, undecylenic alkanolamide, ciclopirox olamine, polyenes, imidazoles, allylamine, thicarbamates, amphotericin B, butylparaben, clindamycin, econaxole, fluconazole, flucytosine, griseofulvin, nystatin, and ketoconazole.
Atherosclerosis therapeutics
In other embodiments, a CMP conjugate is used for the treatment of atherosclerosis. For such applications a CMP is conjugated, for example to an anti-platelet medication (e.g., aspirin), anti-coagulants (e.g., as heparin, warfarin, aspirin, ticlopidine, and clopidogrel) or inhibitors of platelet clumping. Other atherosclerosis therapeutics include, but are not limited to, cholestyramine, colestipol, nicotinic acid, gemfibrozil, probucol, atorvastatin, lovastatin.
Anti-thrombotics
The collagen mimetic peptides are also useful for the delivery of compounds having anti-thrombotic activity. Such compounds include heparin, hirudin, ReoPro™,Streptokinase, urokinase, and tissue plasminogen activator (t-PA). Other drugs include recombinant, or genetically engineered, t-PA (a newer version of t-PA) and TNK (Tenecteplase) or other antithrombotic compounds. In one particular embodiment, the anti-thrombotic is PEG-CMP having the following structure:
In still other embodiments, the anti-thrombotic is a saratin-CMP or a hirudin CMP conjugate having the following sequences, respectively:
Saratin-CMP (anti-platelet)
EEREDCWTFY ANRKYTDFDKSFKKSSDLDECKKTCFKTEYCYIVFEDTVNKECYYN VVDGEELDQEKFVVDENFTENYLTDCEGKDAGNAAGTGDESDEVDED-K-(CMP)2
Hirudin-CMP (anti-platelet)
LTYTDC(6)TESGQNLC(14)LC(16)EGSNVC(22)GQGNKC(28)ILGSDGEKNQC(39)VTG EGTPKPQSHNDGDFEEIPEEY(SCe)LQ-K-(CMP)2.
Cell adhesion molecules
Cell adhesion molecules suitable for CMP conjugation include components of the extracellular matrix that promote cell spreading or extension or fragments thereof. Preferably, fragments of a cell adhesion molecule include the adhesion molecule binding domaing. Such binding domains include consensus sequences that mediate cell-cell interactions, including the RGD peptide. Integrins bind the RGD motif in cell attachment proteins (See, for example, Tosatti et al., J Biomed Mater Res. 68(3):458-72, 2004; and Reyes et al., J Biomed Mater Res 69:591-600, 2004, which are hereby incorporated by reference). Such molecules may be conjugated to a collagen mimetic peptide of the invention for use in the therapeutic compositions described herein. Exemplary cell adhesion molecules include cadherin (e.g., E-cadherin, N-cadherin), cell adhesion molecule (CAM) (e.g., vascular cell adhesion molecule (VCAM)-I and intracellular adhesion molecule (ICAM)-I neuronal cell adhesion molecule), fibronectin, integrin (e.g., β-integrin), laminin, and selectin.
Growth factors
Growth factors are typically polypeptides or fragments thereof that support the survival, growth, or differentiation of a cell. A collagen mimetic peptide described herein can be conjugated to virtually any growth factor known in the art. Such growth factors include angiopoietin, acidic fibroblast growth factors (aFGF) (GenBank Accession No. NP_149127) and basic FGF (GenBank Accession No. AAA52448), bone morphogenic protein (GenBank Accession No. BAD92827), vascular endothelial growth factor (VEGF) (GenBank Accession No. AAA35789 or NP_001020539), epidermal growth factor (EGF)(GenBank Accession No. NP_001954), transforming growth factor α (TGF-α) (GenBank Accession No. NP_003227) and transforming growth factor β (TFG-β) (GenBank Accession No. 1109243 A), platelet-derived endothelial cell growth factor (PD- ECGF)(GenBank Accession No. NPJ)Ol 944), platelet-derived growth factor (PDGF)( GenBank Accession No. 1109245 A), tumor necrosis factor α (TNF-cc)(GenBank Accession No. CAA26669), hepatocyte growth factor (HGF)(GenBank Accession No. BAA14348), insulin like growth factor (IGF)(GenBank Accession No. P08833), erythropoietin (GenBank Accession No. POl 588), colony stimulating factor (CSF), macrophage-CSF (M- CSF)(GenBank Accession No. AAB59527), granulocyte/macrophage CSF (GM-CSF)
(GenBank Accession No. NP_000749) and nitric oxide synthase (NOS)(GenBank Accession No. AAA36365).
Components of the extracellular matrix
In still other embodiments, a CMP is conjugated to a component of the extracellular matrix (ECM). ECM components include structural proteins, such as collagen and elastin; proteins having specialized functions, such as fibrillin, fϊbronectin, and laminin; and proteoglycans that include long chains of repeating disaccharide units termed of glycosaminoglycans (e.g., hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, aggrecan).
Antiinflammatories
In other embodiments, a CMP is conjugated to an anti-inflammatory agent. Such anti-inflammatory agents include, but are not limited to, Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafϊde; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Diflorasone Diacetate; Diflumidone Sodium; Diflunisal; Difluprednate; Diftalone; Dimethyl Sulfoxide; Drocinonide; Endrysone; Enlimomab; Enolicam Sodium; Epirizole; Etodolac; Etofenamate; Felbinac; Fenamole; Fenbufen; Fenclofenac; Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; FIufenamic Acid; Flumizole; Flunisolide Acetate; Flunixin; Flunixin Meglumine; Fluocortin Butyl; Fluorometholone Acetate; Fluquazone; Flurbiprofen; Fluretofen; Fluticasone Propionate; Furaprofen; Furobufen; Halcinonide; Halobetasol Propionate; Halopredone Acetate; Ibufenac; Ibuprofen; Ibuprofen Aluminum; Ibuprofen Piconol; Ilonidap; Indomethacin; Indomethacin Sodium; Indoprofen; Indoxole; Intrazole; Isoflupredone Acetate; Isoxepac; Isoxicam; Ketoprofen; Lofemizole Hydrochloride; Lornoxicam; Loteprednol Etabonate; Meclofenamate Sodium; Meclofenamic Acid; Meclorisone Dibutyrate; Mefenamic Acid; Mesalamine; Meseclazone; Methylprednisolone Suleptanate; Morniflumate; Nabumetone; Naproxen; Naproxen Sodium; Naproxol; Nimazone; Olsalazine Sodium; Orgotein; Orpanoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride;
Pentosan Polysulfate Sodium; Phenbutazone Sodium Glycerate; Pirfenidone; Piroxicam; Piroxicam Cinnamate; Piroxicam Olamine; Pirprofen; Prednazate; Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate; Rimexolone; Romazarit; Salcolex; Salnacedin; Salsalate; Sanguinarium Chloride; Seclazone; Sermetacin; Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate; Talosalate; Tebufelone; Tenidap; Tenidap Sodium; Tenoxicam; Tesicam; Tesimide; Tetrydamine; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate; Zidometacin; and Zomepirac Sodium.
In other embodiments, a CMP is conjugated to an agent having diagnostic applications. Such agents include contrast reagents and detectable labels.
Contrast reagents
Magnetic resonance imaging (MRI) is typically used for diagnostic purposes to visualized diseased organs or tissues. The utility of MRI is hampered by poor image quality. Collagen mimetic peptides can be conjugated to conventional MRI contrast reagents and then introduced to a desired tissue or tissue sample where the collagen-contrast reagent conjugate binds to collagens present in the tissue to enhance MRI image quality. Exemplary contrast reagents include gadolinium complex, gadodiamide derivative, ferric ammonium citrate, and mangafodipar trisodium.
Detectable labels
Detectable labels include compositions that when linked to a collagen mimetic peptide render the peptide detectable via spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Exemplary detectable labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, and haptens.
Polymers
Virtually any polymer known in the art may be conjugated to a CMP. hi one embodiment, attachment occurs via an acrylate group (e.g., PEG monoacrylate, PEG diacrylate, see Figure 28). Polymers that are biocompatible, non-immunognic, or that support cell survival or proliferation are preferred. Natural or synthetic polymers capable of forming a matrix are particularly useful. A matrix is a substance that fills the spaces between isolated
cells in culture. For some applications, a matrix is an adhesive substrate used to coat a glass or plastic surface prior to cell culture. For other applications, cells are embedded in a matrix, or injected into a matrix already implanted at a desired site. In another approach, a matrix provides a physical support and an adhesive substrate for isolated cells during in vitro culturing and subsequent implantation. Preferred polymers for use in a matrix have mechanical and biochemical properties that enhance the viability and proliferation of transplanted cells, tissues, or organs. The matrix configuration is dependent on the tissue that is to be treated, repaired, or produced, but desirably, the matrix is a pliable, biocompatible, porous template that allows for cell and/or vascular growth.
Preferred polymers for use in the methods of the invention include poly( ethylene glycol) (PEG), star shaped PEG, grafted linear PEG, poly(ethylene oxide) diacrylate (PEODA), polyacrylic acid, poly vinyl alcohol, collagen gels, poly (D, L-lactide-co-glycolide (PLGA) fiber matrices, polyglactin fibers, calcium alginate gels, polyglycolic acid (PGA) meshes, and other polyesters, such as poly- (L-lactic acid) (PLLA) and polyanhydrides. Matrices can include materials that are non-biodegradable or biodegradable. Desirably, biodegradable materials will degrade over a time period of less than a year, more preferably less than six months.
Desirably, a collagen mimetic peptide is conjugated to a polymer capable of forming a hydrogel. A hydrogel is formed when an organic polymer (natural or synthetic) is cross- linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure that entraps water molecules to form a gel. Examples of materials that can be used to form a hydrogel include poly(ethylene glycol), polysaccharides (e.g., alginate), polyphosphazenes, and polyacrylates (e.g., hydroxyethyl methacrylate). Other materials that can be used include proteins (e.g., fibrin, collagen, fibronectin) and polymers (e.g., polyvinylpyrrolidone), and hyaluronic acid. hi general, these polymers are at least partially soluble in aqueous solutions, such as buffered salt solutions, or aqueous alcohol solutions, hi one embodiment, the polymer includes a charged side group, or monovalent ionic salt thereof. Examples of polymers with acidic side groups that can be reacted with cations are poly (phosphazenes), poly (acrylic acids), poly (methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly (vinyl acetate), and sulfonated polymers (e. g. , sulfonated polystyrene). Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used. Examples of acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and
acidic OH groups. Examples of polymers with basic side groups that can be reacted with anions are poly (vinyl amines), poly (vinyl pyridine), poly (vinyl imidazole), and some imino substituted polyphosphazenes. The ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups. Examples of basic side groups are amino and imino groups.
Alginate can be ionically cross-linked with divalent cations in water at room temperature to form a hydrogel matrix. Additional methods for the synthesis of the other polymers described above are known to those skilled in the art (see, for example, Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, E. Goethals, editor, Pergamen Press, Elmsford, NY 1980). Many polymers, such as poly (acrylic acid), are commercially available.
In another approach, a synthetic polymer capable of forming a matrix is used. For some applications, synthetic polymers are preferred for reproducibility and controlled release kinetics. Synthetic polymers that can be used include biodegradable polymers, such as poly(lactide), poly(glycolic acid), poly(lactide-co-glycolide), poly (caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly (vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, Teflon and nylon. Non-degradable materials can also be used to form a matrix.
One preferred non-degradable material for implantation of a matrix is a polyvinyl alcohol sponge, or alkylation or acylation derivatives thereof (e. g., ester derivatives), including esters.
Delivery of CMP Conjugates
The invention provides a simple means for delivering biologically active compounds (including nucleic acids, peptides, small molecule inhibitors, and mimetics) conjugated to a collagen mimetic peptide (CMP). Typically, the CMP conjugate is incorporated into a polymer matrix containing natural or synthetic polymers. In one embodiment, the CMP conjugate is incorporated in a collagen matrix. The collagen matrix comprising the CMP conjugate is delivered to a subject and the CMP conjugate is released from the collagen matrix. The CMP conjugate is capable of acting as a therapeutic for the treatment of a
disease or disorder that requires controlled and/or localized drug delivery over some period of time (e.g., 1, 3, 5, 7 days; 2, 3, 4 weeks; 1, 2, 3, 6, 12 months). A biologic agent conjugated to a collagen mimetic peptide and found to have medicinal value using the methods described herein is useful as a drug or as information for structural modification of existing compounds, e.g., by rational drug design. Desirably, the conjugates include antibiotics (e.g., penicillin, tetracycline, plectasin, LAH4), cell adhesion molecules (e.g., cadherin, fibronectin, integrin, laminin, selectin), growth factors that promote angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, or cell survival (e.g., angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, and platelet-derived growth factor), or small molecules, such as antithrombotics (e.g., heparin-CMP, Hirudin-CMP, Saratin-CMP), anti-atherosclerosis agents, cartilage repair agents (e.g., chondroitin sulfate, glucosamine sulfate, hyaluronic acid). The polymers including the collagen mimetic peptide conjugates are administered either as liquids or solids. Where the polymers are administered as a liquid, they are typically converted to a solid in vivo by cross-linking. Such crosslinking may be accomplished using any method known in the art, such as photopolymerization.
If desired, collagen mimetic peptide conjugates are incorporated into hydrogel- forming polymeric materials that are useful as drug delivery devices. Hydrogel-forming polymers are polymers that are capable of absorbing a substantial amount of water to form elastic or inelastic gels. Medical devices incorporating hydrogel-forming polymers are capable of being implanted in liquid or gelled form. Once implanted, the hydrogel forming polymer absorbs water and swells. The release of a pharmacologically active agent incorporated into the device using a collagen mimetic peptide takes place through this gelled matrix via a diffusion mechanism. Many hydrogels, although biocompatible, are not biodegradable or are not capable of being remodeled and incorporated into a host tissue.
For therapeutic uses, the compositions or agents identified using the methods disclosed herein may be administered systemically. In one embodiment, a matrix comprising a CMP conjegate is formulated in a pharmaceutically-acceptable buffer such as physiological saline. Preferable routes of administration include, for example, subcutaneous, intravenous, interperitoneally, intramuscular, or intradermal injections that provide continuous, sustained levels of the drug in the subject. Treatment of subjects (e.g., human patients or other animals) will be carried out using a therapeutically effective amount of a CMP therapeutic conjugate in a physiologically-acceptable carrier, such as a collagen matrix that includes the
CMP therapeutic conjugate. Suitable carriers and their formulation are described, for example, in Remington's Pharmaceutical Sciences by E. W. Martin. The amount of the therapeutic agent to be administered varies depending upon the manner of administration, the age and body weight of the subject, and with the clinical symptoms of the subject. Generally, amounts will be in the range of those used for other agents used in the treatment of similar diseases (e.g., thrombosis, atherosclerosis). A compound is administered at a dosage that controls the clinical or physiological symptoms of the disease as determined by a diagnostic method known to one skilled in the art.
Formulation of Pharmaceutical Compositions
The administration of a compound for the treatment of a disease may be by any suitable means that results in a concentration of the therapeutic that, combined with other components, is effective in ameliorating, reducing, or stabilizing the disease. The compound may be contained in any appropriate amount in a any suitable carrier substance, and is generally present in an amount of 1-95% by weight of the total weight of the composition. The composition may be provided in a dosage form that is suitable for parenteral (e.g., subcutaneously, intravenously, intramuscularly, or intraperitoneally) administration route. The pharmaceutical compositions may be formulated according to conventional pharmaceutical practice (see, e.g., Remington: The Science and Practice of Pharmacy (20th ed.), ed. A. R. Gennaro, Lippincott Williams & Wilkins, 2000 and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).
Pharmaceutical compositions according to the invention may be formulated to release the active compound substantially immediately upon administration or at any predetermined time or time period after administration. The latter types of compositions are generally known as controlled release formulations, which include (i) formulations that create a substantially constant concentration of the drug within the body over an extended period of time; (ii) formulations that after a predetermined lag time create a substantially constant concentration of the drug within the body over an extended period of time; (iii) formulations that sustain action during a predetermined time period by maintaining a relatively, constant, effective level in the body with concomitant minimization of undesirable side effects associated with fluctuations in the plasma level of the active substance (sawtooth kinetic pattern); (iv) formulations that localize action by, e.g., spatial placement of a controlled release composition adjacent to or in proximity to the tissue or organ that requires treatment;
(v) formulations that allow for convenient dosing, such that doses are administered, for example, once every one or two weeks; and (vi) formulations that target an disease by using carriers or chemical derivatives to deliver the therapeutic agent to a particular cell type whose function is perturbed in the disease. For some applications, controlled release formulations obviate the need for frequent dosing during the day to sustain the plasma level at a therapeutic level.
Any of a number of strategies can be pursued in order to obtain controlled release in which the rate of release outweighs the rate of metabolism of the compound in question. In one example, controlled release is obtained by appropriate selection of various formulation parameters and ingredients, including, e.g., various types of controlled release compositions and coatings. Thus, the therapeutic is formulated with appropriate excipients into a pharmaceutical composition that, upon administration, releases the therapeutic in a controlled manner. Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, molecular complexes, nanoparticles, patches, and liposomes that include the CMP therapeutic conjugate.
Typically, a polymer comprising the CMP therapeutic conjugate is delivered to the subject identified as in need of such treatment. A large number of polymers can be used to construct the delivery devices of the present invention. The only requirements are that they are inert, non-immunogenic and of the desired permeability. The rate of passage of the drug through the material by diffusion is generally dependent on the solubility of the drug therein, as well as on the thickness of the wall. This means that selection of appropriate materials for fabricating the wall will be dependent on the particular drug to be used. The rate of diffusion of the effective agent through a polymeric layer(s) of the present invention may be determined via diffusion studies using, for example, a CMP therapeutic conjugate comprising a detectable label as described herein.
In one embodiment, the CMP therapeutic conjugate is contained within a collagen matrix, such that the CMP therapeutic conjugate physically associates with the collagen. The drug delivery devices of the invention may be made in a wide variety of ways, such as by obtaining an effective amount of a CMP therapeutic conjugate in a collagen matrix and compressing the matrix to a desired shape. Once shaped, one or more coating layers is applied. Such coatings are used to delay release of the CMP therapeutic conjugate. The drug delivery system of the invention is administered to subject via any route of administration known in the art. Such routes of administration include intraocular, oral, subcutaneous,
intramuscular, intraperitoneal, intranasal, dermal, and the like. The drug delivery system of the invention is particularly suitable for direct implantation.
The delivery system is disclosed for the controlled release of CMP therapeutic conjugate from a collagen matrix into the surrounding environment. Controlled release delivery systems include those systems capable of site specific delivery, extended release, sustained release, delayed release, repeat action, prolonged release, bimodal release, pulsitile release, modified delivery, pH sensitive delivery, and/or target specific delivery, among others.
As used herein, optionally, the system may include agents added to aid in gastric bypass or to modify the release profile due to pH-specifϊc swelling characteristics or site- specific enzyme degradation within the gastrointestinal tract. These agents may include, but are not limited to, at least one of alginate, polysaccharides such as such as gelatin or collagen, guar gum, xanthan gum, pectin, heterogeneous protein mixtures, and polypeptides. The polysaccharides may be pectin and/or an alginate salt, among others. The galactomannan gums may be guar gum, xanthan gum and/or locust bean gum, among others. The polyethylene derivatives may be polyethylene oxide (PEO) and/or polyethylene glycol (PEG), among others. The hydrolyzed proteins may be gelatin and/or collagen, among others.
Release of the CMP conjugate into the surrounding environment may be accomplished through a rate-controlled hydration and subsequent swelling of hydrophilic agents. The release of the CMP conjugate is determined by the erosion rate and polymeric disentanglement of the swollen hydrophilic matrix. Typically, the swelling of the hydrophilic matrix allows for a highly reproducible, programmable release pattern. The programmability of the system allows for nearly any physiologically relevant release pattern to be accomplished. Formulation specific to the physical characteristics of a CMP therapeutic conjugate and the desired release profile can be accomplished through both theoretical and empirical means, allowing dissolution of the system and CMP therapeutic conjugate release to occur in a specific physiologic region. Release of contents in a given region of the gastrointestinal tract is accomplished by the slowly hydrating hydrophilic matrix containing the biological actives segregated from the external environment until the desired physiologic region of release, which may be employed to achieve gastric bypass. Consideration of both the area and duration of release is essential in formulation so as to program the system with an appropriate ratio of components to ensure the desired release profile.
Parenteral Compositions
The pharmaceutical composition may be administered parenterally by injection, infusion or implantation (subcutaneous, intravenous, intramuscular, intraperitoneal, or the like) in dosage forms, formulations, or via suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants. The formulation and preparation of such compositions are well known to those skilled in the art of pharmaceutical formulation. Formulations can be found in Remington: The Science and Practice of Pharmacy, supra.
Compositions for parenteral use may be provided in unit dosage forms (e.g., in single- dose ampoules), or in vials containing several doses and in which a suitable preservative may be added (see below). The composition may be in the form of a solution, a suspension, an emulsion, an infusion device, or a delivery device for implantation, or it may be presented as a dry powder to be reconstituted with water or another suitable vehicle before use. Apart from the active active inflammatory bowel disorder therapeutic (s), the composition may include suitable parenterally acceptable carriers and/or excipients. The active inflammatory bowel disorder therapeutic (s) may be incorporated into microspheres, microcapsules, nanoparticles, liposomes, or the like for controlled release. Furthermore, the composition may include suspending, solubilizing, stabilizing, pH-adjusting agents, tonicity adjusting agents, and/or dispersing, agents.
As indicated above, the pharmaceutical compositions according to the invention may be in the form suitable for sterile injection. To prepare such a composition, the suitable active CMP therapeutic conjugate(s) are dissolved or suspended in a parenterally acceptable liquid vehicle. Among acceptable vehicles and solvents that may be employed are water, water adjusted to a suitable pH by addition of an appropriate amount of hydrochloric acid, sodium hydroxide or a suitable buffer, 1,3-butanediol, Ringer's solution, and isotonic sodium chloride solution and dextrose solution. The aqueous formulation may also contain one or more preservatives (e.g., methyl, ethyl or n-propyl p-hydroxybenzoate). In cases where one of the compounds is only sparingly or slightly soluble in water, a dissolution enhancing or solubilizing agent can be added, or the solvent may include 10-60% w/w of propylene glycol or the like.
Controlled Release Parenteral Compositions
Controlled release parenteral compositions may be in form of aqueous suspensions, microspheres, microcapsules, magnetic microspheres, oil solutions, oil suspensions, or
emulsions. Alternatively, the active drug may be incorporated in biocompatible carriers, liposomes, nanoparticles, implants, or infusion devices.
Materials for use in the preparation of microspheres and/or microcapsules are, e.g., biodegradable/bioerodible polymers, such as polygalactia poly-(isobutyl cyanoacrylate), poly(2-hydroxyethyl-L-glutam- nine) and, poly(lactic acid). Biocompatible carriers that may be used when formulating a controlled release parenteral formulation are carbohydrates (e.g., dextrans), proteins (e.g., albumin), lipoproteins, or antibodies. Materials for use in implants can be non-biodegradable (e.g., polydimethyl siloxane) or biodegradable (e.g., poly(caprolactone), poly(lactic acid), poly(glycolic acid) or poly(ortho esters) or combinations thereof).
Solid Dosage Forms For Oral Use
Formulations for oral use include tablets containing the active ingredient(s) in a mixture with non-toxic pharmaceutically acceptable excipients. Such formulations are known to the skilled artisan. Excipients may be, for example, inert diluents or fillers (e.g., sucrose, sorbitol, sugar, mannitol, microcrystalline cellulose, starches including potato starch, calcium carbonate, sodium chloride, lactose, calcium phosphate, calcium sulfate, or sodium phosphate); granulating and disintegrating agents (e.g., cellulose derivatives including microcrystalline cellulose, starches including potato starch, croscarmellose sodium, alginates, or alginic acid); binding agents (e.g., sucrose, glucose, sorbitol, acacia, alginic acid, sodium alginate, gelatin, starch, pregelatinized starch, microcrystalline cellulose, magnesium aluminum silicate, carboxymethylcellulose sodium, methylcellulose, hydroxypropyl methylcellulose, ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol); and lubricating agents, glidants, and antiadhesives (e.g., magnesium stearate, zinc stearate, stearic acid, silicas, hydrogenated vegetable oils, or talc). Other pharmaceutically acceptable excipients can be colorants, flavoring agents, plasticizers, humectants, buffering agents, and the like.
The tablets may be uncoated or they may be coated by known techniques, optionally to delay disintegration and absorption in the gastrointestinal tract and thereby providing a sustained action over a longer period. The coating may be adapted to release the active drug in a predetermined pattern (e.g., in order to achieve a controlled release formulation) or it may be adapted not to release the active drug until after passage of the stomach (enteric coating). The coating may be a sugar coating, a film coating (e.g., based on hydroxypropyl methylcellulose, methylcellulose, methyl hydroxyethylcellulose, hydroxypropylcellulose,
carboxymethylcellulose, acrylate copolymers, polyethylene glycols and/or polyvinylpyrrolidone), or an enteric coating (e.g., based on methacrylic acid copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, shellac, and/or ethylcellulose). Furthermore, a time delay material such as, e.g., glyceryl monostearate or glyceryl distearate may be employed.
The solid tablet compositions may include a coating adapted to protect the composition from unwanted chemical changes, (e.g., chemical degradation prior to the release of the active active inflammatory bowel disease therapeutic substance). The coating may be applied on the solid dosage form in a similar manner as that described in Encyclopedia of Pharmaceutical Technology, supra.
At least two active therapeutics may be mixed together in the tablet, or may be partitioned. In one example, the first active therapeutic is contained on the inside of the tablet, and the second active therapeutic is on the outside, such that a substantial portion of the second therapeutic is released prior to the release of the first active therapeutic.
Formulations for oral use may also be presented as chewable tablets, or as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent (e.g., potato starch, lactose, microcrystalline cellulose, calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil. Powders and granulates may be prepared using the ingredients mentioned above under tablets and capsules in a conventional manner using, e.g., a mixer, a fluid bed apparatus or a spray drying equipment.
Controlled Release Oral Dosage Forms
Controlled release compositions for oral use may, e.g., be constructed to release the active therapeutic by controlling the dissolution and/or the diffusion of the active substance. Dissolution or diffusion controlled release can be achieved by appropriate coating of a tablet, capsule, pellet, or granulate formulation of compounds, or by incorporating the compound into an appropriate matrix. A controlled release coating may include one or more of the coating substances mentioned above and/or, e.g., shellac, beeswax, glycowax, castor wax, carnauba wax, stearyl alcohol, glyceryl monostearate, glyceryl distearate, glycerol palmitostearate, ethylcellulose, acrylic resins, dl-polylactic acid, cellulose acetate butyrate, polyvinyl chloride, polyvinyl acetate, vinyl pyrrolidone, polyethylene, polymethacrylate, methylmethacrylate, 2-hydroxymethacrylate, methacrylate hydrogels, 1,3 butylene glycol,
ethylene glycol methacrylate, and/or polyethylene glycols. In a controlled release matrix formulation, the matrix material may also include, e.g., hydrated metylcellulose, carnauba wax and stearyl alcohol, carbopol 934, silicone, glyceryl tristearate, methyl acrylate-methyl methacrylate, polyvinyl chloride, polyethylene, and/or halogenated fluorocarbon.
A controlled release composition containing one or more therapeutic compounds may also be in the form of a buoyant tablet or capsule (i.e., a tablet or capsule that, upon oral administration, floats on top of the gastric content for a certain period of time). A buoyant tablet formulation of the compound(s) can be prepared by granulating a mixture of the compound(s) with excipients and 20-75% w/w of hydrocolloids, such as hydroxyethylcellulose, hydroxypropylcellulose, or hydroxypropylmethylcellulose. The obtained granules can then be compressed into tablets. On contact with the gastric juice, the tablet forms a substantially water-impermeable gel barrier around its surface. This gel barrier takes part in maintaining a density of less than one, thereby allowing the tablet to remain buoyant in the gastric juice.
CMP Conjugates Coatings
A CMP conjugate may be included in a coating material that is used to coat a medical device (e.g., drug delivery or other medical device). Such coatings are used, for example, for altering the adehesive properties of the device or for drug delivery. For example, a polymeric coating, such as collagen, polyethylene glycol, polyurethane, polytetrafluoroethylene, polyalkylmethacrylates, polyarylmethacrylates, poly(ethylene-co-vinyl acetate), or any other polymer or combination of polymers, may be combined with a CMP of the present invention, such that the CMP is fixed to or physically associates with the polymer, and the CMP conjugate polymer combination is applied to a medical device. The CMP conjugate thereby modulates the cell adhesive properties of the medical device or provides for release of a therapeutic from the device. Such coatings can be applied to any medical device known in the art, including, but not limited to, drug-delivering vascular stents (e.g., a balloon-expanded stents); other vascular devices (e.g., grafts, catheters, valves, artificial hearts, heart assist devices); implantable defibrillators; blood oxygenator devices (e.g., tubing, membranes); surgical devices (e.g., sutures, staples, anastomosis devices, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds); membranes; cell culture devices; chromatographic support materials; biosensors; shunts for hydrocephalus; wound management devices; endoscopic devices; infection control devices; orthopedic devices (e.g., for joint implants, fracture
repairs); dental devices (e.g., dental implants, fracture repair devices), urological devices (e.g., penile, sphincter, urethral, bladder and renal devices, and catheters); colostomy bag attachment devices; ophthalmic devices (e.g. intraocular coils/screws); glaucoma drain shunts; synthetic prostheses (e.g., breast); intraocular lenses; respiratory, peripheral cardiovascular, spinal, neurological, dental, ear/nose/throat (e.g., ear drainage tubes); renal devices; and dialysis (e.g., tubing, membranes, grafts), urinary catheters, intravenous catheters, small diameter grafts, vascular grafts, artificial lung catheters, atrial septal defect closures, electro-stimulation leads for cardiac rhythm management (e.g., pacer leads), glucose sensors (long-term and short-term), degradable coronary stents (e.g., degradable, non- degradable, peripheral), blood pressure and stent graft catheters, birth control devices, prostate cancer implants, bone repair/augmentation devices, breast implants, cartilage repair devices, dental implants, implanted drug infusion tubes, intravitreal drug delivery devices, nerve regeneration conduits, oncological implants, electrostimulation leads, pain management implants, spinal/orthopedic repair devices, wound dressings, embolic protection filters, abdominal aortic aneurysm grafts, heart valves (e.g., mechanical, polymeric, tissue, percutaneous, carbon, sewing cuff), valve annuloplasty devices, mitral valve repair devices, vascular intervention devices, left ventricle assist devices, neuro aneurysm treatment coils, neurological catheters, left atrial appendage filters, hemodialysis devices, catheter cuff, anastomotic closures, vascular access catheters, cardiac sensors, uterine bleeding patches, urological catheters/stents/implants, in vitro diagnostics, aneurysm exclusion devices, and neuropatches. Examples of other suitable devices include, but are not limited to, vena cava filters, urinary dialators, endoscopic surgical tissue extractors, atherectomy catheters, clot extraction catheters, coronary guidewires, drug infusion catheters, esophageal stents, circulatory support systems, angiographic catheters, coronary and peripheral guidewires, hemodialysis catheters, neurovascular balloon catheters, tympanostomy vent tubes, cerebrospinal fluid shunts, defibrillator leads, percutaneous closure devices, drainage tubes, thoracic cavity suction drainage catheters, electrophysiology catheters, stroke therapy catheters, abscess drainage catheters, biliary drainage products, dialysis catheters, central venous access catheters, and parental feeding catheters.
Other examples of medical devices suitable for the present invention include, but are not limited to implantable vascular access ports, blood storage bags, blood tubing, central venous catheters, arterial catheters, vascular grafts, intraaortic balloon pumps, cardiovascular sutures, total artificial hearts and ventricular assist pumps, extracorporeal devices such as blood oxygenators, blood filters, hemodialysis units, hemoperfusion units, plasmapheresis
units, and artificial organs. It is noted that in other embodiments of the present invention, the CMP conjugates of the present invention may also be adhered to the medical device by means other than coating materials, such as adhesives or compression.
In one embodiment, a polymeric solution is applied to the surface of a device, and a CMP conjugate is applied subsequently. The polymeric solution comprising the CMP is allowed to dry, cure and/or polymerize thereby fixing the CMP conjugate to the polymeric material coating. In another embodiment, the CMP is allowed to associate with the polymer prior to, during or following application of the CMP polymer conjugate to the device. In still other embodiments, the CMP conjugate includes a therapeutic agent suitable for delivery from a CMP polymer coating.
Any suitable administration method know in the art may be utilized to administer the CMP conjugate to the surface. For example, the CMP conjugate may be administered to the surface by press rolling the polymer coated surface in the CMP conjugate, spraying the CMP conjugate onto the device, or gently heating (e.g., below the transition melting temperature) the polymer coating in the presence of a CMP conjugate, such that the heating facilitates the incorporation of the CMP conjugate into the polymer. Typically, such heating is to a temperature sufficient to denature the CMP.
The polymeric materials with biocompatible surfaces may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, including drug delivery patches, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices, including protein matrix suture material and meshes, skin/bone/tissue grafts, adhesion prevention barriers, cell scaffolding, medical device coatings/films and other biocompatible implants.
Wound Healing Devices
The present invention also provides wound healing compositions that utilize a polymeric material comprising a CMP conjugate. The wound healing devices may be configured by fixing a CMP conjugate to a polymer (e.g., a collagen film or PEODA) and forming the CMP conjugate containing polymer into a shape and size sufficient to accommodate the wound being treated. Such wound healing devices are desirably produced in whatever shape and size is necessary to provide optimum treatment to the wound. These devices can be produced in forms that include, but are not limited to, plugs, meshes, strips, sutures, or any other form able to accommodate and assist in the repair of a wound. The damaged portions of the patient that may be treated with a devices made of the particles of
the present invention include, but are not limited to, skin, tissue (nerve, muscle, cartilage, brain, spinal cord, heart, lung, etc.) and bone. Other similar devices are administered to assist in the treatment repair and remodeling of a damaged tissue, bone, or cartilage. If desired, the wound healing device comprises a matrix containing one or more cells. For some applications, it is desirable for the device to be incorporated into an existing tissue to facilitate wound repair. For other applications, it is desirable for the device to degrade over the course of days, weeks, or months.
If desired the CMP is conjugated to a therapeutic agents and the CMP conjugate is delivered to a wound using a polymeric material to form a delivery system. Preferably, the polymer contains an effective amount of a CMP conjugate that includes a dosage of the chemical or pharmaceutically active component. An adhesive or other adhering means may be applied to the outer edges of the polymeric material to hold the patch in position during the delivery of the chemical or pharmaceutically active component. This polymeric delivery system provides for the systematic and/or locally administration of a desired amount of a therapeutic agent.
Other embodiments of the present invention include wound-healing devices configured and produced as polymeric material biological fasteners, such as threads, sutures and woven sheets. Threads and sutures comprising various embodiments of the polymeric material provide a biocompatible fastening and suturing function for temporarily treating and sealing an open wound. Additionally, the biological fasteners may include pharmacologically active agents that may assist in the healing and remodeling of the tissue within and around the wound.
In other embodiments, the CMP conjugate is administered directly to an injured area. The CMP conjugate is administered by sprinkling, packing, implanting, inserting or applying or by any other administration means to open wounds on the body.
Hemostatic Applications
The invention further provides hemostatic matrices (e.g., hemostatic sponges) that contain a polymer, such as collagen, and a CMP or CMP conjugate capable of absorbing bodily fluids (e.g. blood). Such matrices generally comprise porous compositions formed from a suitable biocompatible matrix. Suitable biocompatible matrix materials include naturally-occurring polymers, such as collagen, and/or synthetic polymers. In general, sponge matrices can be formed by providing a liquid solution or suspension of a matrix- forming material, and causing the material to form a porous three-dimensionally stable
structure. In one embodiment, a collagen solution is prepared. Collagen is derived from a natural source (e.g., bovine, porcine, human) or is synthetically-derived. The collagen is typically digested to form a collagen solution. Such digestion is usually carried out under acidic conditions. Optionally, enzymatic digestion may be utilized using known enzymes for this purpose such as pepsin, trypsin, and/or papain. After digestion, the enzymes are removed using standard methods. Additional information relating to collagenous matrix materials and their preparation, is described in U.S. Patent Nos. 4,511,653, 4,902,508, 4,956,178, 5,554,389, and 6,099,567, and International Publication Nos. WO9825637 and WO9822158, each of which is hereby incorporated herein by reference in its entirety.
A CMP or CMP conjugate is incubated with the collagen prior to, during, or after polymerization, such that the CMP or CMP conjugate is incorporated into the collagen. This incubation is typically carried out at a temperature that is above the melting point of the CMP as determined using methods described herein. If desired, the collagen solution is heated gently (e.g., at or below the transition melting temperature of the CMP) to destabilize the collagen and to facilitate incorporation of the CMP. Preferably, the heating is below the level required to denature the collagen. If desired, the resulting collagen solution is crosslinked. Such crosslinking may be achieved using CMPs. Alternatively, conventional crosslinking agents are used, such as glutaraldehyde, formaldehyde, carbodiimides, UV irradiation, or other crosslinking agents. In one embodiment, a polyepoxide crosslinker is used, such as polyglycidyl ether (e.g., ethylene glycol diglycidyl ether). Typically, polyglycidyl ethers or polyepoxide compounds impart polar groups and a hydrophilic character to the resulting matrix. Preferably, the resulting matrix is wettable and provides for rapid hydration and expansion.
Sponge matrix materials of the invention will advantageously be highly expandable when wetted. Preferably, the sponge has the capacity to expand at least 100%, 200%, 300%, 500%, or 1000% by volume when wetted to saturation with deionized water. Preferred sponge materials achieve rapid volume expansions (e.g., maximum expansion in less than 10 seconds or 5 seconds, when immersed in deionized water) Hemostatic sponges are produced in any size required for application to a wound. Preferably, the expanded sponge exerts compression on surrounding tissues when implanted or delivers an active agent to the implantation site and surrounding tissue.
Compact, dense sponge matrices of the invention are prepared by first hydrating a porous sponge matrix, and then compressing and drying the matrix. Drying will be conducted to reduce the liquid (e.g. water) content of the matrix to less than about 5%, 10%,
or 20% by weight. The sponge matrix is stabilized structurally and remains in a highly dense and compacted state until contacted with a liquid susceptible to absorption by the matrix, for example body fluids. The pores of the matrix are thereby stably retained at a volume substantially reduced from their maximum volume, but return to a partially or fully expanded state when the matrix material is wetted.
For medical use, the compacted or compressed sponge is sterilized using any suitable means (e.g., radiation). The device is packaged in sterile packaging for medical use.
Sponge elements or other devices of the invention may also contain one or more active therapeutic agents. For example, they include agents that promote clotting (e.g., thrombin and/or fibrinogen). Alternatively or in addition, sponge elements or other devices of the invention include growth factors that promote tissue growth and healing.
Methods for Constructing Engineered Tissue Scaffolds
Polymeric matrices that comprise a collagen mimetic peptide are useful for supporting the survival of a variety of cell types including, but not limited to, endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, or chondrocytes. These cell-types may be introduced prior to, during, or after gelation. This introduction may take place in vitro or in vivo. When the cells are introduced in vivo, the introduction may be at the site where implantation is desired or at a location removed from that site. Exemplary routes of administration of the cells include injection (e.g., by catheter) and surgical implantation.
A polymeric matrix comprising a collagen mimetic peptide can be filled with cells from virtually any organ. Because many cell- types can be expanded in vitro, grafts can be made using a limited number of cells (e. g. , 100,500, 1000,10, 000,100, 000,1, 000,000, 10,000, 000, or 100,000, 000), which represent a small percentage (e. g. , 0.0001%, 0.001%, 0.005%, 0.01%, 0.05%, 0.10%, 1.0%, 2.0%, or 5.0%) of the cells present in a naturally-occurring tissue or organ. Exemplary cells for organogenesis include, hepatocytes, myocytes (e. g. , cardiac or skeletal muscle myocytes), keratinocytes, osteocytes, chondrocytes, islet cells, nerve cells, astrocytes, glial cells from the central or peripheral nervous system, preadipocytes derived from fat or breast tissue, and adipocytes. Such cells might be obtained
from the intended implant recipient (an autograft), from a donor (allogeneic graft), or from a cell line. One particular advantage of autografts is that the grafted tissue does not induce an immune response because the grafted cells are recognized as self (Heath etal., Trends Biotechnol, 18 : 17-19,2000). In other embodiments, such cells are obtained from a mammal of a different species (e. g., pig or primate).
Cell Isolation
One aspect of the invention pertains to a matrix that may be used to promote the healing of an injured tissue, for replacement of a damaged or absent tissue, or for tissue augmentation. The implanted cells may be derived from the recipient's own tissue, derived from a different individual of the same species, or derived from a mammalian species that is different from the recipient (e. g. , pig or primate). Cells can be isolated from a number of sources, for example, from biopsies or autopsies using standard methods. The isolated cells are preferably autologous cells obtained by biopsy from the subject. The cells from a biopsy can be expanded in culture. Cells from relatives or other donors of the same species can also be used with appropriate immunosuppression. Methods for the isolation and culture of cells are discussed in Fauza et al. (J. Ped. Surg. 33,7- 12,1998).
Cells are isolated using techniques known to those skilled in the art. For example, a selected tissue or organ can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage. Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with digestive enzymes (e. g. , trypsin, chymotrypsin, collagenase, elastase, hyaluronidase, DNase, pronase, and dispase). Mechanical disruption can be accomplished by scraping the surface of the organ, the use of grinders, blenders, sieves, homogenizers, pressure cells, or sonicators. For a review of tissue disruption techniques, see Freshney, (Culture of Animal Cells. A Manual of Basic Technique, 2d Ed. , A. R. Liss, Inc. , New York, Ch. 9, pp. 107-126, 1987) Preferred cell types include, without limitation, chondrocytes, endothelial cells, osteoblasts, and nerve cells. Once the tissue has been reduced to a suspension of individual cells, the suspension can be fractionated into subpopulations. This may be accomplished using standard techniques (e.g., cloning and positive selection of specific cell types or negative selection, i.e., the destruction of unwanted cells). Selection techniques include separation based upon differential cell agglutination in a mixed cell population, freeze-thaw procedures, differential adherence properties of the cells
in the mixed population, filtration, conventional and zonal centrifugation, unit gravity separation, countercurrent distribution, electrophoresis and fluorescence-activated cell sorting. For a review of clonal selection and cell separation techniques, seeFreshney, Culture of Animal Cells, A Manual of Basic Techniques, 2d Ed. , A. R. Liss, Inc. , New York, Ch. 11 and 12, pp. 137-168,1987).
Cell fractionation may be useful when the donor has a disease, such as cancer. Isolated cells can be cultured in vitro to increase the number of cells available for transplantation. The use of allogenic cells, and more preferably autologous cells, is preferred to prevent tissue rejection. However, if an immunological response does occur in the subject after implantation of the engineered organ, the subject may be treated withimmunosuppressive agents, such as cyclosporin or FK506, to reduce the likelihood of rejection.
Isolated cells may be transfected. Useful genetic material may be, for example, genetic sequences that are capable of reducing or eliminating an immune response in the host. For example, the expression of cell surface antigens such as class I and class II histocompatibility antigens may be suppressed. This may allow the transplanted cells to have reduced chance of rejection by the host. In addition, transfection could also be used for gene delivery. The cell-substrate construct can carry genetic information required for the long- term survival of the host or the artificial organ or for detecting or monitoring the cells. In one example, the implanted cell or cells are genetically modified to express a bioactive molecule that promotes cell growth or survival. In another example, the cell or cells are genetically modified to expresses a fluorescent protein marker. Exemplary markers include GFP, EGFP, BFP, CFP, YFP, and RFP. The cell- substrate construct can also carry genetic information required for promoting or maintaining angiogenesis. Transfection may be used for transient gene expression or stable gene expression by incorporation of the gene into the host cell.
Isolated cells can be normal or genetically-engineered to provide additional or normal function. Methods for genetically engineering cells with viral vectors such as retroviral vectors or other methods known to those skilled in the art can be used. These include using expression vectors which transport and express nucleic acid molecules in the cells (see, for example, Goeddel etal., (Gene Expression Technology: Methods in Enzymology 185, AcademiPress, San Diego, Calif. , 1990). Vector DNA is introduced into prokaryotic oreukaryotic cells via conventional transformation or transfection techniques. Suitable methods for transforming or transfecting host cells can be found in Sambrook et al.
(Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989) ), and other laboratory textbooks.
Methods for Repairing Damaged Tissues and Organs
The invention features methods of repairing diseased or damaged tissues and organs. Cells are administered to a damaged or diseased tissue or organ. These methods may stabilize a damaged tissue or organ in a patient on a transplantation waiting list; or the methods may repair a damaged or diseased tissue or organ, thereby obviating the need for transplantation. Methods for repairing damaged tissue or organs may be carried out either in vitro, in vivo, or ex vivo.
Methods for Producing Engineered Tissues or Organs
The invention features methods of producing an engineered replacement tissue. Cells are preferably cultured in the presence of a matrix that contains a CMP or CMP conjugate. If desired, a CMP conjugate is used to modulate the adhesive properties of the matrix. For some applications, the CMP is conjugated to a PEG, such that the CMP PEG conjugate is designed to repel the adhesion of a cell. Pn another embodiment, the CMP conjugate is designed to promote cell adhesion, thereby promoting incorporation of the matrix (e.g., a synthetic polymer based matrix, decellularized skin or other tissue source; collagen or other extracellular matrix gel) into an existing tissue as described herein. Methods for producing an engineered tissue or organ may be carried out either in vitro, in vivo, or ex vivo. It is also contemplated that matrices of the invention comprising cells are administered to a mammal to treat damage or deficiency of cells in an organ, muscle, or other body structure, or to form an organ, muscle, or other body structure. Desirable organs include the bladder, brain, nervous tissue, glial tissue, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, ovaries, prostate, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, breast, skeletal muscle, skin, bone, and cartilage.
Engineered Bone or Cartilage
Exemplary transplantation methods of the present invention include repairing or replacing bone or cartilaginous tissue, such as articular cartilage. Traditional bone or cartilage tissue engineering methods can be improved by administering chondrocytes in a matrix comprising collagen mimetic peptides to the damaged or diseased bone or cartilage in vivo or to a bone or cartilage transplant tissue before, during, or after the transplant tissue is
administered to a mammal. Traditional bone and cartilaginous tissue reconstruction methods are described, for example, in U. S.patentNos. 6,197, 061; 6,197, 586; 6,228, 117; 6,419, 702;and 6, 451,060. Engineered bone is useful for the treatment of a variety of diseases or disorders, including arthritis, cancer, congenital defects of bone or cartilage such as worn or torn cartilage in joint linings (e.g., knee joint, hip joint, and temporomandibular joint) and trauma. It is known that connective-tissue cells, including fibroblasts, cartilage cells, and bone cells, can undergo radical changes of character. A great variety of materials are useful as matrices for this purpose. For example, materials such as PEODA, collagen gels, poly (D, L-lactide-co-glycolide (PLGA) fiber matrices, polyglactin fibers, calcium alginate gels, polyglycolic acid (PGA) meshes, and other polyesters such as poly- (L-lactic acid) (PLLA) and polyanhydrides are among those suggested. Matrices can include materials that are nonbiodegradable or biodegradable. Desirably, biodegradable materials will degrade over a time period of less than a year, more preferably less than six months.
Methods for treating connective tissue disorders using engineered cartilaginous or connective tissues are described, for example, in U. S. Patent Nos.: 5,226, 914; 5,041, 138; 5,368, 858; 5,632, 745; 6,451, 060; 6,197, 586; and 6,197, 061. Surgical procedures related to bone tissue deficiencies vary from joint replacement or bone grafting to maxillo-facial reconstructive surgery. Such methods are known to the skilled artisan.
Engineered Soft Tissue
Traditional methods of soft tissue reconstruction, as described in U. S. Patent No. 5,716, 404, can be improved by administering cells of the invention in a matrix comprising collagen mimetic peptides to the soft tissue to be transplanted. For example, engineered soft tissue is useful for cosmetic surgery or for reconstruction of the breast, face, or other body part after cancer surgery or trauma. For soft tissue reconstruction, the matrix, which is mixed with cells may form a hydrogel.
Engineered Tissue and Organ Transplantation
A donor organ, donor cell, engineered tissue, or engineered organ is transplanted into a patient (e.g.,, a human or mammal) for the treatment or stabilization of a condition, disease, or disorder using standard methods known to the skilled artisan. Methods for three- dimensional skeletal muscle tissue-engineering are described by Saxena etal., (Biomed. Mater. Eng. 11 (4): 275-281,2001).
Corneal Shields
Corneal shields of the invention are ophthalmic lens that contain collagen in association with a collagen mimetic peptide Collagen is a major component of the white sclera and the clear cornea. Natural or synthetic collagens are shaped into a contact lens that can be placed on the surface of the eye. The collagen shield provides a protective environment that promotes the healing of surgical and traumatic wounds to the eye. Such shields are useful as ophthalmic dressings and as ophthalmic drug delivery devices. Drugs or diagnostic agents which can be administered include antibiotics, such as beta-lactam antibiotics, such as cefoxitin, n-formamidoylthienamycin and other thienamycin derivatives, tetracyclines, chloramphenicol, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides; antiinflammatories, such as cortisone, hydrocortisone, hydrocortisone acetate, betamethasone, dexamethasone, dexamethasone sodium phosphate, prednisone, methylprednisolone, medrysone, fiuorometholone, prednisolone, prednisolone sodium phosphate, triamcinolone, indainethacin, sulindac. Desirably, the corneal shield comprises a physiologically acceptable vehicle having a buffered pH and hypoosmotic, hyperosmotic, or isoosmotic characteristics. Typically, the pH and osmolality of the ophthalmic delivery device is matched to the pH and osmolality of the eye. In some embodiments, the corneal shield is subject to degradation over time. Such degradation is typically accomplished via a naturally occurring enzyme present in tears.
Delivery of Collagen Mimetic Peptide Therapeutics
Collagen mimetic peptide therapeutics include cell containing matrices as well as collagen mimetic peptide conjugates. These therapeutics can be delivered by any method known to the skilled artisan. In one approach, a CMP conjugate is administered via an intravenous catheter that is inserted into a blood vessel and guided through am artery or vein to a desired location. For example, a CMP conjugate that includes an anti-thrombotic is administered via a catheter directly to a clot. The end of the catheter may be placed in the vessels leading to the brain, lung, heart, arm, or leg depending upon the location of the clot. In another approach, a liquid solution containing cells and CMP-polymer conjugates is injected into a desired site or is surgically implanted. The liquid is then polymerized in vivo. Alternatively, the CMP-polymer conjugate is polymerized in vitro and subsequently administered.
The present invention provides methods of treating diseases and/or disorders or symptoms thereof which comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a collagen mimetic peptide of a formulae herein to a subject (e.g., a mammal such as a human). Thus, one embodiment is a method of treating a subject suffering from or susceptible to a disease or disorder that requires targeting of a therapeutic composition to a site comprising collagen or a symptom thereof. The method includes the step of administering to the mammal a therapeutic amount of a compound herein sufficient to treat the disease or disorder or symptom thereof, under conditions such that the disease or disorder is treated.
The methods herein include administering to the subject (including a subject identified as in need of such treatment) an effective amount of a compound described herein, or a composition described herein to produce such effect. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
The therapeutic methods of the invention (which include prophylactic treatment) in general comprise administration of a therapeutically effective amount of the compounds herein, such as a compound of the formulae herein to a subject (e.g., animal, human) in need thereof, including a mammal, particularly a human. Such treatment will be suitably administered to subjects, particularly humans, suffering from, having, susceptible to, or at risk for a disease, disorder, or symptom thereof. Determination of those subjects "at risk" can be made by any objective or subjective determination by a diagnostic test or opinion of a subject or health care provider (e.g., genetic test, enzyme or protein marker, Marker (as defined herein), family history, and the like). The compounds herein may be also used in the treatment of any other disorders in which it is desirable to target a tissue comprising collagen may be implicated.
In one embodiment, the invention provides a method of monitoring treatment progress. The method includes the step of determining a level of diagnostic marker (Marker) (e.g., any target delineated herein modulated by a compound herein, a protein or indicator thereof, etc.) or diagnostic measurement (e.g., screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof, in which the subject has been administered a therapeutic amount of a compound herein sufficient to treat the disease or symptoms thereof. The level of Marker determined in the method can be compared to known levels of Marker in either healthy normal controls or in other afflicted patients to establish the subject's disease status. In preferred embodiments, a second level of Marker in the subject is determined at a
time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy, hi certain preferred embodiments, a pre- treatment level of Marker in the subject is determined prior to beginning treatment according to this invention; this pre- treatment level of Marker can then be compared to the level of Marker in the subject after the treatment commences, to determine the efficacy of the treatment.
Methods for Evaluating Therapeutic Efficacy
Methods of the invention are useful for treating or stabilizing in a patient (e.g.,, a human or mammal) a condition, disease, or disorder affecting a tissue or organ. Therapeutic efficacy is optionally assayed by measuring, for example, the biological function of the treated or transplanted organ (e.g.,, bladder, bone, brain, breast, cartilage, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, nervous tissue, ovaries, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, ureter, urethra, urogenital tract, and uterus). Such methods are standard in the art and exemplary methods follow. Preferably, a transplantation method of the present invention, increases the biological function of a tissue or organ by at least 5%, 10%, 20%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, or even by as much as 300%, 400%, or 500%. hi addition, the therapeutic efficacy of the methods of the invention can optionally be assayed by measuring an increase in cell number in the treated or transplanted tissue or organ as compared to a corresponding control tissue or organ (e.g.,, a tissue or organ that did not receive treatment). Preferably cell number in a tissue or organ is increased by at least 5%, 10%, 20%, 40%, 60%, 80%, 100%, 150%, or 200% relative to a corresponding tissue or organ. Methods for assaying cell proliferation are known to the skilled artisan and are described in (Bonifacino etal., Current Protocols in Cell Biology Loose-leaf, John Wiley and Sons, Inc. , San Francisco, CA).)
Screening Assays
As described herein, the present invention provides for the delivery of therapeutic agents to cells, tissues, or organs in vitro or in vivo. The invention is based in part on the discovery that therapeutic agents can be conjugated to a collagen mimetic peptide. Collagen is then contacted with the collagen mimetic peptide conjugate, such that the collagen mimetic peptide conjugate physically associates with collagen. Based in part on this discovery, compositions of the invention are useful for the high-throughput low-cost screening of
compounds conjugated to CMP. Desired CMP conjugates physically interact with collagen (e.g., bind with high affinity) without disrupting collagen structure. The CMP conjugate thereby modulates a biological function of a cell, tissue, or organ. Collagen, or tissues or cells comprising collagen are treated with a collagen mimetic peptide conjugate and are subsequently compared to untreated control samples to identify therapeutic CMP conjugates that bind collagen with high affinity without disrupting collagen structure and/or enhance a biological function of the cell, tissue, or organ. Any number of methods are available for carrying out screening assays to identify such compounds.
In one working example, candidate compounds are added at varying concentrations to the culture medium of cultured cells. Any desired biological function is then measured using standard methods. The biological function in the presence of the candidate compound is compared to the level measured in a control culture medium lacking the candidate molecule. A compound that enhances cell function is considered useful in the invention; such a candidate compound may be used, for example, as a therapeutic to prevent, delay, ameliorate, stabilize, or treat a disease described herein (e.g., atherosclerosis, thrombosis, inflammation, tissue damage). In other embodiments, the candidate compound prevents, delays, ameliorates, stabilizes, or treats a disease or disorder described herein. Such therapeutic compounds are useful in vivo as well as ex vivo.
In one working example, CMP conjugates are screened for those that specifically bind to collagen. The efficacy of such a candidate compound is dependent upon its ability to interact with collagen, or with functional equivalents thereof. Such an interaction can be readily assayed using any number of standard binding techniques and functional assays (e.g., those described in herein).
In one example, a CMP conjugate that binds to a collagen is identified using a chromatography-based technique. For example, collagen is immobilized on a column. A solution comprising a CMP conjugate is then passed through the column, and a CMP conjugate is identified on the basis of its ability to bind to the collagen and be immobilized on the column. To isolate the CMP conjugate, the column is washed to remove non-specifically bound molecules, and the CMP conjugate of interest is then released from the column and collected. Similar methods may be used to isolate a CMP conjugate bound to a collagen microarray comprising any collagen type desired (e.g., collagen types 1-29). A CMP conjugate identified using such methods is assayed for an effect on the biological function of a cell, tissue, or organ as described herein.
In another example, the CMP conjugate, e.g., the substrate, is coupled to a radioisotope or enzymatic label such that binding of the compound, e.g., the substrate, to collagen can be determined by detecting the labeled compound, e.g., substrate, in a complex. For example, compounds can be labeled with 1251, 35S, 14C, or 3H, either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
In yet another embodiment, a cell-free assay is provided in which a CMP conjugate or a biologically active portion thereof is contacted with a collagen and the ability of the CMP conjugate to bind to the collagen thereof is evaluated.
The interaction between two molecules can also be detected, e.g., using fluorescence energy transfer (FET) (see, for example, Lakowicz et al, U.S. Patent No. 5,631,169; Stavrianopoulos et al, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).
In another embodiment, determining the ability of a CMP conjugate to bind to a collagen can be accomplished using real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C, Anal. Chem. 63:2338-2345, 1991; and Szabo et al, Curr. Opin. Struct. Biol. 5:699-705, 1995). "Surface plasmon resonance" or "BIA" detects biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal that can be used as an indication of realtime reactions between biological molecules.
It may be desirable to immobilize either the CMP conjugate or the collagen target to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a CMP conjugate to a collagen, or interaction of a CMP conjugate with a target collagen in the presence and absence of a CMP conjugate, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above.
Alternatively, cell free assays can be conducted in a liquid phase. In such an assay, the reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation (see, for example, Rivas, G., and Minton, A.P., Trends Biochem Sd 18:284-7, 1993); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis and immunoprecipitation (see, for example, Ausubel, F. et al, eds. (1999) Current Protocols in Molecular Biology, J. Wiley: New York). Such resins and chromatographic techniques are known to one skilled in the art (see, e.g., Heegaard, N.H., J MoI Recognit 11 :141-8, 1998; Hage, D.S., and Tweed, S.A., J Chromatogr B Biomed Sci Appl. 699:499-525, 1997). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.
One skilled in the art appreciates that the effects of a CMP conjugate on biological activity are typically compared to the biological activity in the absence of the CMP conjugate. Thus, the screening methods include comparing the value of a cell modulated by a candidate CMP conjugate to a reference value of an untreated control cell. Changes in tissue or organ morphology further comprise values and/or profiles that can be assayed by methods of the invention by any method known in the art.
Test Compounds and Extracts
In general, therapeutic compounds suitable for coupling to CMP are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries or from polypeptide or nucleic acid libraries, according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Compounds used in screens may include known compounds (for example, known
therapeutics used for other diseases or disorders). Alternatively, virtually any number of unknown chemical extracts or compounds can be screened using the methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds.
Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, N.H.) and Aldrich Chemical (Milwaukee, Wis.). Alternatively, chemical compounds to be used as candidate compounds can be synthesized from readily available starting materials using standard synthetic techniques and methodologies known to those of ordinary skill in the art. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds identified by the methods described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.
Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceangraphics Institute (Ft. Pierce, FIa.), and PharmaMar, U.S.A. (Cambridge, Mass.). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al, Proc. Natl. Acad. Sd. U.S.A. 90:6909, 1993; Erb et al., Proc. Natl. Acad. ScL USA 91:11422, 1994; Zuckermann et al, J. Med. Chem. 37:2678, 1994; Cho et al, Science 261 :1303, 1993; Carrell et al, Angew. Chem. Int. Ed. Engl. 33:2059, 1994; Carell et al., Angew. Chem. Int. Ed. Engl. 33:2061, 1994; and Gallop et al., J. Med. Chem. 37:1233, 1994. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.
Libraries of compounds may be presented in solution (e.g., Houghten, Biotechniques 13:412-421, 1992), or on beads (Lam, Nature 354:82-84, 1991), chips (Fodor, Nature 364:555-556, 1993), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner U.S. Patent No. 5,223,409), plasmids (Cull et al, Proc Natl Acad Sd USA 89:1865-1869, 1992) or on phage (Scott and Smith, Science 249:386-390, 1990; Devlin, Science 249:404-406, 1990; Cwirla et al. Proc. Natl. Acad. Sci. 87:6378-6382, 1990; Felici, J. MoI. Biol. 222:301-310, 1991; Ladner supra.).
In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their activity should be employed whenever possible.
When a crude extract is identified as containing a compound of interest, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract that achieves a desired biological effect. Methods of fractionation and purification of such heterogenous extracts are known in the art.
Small molecules of the invention preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.
Kits
The invention provides diagnostic and therapeutic kits that include CMP or CMP conjugates capable of interacting with collagen in vitro or in vivo. In one embodiment, the kit includes a diagnostic composition containing a detectable CMP conjugate (e.g., CMP conjugated to a nanoparticle, a detectable label, or a contrast reagent). In other embodiments, the kit contains a therapeutic device, such as a wound healing device, hemostatic sponge, or drug delivery device containing a CMP conjugate and a polymer.
In some embodiments, the kit comprises a sterile container which contains a CMP conjugate or a CMP conjugate and a polymer; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.
If desired a CMP conjugate of the invention is provided together with instructions for using it in a diagnostic or therapeutic method described herein. The instructions will generally include information about the use of the composition for the diagnosis or treatment of a disease in a subject in need thereof. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.
EXAMPLES
Example 1: Methods of characterizing a CMP or CMP conjugate
To determine whether the propensity of CMPs to form collagen- like triple helices enables it to bind to partially denatured collagen by associating with disentangled domains of the collagen molecules, CMP and 5-carboxy fluorescein (5CF) labeled CMP derivatives were prepared as shown in Table 1 (Table 1 : 1 and 2, respectively), which provides the sequence and transition melting temperature (Tm) of peptides 1-5, as determined by circular dichroism spectroscopy (Figures 1-3).
Table 1 : Transition Temperatures of Collagen Mimetic Peptide Derivatives Determined by Circular Dichroism Spectroscopy8.
Compound Sequence Tm
1 -(ProHypGly)lO- 69°C
2 5CF-Gly3-(ProHypGly)10- 75°C 3b 5CF-Gly3-randomProlOHyplOGlylO-
4 5CF-Gly3-(ProHypGIy)6- 25°C
5C mPEG2000-Gly3-(ProHypGly)7- 29°C
"measured in 57.5 μM acetic acid solution. b5CF-GGGGPPPHPHGPGGG PPHPPHGPHGPPHPGPHPHPGGPHPHPP, (PH:Hyp). cmPEG2ooo: CH3O-(C H2-CH2-O)n-OH, 2250 Da
In addition, peptide 3 was synthesized having the same amino acid composition as peptide 2, but the Pro, Hyp, GIy sequence was scrambled, rendering peptide 3 non- helicogenic. Three consecutive glycines were inserted as a spacer between the fluorescence tag and the CMP. Attaching 5CF and three glycines to 1 elevated its melting temperature from 69°C to 75°C (Table 1). This is due in part to the hydrophobic nature of the fluorescence tag. Attachment of a hydrophobic fatty acid to the CMP was previously shown to stabilize the triple helix elevating its melting temperature.5 As expected, no melting behavior was observed for compound 3.
The binding of CMP to natural collagen (acid soluble, bovine type I) or denatured collagen (gelatin) was demonstrated by treating collagen films with solutions of the fluorescently labeled CMP, rinsing, and measuring the fluorescence intensity of the exposed film. The transition melting temperature of collagen film as determined by circular dichroism spectroscopy is shown at Figure 4. To the collagen-coated cell culture wells (at room temperature) was added a solution of 2 which was pre-equilibrated at either 250C or 800C. After three hours of incubation at room temperature, the collagen films were washed with buffer solution and observed by fluorescence microscope. As control samples, 5CF, fluorescein isothiocyanate-dextran (FITC-Dextran), and peptide 3 were used to treat collagen films under identical experimental conditions. All control samples exhibited negligible affinity toward collagen film evidenced by low fluorescence intensity at both experimental conditions (Figure 5A: Group a and b). Collagen film treated with peptide 2 at 25°C also showed negligible fluorescence. In contrast, the collagen film treated with peptide 2 that was pre-equilibrated at 8O0C, the temperature above peptide 2's melting transition temperature (75°C), exhibited strong fluorescence. Similar results were obtained when gelatin films were used as a substrate (Figure 5 A: Group c). In addition, the helical content of CMP treated collagen film was 3.5 times higher than that of the film treated with a blank solution (see support information). These results suggested that peptide 2 tightly attached to partially denatured collagen when it is introduced as a single strand and that its ability to assemble into triple helix is relevant for the attachment. hi order to understand the effect of collagen film denaturation in the CMP binding process, a shorter CMP derivative was synthesized, peptide 4, with a melting temperature (25°C) well below that of the collagen film. Little binding was observed when a peptide 4 solution at 100C was used to treat the collagen film (Figure 5B). Treatment with the same solution pre-equilibrated at 300C, the temperature above 4's melting temperature but below the denaturation temperature of collagen film (37°C), induced more than three- fold increase in CMP attachment compared to that of the 100C solution, hi addition, the modified collagen fiber retained its native banding texture when investigated by transmission electron microscopy (Figure 6). Hotter solutions (600C and 800C) which denature the collagen film during the treatment produced collagen films with slightly higher CMP content (approximately 20% increase from that of the 3O0C solution). These results indicated that the CMP melting into monomers, but not collagen denaturation supported CMP immobilization.
The observed adhesion arises from a strand exchange reaction and triple helix association between CMP and the collagen. It is interesting to note that a number of researchers have proposed existence of thermally labile domains within the type I collagen sequence which may serve as potential sites for the presumed strand exchange reaction.6 Within the collagen family a class of collagen known as Fibril Associated Collagens with Interrupted Triple-helices exists (FACITs)22"24 . FACITs do not form fibrous structure by themselves but are always found as individual collagen molecules decorating the surface of collagen fibers. The findings reported herein do not indicate if CMP is binding to the thermally labile domains, or if the binding event mimics that of a FACIT protein.
To evaluate the potential of the new modification technique in tissue engineering, poly(ethyleneglycol)2ooo-CMP conjugate polymer25'26 (Table 1 : 5) was prepared. This modified collagen was designed to reduce the adhesiveness of collagen to cells.
The melting temperature of 5 was determined to be 29°C which is 7°C lower than the melting temperature of (ProHypGly)7 (Table I).27 Here, the hydrophilic and bulky PEG group seems to destabilize the triple helix in water. A solution containing 5 at 45 °C was added to the collagen coated culture plate (prepared as above) and human fibroblasts or breast epithelial cells were seeded and incubated for three days at 37°C. Homogenous distribution of fibroblasts is seen on the collagen film that was treated with mPEG2Ooo (Control sample, Figure 7A). In contrast, areas of collagen films treated with 5 are almost devoid of fibroblasts (Figure 7B) and epithelial cells (Figure7C). This experiment demonstrates that the adhesive properties of prefabricated collagen film can be readily modified by the simple action of delivering CMP conjugate solutions to the target area.
These results demonstrate that a prefabricated collagen matrix can be readily modified by delivering CMP conjugate solutions to a target area (Figure 8). Such methods are useful for applications where it is desirable to repel cell growth while new tissue structures are organized.
For applications where it is desirable to repel cell growth for prolonged periods (e.g., weeks or months), it is desirable to employ CMPs of increased length. In films that were treated with mPEG2o00-Gly3-(Pro-Hyp-Gly)7, cell growth extending into the treated area was observed after 3 days in culture (Figures 9A, 9B, and 9C). This might be due to the release of mPEG2oo0-Gly3-(Pro-Hyp-Gly)7 from the PEG-CMP modified collagen film during incubation at 37 °C.
(Pro-Hyp-Gly)8-Gly3-PEG5000-OH with lengthened CMP and PEG, was designed to prolong the anti-adhesive property of pegylated CMP modified collagen to cells. Its melting temperature is 38 0C in PBS solution. A delay in invasive cell growth was observed on areas of the collagen film treated with (Pro-Hyp-Gly)8-Gly3-PEG5000-OH (Figures 1OA and Figure 10B). The treated gel repelled extensive cell growth for close to eleven days. After five days in culture, little invasion into treated areas of the collagen film is observed. After nine days in culture only moderate invasion is observed. Extensive invasion is observed after eleven days in culture. It can also be seen from the images that cells outside the treated area grow vertically before invading the treated area.
To determine whether PEG-CMP derivatives are diffusing out of the gel, fluorescence labeled PEG-CMPs, FL-PEG2000-Gly3-(Pro-Hyp-Gly)7 and 5CF-Gly3-(Pro-Hyp-Gly)8-Gly3- PEG50O0-OH, were prepared. The CF-GIy-(PrO-HyP-GIy)10 derivatives bound collagen film with high affinity. Figure 11 shows a quantitation of the release of fluorescence-labeled CMP derivatives from culture dish and collagen film at 37 °C in PBS solution (pH 7.4). On the fluorescence labeled PEG-CMP modified area of collagen film, the release of FL- PEG2000-Gly3-(Pro-Hyp-Gly)7 from collagen film was faster than that of 5CF-Gly3-(Pro-Hyp- GIy)8-GIy3-PEG5000-OH. The release of fluorescence-labeled PEG-CMPs derivatives from collagen films is shown in (Figure 11). These results suggest that a collagen matrix or other polmer matrix that incorporates a CMP conjugate (e.g., a CMP conjugated to a biologically active agent, is useful for the controlled release of that CMP conjugate as described herein.
These experiments indicate that fibroblast and epithelial cell adhesion to natural collagen can be readily altered by applying CMP-poly(ethylene glycol) conjugates to prefabricated collagen films. These PEG-CMP derivatives include methoxy-PEG2ooo-Gly3-(Pro- Hyp-Gly)7 and (Pro-Hyp-Gly)8-Gly3-PEG500o. Films treated with these compounds showed dramatically reduced invasion by fibroblasts or epithelial cells. For applications where prolonged repellant activity is required stable CMP-PEG derivatives, such as (Pro-Hyp-Gly)8, will be utilized. (Pro-Hyp-Gly)8 exhibits stronger affinity for collagen. Also useful in such methods are linear PEG of suitable lengths or star-shaped PEG. Such molecules have increased surface-shielding effects, and are more effective in protecting the conjugates from cell adhesion and protein adsorption (see Figure 12). A comparison of protein and cell repellent properties of grafted linear PEG and star shaped PEG has been described13"16, hi particular, star shaped PEG-coated glass, titanium and silicon samples inhibit cell adhesion17.
In order to increase the cell repelling activity CMP is conjugated to multi-armed PEG or to star shaped PEG (MW: 10,000 Da). These molecules provide for an increase in the number of collagen binding sites. [AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG (MW: 10,000 Da) will be synthesized by conjugation of four NHS activated sites on 4-armed star PEG with AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8 ( Figurel2 ). The amount of PEG-CMP immobilized in the collagen scaffold will be empirically determined. [Carboxyfiuorescein- Gly3-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG will be prepared ( Figure 13). Fluorescence tagged star shaped PEG-CMP that can be quantified and visualized by fluorescence techniques will also be prepared to facilitate detection of star shaped PEG-CMP release. HPLC will be used to purify the CMP-star shaped PEGs and MALDI-TOF will be used to identify the target products and check for purity.
The ability to control the organization of cells in collagen matrix provides a new pathway for engineered tissues. Furthermore, the affinity between the CMP and collagen could issued to immobilize therapeutic drugs to collagens in the living tissues, and to biomaterials that incorporate natural collagens.
Example 2: Use of PEG-CMP for the organization of endothelial cell growth
Results using PEG-CMP to repel fibrobast cell growth suggest that PEG-CMP can be used to direct the growth and organization of endothelial cell growth as well, given the similarities that exist between the two cell types. Like fibroblasts, endothelial cells rely on integrin-ECM interaction for initial binding to the scaffolds. To determine the effects of PEG-CMP collagen gels on proliferation, tubulogenesis, and capillary sprouting collagen (type I) films are treated with PEG-CMP of varying concentrations. The amount and pattern of immobilized PEG-CMP present in the collagen film is determined using fluororescien labeled-PEG. Endothelial cells are then plated on PEG-CMP modified collagen and cell attachment, morphology, and cytoskeletal organization is assessed to determine the effect of CMP-PEG modified collagen on cell attachment pattern and cell proliferation. Methods of characterizing cytoskeletal organization include staining with Oregon-Green conjugated phalloidin.
To determine the effects of PEG-CMP on the growth and organization of endothelial cells in three dimensional collagen gel, endothelial cells are cultured in PEG-CMP modified three dimensional collagen gels. On a two dimensional collagen film the PEG-CMP inhibits fibroblast attachment. Without wishing to be bound by theory, this effect is likely due to the PEG blocking the ECM-integrin interaction. To determine whether similar effects are
observed in three dimensional ECMs, a three dimensional collagen gel containing varying concentrations of PEG-CMP is prepared by adding PEG-CMP to a collagen solution prior to gelation. Cell morphology is analysed to assess the efficacy of PEG-CMP in regulating cell growth, proliferation, tubulogenesis, and capillary sprouting in a three dimensional collagen gel. Samples of the gel are easily fixed and fluorescently labeled using actin and nuclear immunostaining. One end of the collagen gel is immersed in fluorescein labeled PEG -CMP solution to create a detectable PEG gradient along the length of the collagen gel. Cell morphology is visualized by actin and nuclear immunostaining, and evaluated using fluorescence microscope, which also provides for visualization of the PEG gradient.
In another approach, CMP-PEG is injected into the collagen gel via microsyringe. This injection is performed at the final stage of gel formation thus minimizing damage to the collagen matrix. The distribution of immobilized fluororescein labeled PEG-CMP is visualized and quantified by fluorescence microscope and the morphology of endothelial cells and capillary distribution is evaluated with respect to the local concentration of PEG- CMP.
Example 3: Tissue fixation using (CMP)n conjugated- homo multifunctional PEG as a cross-linker
Present methods for tissue fixation use crosslinking reagents, such as formaldehyde, glutaraldehyde (GA), expoxy compounds, carbodiimide, proanthocyanidin and reactive multifunctional PEGs18'19. The use of such reagents reduces the antigenicity of many proteins and increases their resistance to enzymatic degradation when tissues treated with these reagents are implanted20'21]. Additional drawbacks to the use of such agents includes their toxicity, unmanageable crosslinking rates, and instability. The present invention provides a a collagen crosslinking reagent that exhibits low cytotoxicity and can form biocompatible crosslinked products. CMPs conjugated onto multi-armed PEG compounds mediate physical binding to collagen and can serve as crosslinking reagents. CMP conjugated with homo- bifunctional or homo-tetrafunctional PEG, which are commercially available from NEKTAR (San Carlos, CA) (such as NHS or thiol) are prepared and purified by HPLC. The reaction products are characterized using MALDI-TOF and CD measurements and rheometry, tensile gel swelling analyses and gel degradation analyses using collagenase are carried out on CMPs-multi armed PEG conjugate cross-linked collagen gels and fixed tissues.
Example 4: CMP functionalized gold nanoparticles
CMP, (Pro-Hyp-Gly)x (Hyp=hydroxyproline), binds to type I collagen molecules through a process involving both strand invasion and triple-helix assembly. In an effort to visualize this interaction in collagen fibers, CMP functionalized gold nanoparticles (NPs) were prepared to use as a transmission electron microscopy marker. The CMP functionalized gold NPs were highly stable in aqueous solution and exhibited a preferential affinity to the gap regions of intact type I collagen fibers.
The triple helical structure of collagen and CMP bears similarity in structure to the DNA double helix. Both collagen and DNA are composed of long coaxial multiplex helices that are held together by inter-chain hydrogen bonds. They exhibit reversible melting transitions that reflect the stability and strength of the helix assembly. In DNA, strand invasion by short DNAs or peptide nucleic acids is well documented in the literature.28 Although collagens are known to incorporate thermally unstable domains where small segments of the triple helix are thought to be partially unraveled, strand invasion by other collagen molecules or collagen analogs have not been previously reported.
Under transmission electron microscopy, collagen fibers exhibit characteristic banding patterns that indicate the structural integrity of the collagen molecules and their assembly.30 The banding patterns also provide approximate position markers along the length of collagen molecules. The binding event between type I collagen fibers and CMP conjugated gold NPs was investigated to see if strand invasion occurs without destroying the native structure of collagen fibers. Antibody passivated gold NPs have been used successfully to identify specific types of collagen fibers in tissue samples.31
A series of three CMPs was synthesized, each with a single cysteine at the N terminus (Table 2, peptides 1 '~3') using conventional Fmoc-mediated solid phase peptide coupling methods.
Table 2. CD Melting Transition Temperatures of CMP Derivatives"
Compound Sequence Tm
1 Cys-(Pro-Hyp-Gly)3 -
2 Cys-(Pro-Hyp-Gly)5 21°C
3 Cys-(Pro-Hyp-GIy)7 39°C
Cys-
4a randomPro7Hyp7Gly7 - aCys-GPGP*PP*PPGPPP*GP*P*PP*GP*GG (P*=Hyp)
A fourth peptide, peptide 4', with an amino acid composition identical to that of peptide 3' but with a scrambled amino acid sequence that is unable to support a triple helical structure was also prepared. The melting transition temperatures (Table 3) of these compounds determined by circular dichroism (CD) spectrometry was consistent with those of other CMP analogs reported previously.32'33 The citrate reduction method was used to prepare relatively monodisperse gold NPs of diameter 13.2±3.5 nm.38 Incubating the gold NPs and Cys-CMPs (l'~4') at room temperature produced CMP functionalized gold NPs (Table 3; NP-X, X=l '~4').
Table 3. Properties of CMP functionalized Au NPs.
Particle Size Measured Calculated Number of by DLS Peptide layer Peptide peptides per NP thickness layer thickness
NP-I 17.2±3.7 nm 2.0 nm 2.6a (2.8)b 582±32 nm
NP-2 20.5±3.3 nm 3.65 nm 4.3 (4.7) 444±18 nm
NP-3 26.9±4.6 nm 6.85 nm 6.0 (6.6) 399±21 nm
NP-4 16.2±3.1 nm 1.5 nm 524±59
11 CMP triple helix, h poly(prohne)-ll helix
The melting temperatures of CMPs bound to the NP surfaces could not be determined because circular dichroism measurements were hampered by light scattering from the NPs; calorimetric analysis was unsuccessful due to a trace amount of CMPs present on the NP surfaces. Thermal melting curves as determined by ellipicity of CMPs is shown in Figure 14.
The thickness of the peptide layer on the gold NP surface was determined by dynamic light scattering (DLS) (Figure 15). The peptide layer thicknesses of NP-I, NP-2 and NP-3 were 2.0 run, 3.65 run and 6.85 run, respectively (Table 3). These values were commensurate with the estimated lengths of the corresponding CMPs in helical conformation.35 In contrast, the peptide layer thickness of NP -4 was only 1.5 nm, indicating that this peptide was either a random coil or had a distinctively different secondary structure that tended to lie flat on the particle surface.
The average number of CMPs on the NPs was determined by measuring the concentrations of free CMPs remaining in solution after the removal of the NPs from a series of incubation mixtures with varying CMP/NP ratios (Figure 16 and Table 3).36 The numbers of CMPs immobilized on the NP surfaces were 582, 444, and 399 for NP-I, NP-2, and NP-3, respectively. These values correspond to the effective footprint areas (per single chain) of 94 A2, 123 A2, and 137 A2, which are comparable to the cross-sectional area of the CMP triple helix, 80 A2.35 The peptide layer is likely composed of laterally packed single stranded CMPs. This may have been caused by surface anchoring of the chain ends that prohibited the staggered arrangement of the peptide chains required for the formation of triple helix.
The DLS and average number of peptides per NP data are in agreement with CMPs standing upright on the NP surfaces in an extended conformation that resembles the poly(proline)-II helix. In negatively stained transmission electron microscopy micrographs, the peptides appear as a dense white layer covering the NP surface (Figures 17A- 17D). All CMP functionalized NPs were able to assemble into a pseudo-hexagonal lattice, indicating that the CMPs fully passivated the NP surfaces and prevented the NPs from aggregating.
The CMP conjugated NPs were highly stable in aqueous solution. No sign of aggregation was detected in buffer solutions of up to 5 M NaCl or within a pH range from 0 to 14 (Figures 18A and 18B). All NPs can be freeze-dried and resuspended without aggregation of the particles. Peptides usually make poor passivating layers for NPs and even peptides that are carefully designed to disperse NPs did not protect NPs under such wide range of conditions.36 CMP triple helices consist of three parallel peptide chains; hence the association of peptides with anti-parallel alignment from two different NPs is unlikely. It is likely that the high Hyp content and extended conformation of the peptides, as shown by DLS, caused the CMPs to mimic the behavior of poly(ethylene glycol) brushes on surfaces and prevent the NPs from aggregating in aqueous solution.
Type I collagen fibers were prepared by adjusting the pH and ionic strength of an acid soluble type I collagen solution.37 hi forming a fiber, collagen molecules aligned head to tail
in the direction of the long axis in overlapping rows with a gap between the molecules within each row. Accumulation of staining agents (uranyl acetate) in these gap regions produced dark bands that repeated every 67 ran along the length of the fiber. Compound 3 had the highest melting temperature among the three CMPs, suggesting that it likely makes the most stable adduct with the collagen fiber. Therefore, NP-3 binding to reconstituted collagen fibers was characterized.
When NP-3 or NP-4 was allowed to bind to type I collagen fibers by incubating in a phosphate buffer at 25°C, transmission electron microscopy studies revealed drastically contrasting results. NP-4 exhibited little binding to the collagen fibers, whereas NP-3 was highly attracted to collagen fibers (Figure 19A, 19B, and 19C). Moreover, NP-3 seemed to bind to defined locations within the gap regions along the fiber axis (Figure 19C). Due to the large particle size and limitations of transmission electron microscopy resolution, the exact locations of these binding sites could not be determined. Twice as many NP-3 particles per unit area was found in the gap regions (dark bands) than on the overlap regions (light bands) of the collagen fibers. This difference was abolished at incubation temperatures above 40°C (Figure 20).
These results indicated that CMP-functionalized NPs bind to the collagen fiber in its native state, possibly at specific locations within collagen molecules, and that the CMP 's propensity to form a triple-helix was critical in the binding process. Collagen fibers exhibited clear banding morphology even after incubating with NPs, suggesting that they remained intact. This was not surprising since the incubation temperatures in these experiments was kept below the melting temperature of collagen fibers (65.1 °C). Recent studies using calorimetry and isothermal circular dichroism spectroscopy demonstrated that type I collagen molecules are unstable at body temperature.39 Miles and Bailey identified three thermally unstable domains in type I collagen that lack helix stabilizing Hyps. Interestingly, all three domains are located within the gap region of the collagen fiber.29 Without wishing to be bound by theory, it is likely that accumulation of NPs in this gap region indicates a preferential CMP interaction with the thermally labile domains of collagen molecules (Figure 21). This selectivity in binding is not apparent at higher temperatures since additional thermal energy makes other regions of the molecules unstable and susceptible to invasion by CMPs.
The NP labeling technique may be used to identify structural abnormalities in collagen fibers that are related to debilitating human diseases.15 Strand invasion or similar forms of strand association by collagen and collagen derivatives may uncover the behaviors
of fibril-associated collagens (type IX and XII) and other proteins that incorporate collagen- like sequences.
Example 5: CMP-containing hydrogels are useful for cartilage repair
The discovery that collagen mimetic peptides can be used to modified collagen compositions provides for the development of a variety of therapeutic compositions featuring such peptides. For example, collagen mimetic peptides may be used to produce improved biocompatible tissue scaffolds that contain CMP conjugated to biochemically inert polymers. Such scaffolds retain collagens and other extraceullular matrix components secreted by the cells cultured within them. Thus, tissue scaffolds containing CMP reproduce a microenvironment that more closely resembles the cell's natural environment than conventional scaffolds (Figure 22).
Example 6: Acryloyl-PEG-CMP is a photopolymerizable CMP derivative
The CMP, (PrO-HyP-GIy)7-TyT, was synthesized at greater than 99 % purity. Purity was analyzed using MALDI-TOF spectrometry. (ProHypGly)7-Tyr was selected because the (ProHypGly)7- CMP unit was shown, as described above, to bind to collagen fiber at physiological temperatures. Tyr was added to the peptide to facilitate the accurate measurement of CMP concentration by UV- Vis spectrophotometer. The peptide was synthesized on a solid support (Wang resin), cleaved, and purified by reverse phase HPLC. The peptide's ability to form a collagen triple helix was confirmed using circular dichroism. The CD trace included a positive peak near 225 nm, a crossover around 215 nm, and a minimum at around 180 nm.
The CD melting temperature (midpoint of CD melting curve) of the (ProHypGly)7- Tyr CMP was determined to be 38.5°C. This melting temperature is slightly higher than that of the (Pro-Hyp-Gly)7 CMP, which had a melting temperature of 37 0C. A similar change in melting temperature was observed when a hydrophobic fluorescence tag was attached to the N-termini of a CMP.
Reaction of the purified (ProHypGly)7-Tyr CMP with acryloyl -PEG-N- hydroxysuccinimide produced acryloyl-PEG-CMP, a photopolymerizable CMP derivative. A CMP/ poly( ethylene oxide) diacrylate (PEODA) hydrogel was prepared by photopolymerizing an aqueous solution containing the acryloyl-PEG-CMP and PEODA monomers (combined weight percent: 10%) as well as a photo reactive initiator (0.05%).
Unconjugated reactants were removed using ultrafiltration and gel permeation chromatography. Purity of the final peptide-polymer conjugate was 80% as determined using MALDI-TOF.
Example 7: A CMP /PEODA hydrogel retained added collagen
To determine whether a CMP/PEODA hydrogel was capable of retaining added collagen, varying concentrations of type I collagen were added to the initial CMP/PEODA polymer solution. The solution was then exposed to UV radiation to produce a hydrogel and the hydrogel was incubated for one week in PBS buffer. The incubation in PBS provided an opportunity for the collagen to leach out of the hydrogel. Following the incubation in PBS buffer, the hydroxyproline content of the hydrogel was assayed. Hydroxyproline content is used to measure the presence of collagen. Hydroxyproline content in the CMP containing hydrogel was significantly greater than that observed in control gels that did not contain CMP (Figure 23). The amount of collagen retained by the CMP/PEODA hydrogel reached saturation when the gel was incubated with 0.2 mg/mL of collagen. The amount of collagen retained did not increase when 0.5 mg/mL of collagen was added to the CMP/PEODA hydrogels.
Example 8: CMP containing hydrogels have increased water content
Water content of a hydrogel is closely correlated to crosslinking density and mesh size of the scaffold. The water content of hydrogels with and without CMP was determined following a twenty- four hour equilibration in chondrocyte medium. The wet and dry weights of gels crosslinked with various concentrations of collagen mimetic peptides was measured and the water content of each hydrogel was determined. Hydrogels crosslinked to CMP contained 10% more water than hydrogels that did not contain CMP (Table 4).
Table 4. Water content of hydrogels as a function of CMP concentration
Percentage of CMP (%) Water Content (Q, %) SJX
0 82.963 0.11401 0.1 90.355 0.22550 0.5 90.444 0.30966
1 90.608 3.3092
2 90.844 0.60216
Water content was significantly higher in the CMP/PEODA hydrogels relative to the PEODA hydrogel. This was not surprising because a single PEG-CMP molecule is crosslinked to each PEODA molecule the hydrogel containing CMP has a lower crosslinking density than the hydrogel without CMP.
Little difference in water content was observed in CMP/PEODA hydrogels containing greater than 0.1% of ACRL-PEG-CMP. In fact, hydrogels containing 0.1- 2% CMP all had similar water contents (approximately90 % water). This may be a result of CMP's tendency to associate with and form triple helixes with other CMPs. Since the triple helix brings together three separate chains to form a single complex, these association effectively crosslink the hydrogel and may affect the swelling characteristics of the gel.
Example 9: A CMP /PEODA hydrogel supported cell survival
To determine whether the peptide-polymer conjugate was capable of supporting cell survival, chondrocytes were harvested and encapsulated in control, 1 %, and 2% CMP/PEODA hydrogels. The CMP containing hydrogel successfully supported cell survival as shown by a cell viability assay (Figure 24). Moreover, cell viability was homogenous throughout the CMP/PEODA gels (Figure 24).
Example 10: A CMP /PEODA hydrogel retained cell-secreted collagen
Cartilage is mainly comprised of collagen and proteoglycans. Collagen is a good marker of the cultured chondrocyte's biosynthetic capability because collagen is the most abundant extracellular matrix component in cartilage. The collagen produced by chondrocytes is mostly type II collagen. Type II collagen is also expected to physically interact with CMP. To determine whether the collagen secreted from the encapsulated cells bound to the CMP/PEODA hydrogel, collagen content present in the hydrogel was assayed following one week of chondrocyte culture. Collagen content was 37% higher in the 2% CMP/PEODA hydrogel than in the 1% CMP/PEODA hydrogel. Total collagen production was CMP dose dependent and for the 2% CMP/PEODA gel, the ratio of collagen content in the two gel (PEODA:2%CMP/PEODA=1:2) was comparable to that determined from the model collagen retention experiment. Only negligible amounts of collagen were detected in acellular hydrogels.
Example 11: Cells grown in CMP/PEODA hydrogel secreted extracellular matrix components that were retained by the hydrogel
Production of extracellular matrix components, such as collagen and glycosaminoglycan, is indicative not only of cell viability, but also of functionality. Histological evaluation was used to determine whether encapsulated chondrocyte cells were distributed evenly throughout of the hydrogel and whether the cells were secreting extracellular matrix components (Figure 17). To determine whether chondrocytes were producing glycosaminoglycan (GAG), which is a component of the extracellular matrix, GAG content in the hydrogel was assayed following two weeks of culture. GAG is a hydrophilic polysaccharide unit attached to proteoglycans that , in combination with collagen, is a major constituent of cartilage extracellular matrix. GAG synthesis in the 2% CMP/PEODA hydrogel was significantly greater than that in thel% CMP/PEODA hydrogel and control PEG gel, by 105% and 87%, respectively. However, there was no significant difference in GAG production between the control and 1% CMP/PEODA hydrogel.
The total GAG assay indicated that the GAG production was not influenced by the presence of 1% PEODA-CMP in the hydrogel, even though the PEODA-CMP hydrogel had significantly higher water content than PEODA. Typically, increasing the water content of a hydrogel increases the tissue remodeling ability at the expense of mechanical properties. The mechanical strength of the hydrogel is weakened but due to higher water content, cell can take up nutrients easily and produce high levels of ECM. This was not observed in the CMP/PEODA hydrogel. Although 1% and 2% CMP/PEODA had similar water content, the GAG content of 2% CMP/PEODA was 1.9 times higher than that of the 1% CMP/PEODA. This indicates that the increase in GAG production was not the result of an increase in water content.
Proteoglycan deposition was also examined using safranin-0 staining. The intensity of safranin-0 staining was highest in the 2% CMP/PEODA gels, and was next highest in the 1% CMP/PEODA hydrogel. Total collagen staining in the CMP/PEODA hydrogel was also examined using Masson's Trichrome stain. The CMP/PEODA hydrogel was more intensely stained than the PEODA gel. No difference in staining intensity was observed in hydrogel's containing varying CMP concentrations. No staining was observed in a control acellular CMP/PEODA hydrogel. Immunohistochemical staining for collagen type II also showed strong positive staining in 1% and 2% CMP/PEODA hydrogels (Figure 26).
Chondrocytes produce the matrix material and the collagen fibers present in bone. As the chondrocytes secrete matrix material around them, they become walled off into small
chambers or lacunae. The chondrocytes embedded in the hydrogel had a spherical morphology and were present in isolated pockets resembling lacunae. Immediately surrounding the lacunae was a territorial matrix where newly synthesized ECM products were present. Heavy staining for collagen (both total collagen staining and type II collagen immunostaining) was observed in the territorial regions of the CMP/PEODA hydrogel indicating that the cell-secreted collagen remains in the chondrocytes microenvironment. It is likely that the high collagen concentration around the chondrocytes simulated a more natural microenviroment for the cells and enhanced its productivity of GAG and possibly other ECM molecules. GAG immunostaining was not confined to areas immediately surrounding the cell, suggesting that GAGs are capable of diffusing through the hydrogel. This is not surprising because CMP has no affinity for GAGs. There was enhanced matrix production in CMP/PEODA hydrogel. This may be the result of either collagen retention or an upregulation in gene expression.
Collagen synthesis in the 1% and 2% CMP/PEODA hydrogels was 47% and 103% respectively. Chondrocytes in CMP-containing hydrogels synthesized more collagen than chondrocytes in control hydrogels lacking CMP. Tissue formation was greater in CMP/PEODA hydrogels. Results of the biochemical assays of chondrocyte-encapsulated hydrogel were consistent with the histological findings (Figure 27). DNA contents were similar in all samples. The high initial density of chondrocytes prevented their proliferation in the hydrogel. hi sum, the results reported herein indicate that CMP/PEODA hydrogel provides an effective scaffold for cartilage regeneration that is superior to existing tissue scaffolds. Given these results, CMP/PEODA hydrogels are useful for the repair of damaged cartilage, and are particularly useful for applications involving the repair of articular cartilage.
Example 12: Reduction of thrombus deposition by applying CMP derivatives
Angioplasty denudes the vessel wall of the endothelial layer. Vessel healing is often accompanied by the overproliferation of smooth muscle under the endothelial layer. This process can narrow or even block blood vessels causing thrombosis formation40. Methods for preventing intimal hyperplasia and thrombosis subsequent to angioplasty are urgently required. The present invention provides a method of treating blood vessel injury using CMP to deliver anti-thrombotics. CMP may be conjugated to virtually any anti-thrombotic agent known in the art. Such agents include aspirin, thienopyridine, heparin, saratin (a 12,000 Da
recombinant protein isolated from the saliva of the medicinal leech Hirudo medicinalis), hirudin (a 65 amino-acid polypeptide), pegylated hirudin, and unfractionated heparin (UH).
Desirably CMP-anti-thrombotic conjugates bind collagen (type III)49 and repel cell attachment. Saratin-CMPs, hirudin-CMPs, and PEG-CMPs are produced using standard methods and purified using HPLC. Purified conjugates are then characterized using MALDI- TOF and CD analysis as described herein. The activity of the CMP conjugates will be assessed in anti-platelet activation and anti-thrombin formation assays. Specifically, plasma levels of β-thromboglobulin (β-TG) and thrombin-antithrombin complexes (T-AT) will be determined using immunoenzymoassays50. Optionally, the activity of CMP-anti-thrombotic conjugates are assessed in animal experiments.
In particular embodiments, the following CMP conjugates are employed as antithrombotics.
EEREDCWTFYANRKYTDFDKSFKKSSDLDECKKTCFKTEYCYIVFEDTVNKE
CYYNVVDGEELDQEKFVVDENFTENYLTDCEGKDAGNAAGTGDESDEVDE
D-K-(CMP)2
Saratin-CMP (anti-platelet)
LTYTDC(6)TESGQNLC(14)LC(16)EGSNVC(22)GQGNKC(28)ILGSDGEKNQC(3 9)VTGEGTPKPQSHNDGDFEEIPEEY(SO3)LQ-K-(CMP)2
Cys-Cys: 6,14 Cys-Cys: 16,28 Cys-Cys: 22,39
Hirudin-CMP (anti-platelet)
The foregoing results were obtained using the following methods and materials.
Materials
Fmoc-amino acids were purchased from Advanced ChemTech (Louisville, KY) and Fmoc-Gly-Wang resin was purchased from Novabiochem (La Jolla, CA). Acid soluble, type I bovine collagen was purchased from Sigma (St. Louis, MO) and mPEG2OOo-Gly3- (ProHypGly)7 (peptide 5) was purchased from Genscript Corporation (Piscataway, NJ). AU other chemicals were purchased from Sigma- Aldrich and used without further purification.
Fibroblast (CRL- 1502) cells and breast epithelial cells (MCF-7) were from ATCC (Manassas, VA). Dulbecco's modified eagle's medium (DMEM) and Iscove's modified Dulbecco's medium (IMDM) were purchased from Invitrogen Corporation (Carlsbad, CA). TEM images were acquired on a Philips 420 EM using holey carbon grids from Ted Pella Inc (Redding, CA). UV- Vis spectra were measured in a Cary 50 Bio spectrophotometer. Thermal melting transition measurements were performed in a Jasco 710 spectropolarimeter. DLS data was acquired on a Malvern Zetasizer 3000.
Synthesis and purification of collagen mimetic peptides (CMPs)
The peptides were synthesized by condensation of the corresponding Fmoc-amino acids (Fmoc-Gly-OH, Fmoc-Hyp-OH, and Fmoc-Pro-OH) and 5-carboxyfluorescein (5CF) on a solid support (Wang resin). Both manual and automated systems (Applied Biosystems 43 IA Peptide Synthesizer) were used to prepare peptides 1-4. Four- fold molar excess of the above amino acids was used in a typical coupling reaction. Fmoc-deprotection was accomplished by treatment with 20% (v/v) piperidine in dimethyl formamide (DMF) for 1 hour. The coupling was achieved by treatment with 2-(lH-benzo-triazole-l-yl)-l,l,3,3- tetramethyluronium hexafluorophosphate (HBTU) in N, N-diisopropylethylamine (DIPEA). All the coupling reactions were completed within 3~4 hours and were monitored by ninhydrin or chloranil tests.
The CMPs were cleaved from the resins by treatment with water/triisopropylsilane/trifluoroacetic acid (2.5:2.5:95) for 3 hours. The crude CMPs were precipitated with cold ether and dried. Reverse-phase HPLC purification was performed on a Varian Polaris 210 series Liquid Chromatograph with a Vydac C- 18 reversed-phase column at a flow rate of 1 ml/min. The purified peptides were analyzed by a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer (Kompact SEQ, KRATOS or Voyager DE-STR, Applied Biosystems). (M + H)+ = (peptide 1, 2690.7 Da; peptide 2, 3220.23 Da; peptide 3, 3221.65 Da; peptide 4, 2296.0 Da; peptide 5, 4305.1 Da).
Circular dichroism measurements
Circular dichroism (CD) spectra were recorded on JASCO 710 spectrometer equipped with JASCO PTC-348 WI temperature controller and Hellma cell (400 μL, 0.1 mm pathlength). The thermal melting curves were obtained by measuring the molar ellipticity at
225 nm with l°C/min heating rate. All samples (57 μM in 50 mM acetic acid) were stored at 4°C for 24 hours before the CD measurement.
CMP -collagen film affinity study
To each well of a 96-well culture plate was added 200 μl of saturated collagen (acid soluble, type I bovine) solution in 0.5 M acetic acid. The culture plate was air-dried to form transparent collagen films. The films were neutralized with 0.01 M potassium phosphate buffer (pH 7.4), and washed with distilled water. To the collagen-coated wells were added 40 μl of 0.01 M potassium phosphate solutions (pH 7.4) containing 50 μM of either CF (5- carboxyfluorescein), FITC-Dextran, and peptides 2, 3, or 4, which were pre-equilibrated at 25°C or 80°C. After 3 hours of incubation at room temperature, the wells were washed with 0.01 M potassium phosphate buffer solution (pH 7.4) and observed by fluorescence microscope (Eclips ME 600, Nikon Corp). The total fluorescence intensity was acquired from the fluorescence micrographs using Meta Imaging Series V4.5, (Universal Imaging Corporation, Dowingtown PA). Average values of four independent experiments are reported.
Helical content estimation of the modified collagen films.
Collagen (type I, bovine) film was treated with either peptide 2 solution or blank buffer solution as described before. After 3 hr of incubation at room temperature, the wells were washed with 0.01 M potassium phosphate buffer solution (pH 7.4) and deionized water. All samples were dissolved in 50 mM acetic acid to a concentration of 1.80 μM or 3.60 μM and stored at 40C for 24 hours before the CD measurement. Average values of four independent experiments are reported (Figure 4).
TEM analysis of the modified collagen fibers
Collagen fibers were prepared by dialysis of collagen in 0.0 IM acetic acid solution against dilute NaCl solution. Peptide 4 in potassium phosphate buffer (400 μl, 500 μM, pH 7.4) was added to the collagen fibers in the PBS buffer (1 ml, 1 mg/ml, pH 7.4). The mixture was incubated for 3 hours and excess peptide 4 was removed by repeated centrifugation. The collagen fibers were resuspended in deionized water and transferred to a TEM grid. Uranyl acetate was used to stain the collagen fiber. (Figure 6)
Cell (human fibroblasts and breast epithelial cells) adhesion study
To the collagen film (prepared as above) was added 10 μl of peptide 5 solution (2 mM in pH 7.4 potassium phosphate buffer). The film was allowed to dry and excess materials were removed by washing with potassium phosphate buffer (pH 7.4, 50 mM) and culture medium (DMEM or IMDM). Cells were added to the culture well and incubated at room temperature for 30 minutes. Human fibroblasts (CRL-1502) were seeded at 4.5χlO5 cell/ml cell density in DMEM and breast epithelial cells (MCF-7) at 5.6x105 cells/ml density in cell culture media (IMDM). The nonattached cells were removed by rinsing the well three times with growth medium and PBS buffer. The remaining cells were incubated at 37°C (5% CO2) for three days. The growth medium was exchanged after 48 hours.
Synthesis of gold nanoparticles.
Gold nanoparticles were synthesized by citrate reduction method according using standard methods.41 Briefly, tri-sodium citrate solution (25 mL, 38.8 mM) was quickly added to a refluxing aqueous solution OfHAuCl4 (250 mL, 1 mM) with vigorous stirring. The color of the solution changed from pale yellow to deep red after adding the citrate solution. The solution was refluxed for an additional 15 minutes, cooled, and filtered through a glass filter.
Synthesis and purification of CMPs.
CMP 1 '~4' were synthesized and purified as described above.42
Thermal melting curves of CMPs.
The thermal melting curves were obtained by measuring the ellipticity of peptide in deionized (DI) water (0.5-2 mM) at 225 nm with 0.1°C/min heating rate. All samples were stored at 4°C for 24 hours before the measurement. (Figure 15)
Surface functionalization of gold NP with Cys-CMPs.
Purified Cys-CMP (peptides l '~4') (0.5 mL, 500 μM) was added to gold nanoparticle solution (5 mL, 17 nM), and the reaction mixture was incubated at room temperature for twenty- four hours. Excess CMPs were removed by repeated centrifugation and washing in deionized water. The DLS results of NP-Xs are shown in Figure 16.
Stability of NP-Xs.
The aggregation parameter (AP) is defined as follows: AP = (A - AQ)ZAQ, where A is the integrated absorbance between 600 and 700 nm of a sample at a given condition, and Ao is the integrated absorbance of a fully dispersed NP solution.
Regeneration of type I collagen fibers.
Collagen fibers were regenerated by mixing 0.5 mL of acid soluble type I collagen (1 mg/mL) in 50 mM acetic acid solution with 1 mL of sodium phosphate buffer (10 mM, pH 8.25). The mixture was incubated at room temperature for 12 hours.
TEM analysis ofNP-3 decorated collagen fibers.
A drop (8 μL) of type I collagen solution (0.3 mg/mL in PBS containing 1% BSA) was added to a holey carbon TEM grid. NP-3 solution (3 nM in PBS containing 1% BSA) was added to the grid and incubated for 5 minutes at room temperature or at 4O0C, followed by washing with deionized water. The collagen fibers were stained with uranyl acetate (1%).
Measurement of number of peptides per NP (passivation number).
Seven 10 μM Cys-CMP solutions with varying concentrations of citrate-stabilized gold NP (2-14 nM) were prepared. The mixtures were incubated for 2 hours at 250C and the gold NPs were removed by centrifugation. The concentrations of free peptides remaining in the supernatant were determined from the UV- Vis absorbance at 215 nm with citrate ion background subtraction. The number of peptides per Au NP was calculated from the slope of the linear fit of the data points. (Figure 17)
Synthesis and purification of collagen mimetic peptide (CMP)
(Pro-Hyp-Gly)7-Tyr, CMP, was synthesized by Fmoc mediated solid phase peptide coupling methods starting from a tyrosine preloaded Wang resin. High performance liquid chromatography (HPLC: C18 Vydac column) was used to purify the peptide. The peptide product was lyophilized and stored at -20°C. The molecular weight of the product was confirmed by Matrix-assisted laser-desorption ionization time-of- flight mass spectrometry (MALDI-TOF MS, Voyager DE-STR, Applied Biosystems).
Triple-helical conformation of the CMP was confirmed by circular dichroism (CD) spectroscopy. Peptide samples (250 or 500 μM) were prepared in distilled water and incubated at 4°C overnight before the CD measurement. CD was recorded between 180 and
280 nm on a JASCO' 710 CD spectrometer at various temperatures under a nitrogen flow. Each measurement had static equilibrium time of 30 minutes.
Synthesis and purification of acryloly-PEG-peptide
One milligram (4.9 μM) of (Pro-Hyp-Gly)7-Tyr was dissolved in 1 ml of 0.05 M sodium bicarbonate solution. Acryloyl (ACRL)-PEG-peptide was prepared as previously described44. Briefly, acryloyl-PEG-N-hydroxysuccinimide (ACRL-PEG-NHS, Nektar, 3.4 mg, 10 μM) was dissolved in 200 μL of 0.05 M sodium bicarbonate solution and the resulting solution was added drop-wise to the CMP solution. The solution was shaken on an orbital shaker for 2 hours at room temperature. Ultrafilration (Millipore, molecular weight cut off = 3500) was used to remove unreacted CMP and ACRL-PEG-NHS, and the solution containing the pure product was lyophilized. The dried powder was dissolved in deionized water and run through a size exclusion column Sephadex® G-25 (Pharmacia, motive phase: deionized water) to remove small molecule impurities. Elution fractions containing the target product were combined and lyophilized. MALDI-TOF was used to confirm the molecular weight of the target product. Product was stored at -20 °C and used within a week.
Collagen encapsulation in hydrogels
Type I collagen in 0.1 N acetic acid (Sigma) was neutralized and resuspended in macromer solutions (0.05 wt% initiator (D-2959, Ciba), 8 wt% PEODA (molecular weight: 3400, Nektar) and 2% of ACRL-PEG-(Pro-Hyp-Gly)7-Tyr) at a concentration of 0.2 or 0.5 mg/ml. Control samples composed of 10 wt% PEODA were also prepared. Ultraviolet lamp (EXFO Acticure 4000; wavelength: 365 nm; intensity 5 mW/cm2; 5 min. exposure time) was used to photopolymerize 100 μL of the macromer collagen solution mixture. The polymerized gel constructs were transferred to 12 well tissue culture plates with each well containing 2 ml PBS buffer. The culture plate was incubated at 37°C in 5 % CO2 atmosphere, and PBS buffer was replaced every 2-3 days for one-week period.
Collagen assay
After one week of incubation, the wet weight and dry weight of collagen-encapsulated hydrogel was determined by measurement of the hydrogel before and after 48 hours of lyophilization, respectively. A dry construct was digested in 900 ml of papain solution (250 μg/ml papain type II (Worthington Biomedical Corporation, Lakewood, NJ), 100 niM
phosphate buffer, 10 mM EDTA, 10 mM cysteine at pH 6.3) for overnight at 60°C. The digests were then centrifuged at 10,000 rpm for 5 minutes, and supernatants were taken.
Total collagen content of the gel was estimated from the hydroxyproline assay conducted with papain-digested solution after overnight hydrolysis reaction with 6N hydrochloric acid at 115°C45. Hydrolyzed samples were reacted with/7-dimethylamino benzaldehyde and chloramines-T hydrate46. Absorbance was measured at 550 nm on a UV- Vis spectrophotometer. Standard curve was generated using pure trans-4-hydroxy-L-proline (Sigma- Aldrich). Collagen content of the blank gel (no collagen) was determined and subtracted in the calculation of the total collagen content.
Chondrocyte isolation and encapsulation
Chondrocytes were isolated from the femoral patellar groove and femoral condyles of three 5- to 8-week-old calves. The articular cartilage was excised under aseptic conditions and digested overnight at 37°C in 0.2 % Collagenase type II (Gibco) and 5 % fetal bovine serum (FBS, Gibco, Carlsbad, California) in Dulbecco's modified Eagle medium (DMEM, Gibco). The digested suspension was filtered through a cell strainer (Fisher Scientific Co.) and centrifuged at 1500 rpm for 10 minutes. The supernatant was removed and the pellet was washed and resuspended in PBS buffer (Gibco) supplemented with 1 % penicillin- streptomycin (Gibco). The pellet was washed twice and resuspended in medium.
Harvested cells were resuspended in the macromer solutions at a concentration of 20 x 106 per ml. For example, macromer solutions for 2 wt% CMP-PEG gel contained initiator (0.05 wt%; D-2959, Ciba), PEODA (8 wt%; Nektar), ACRL-PEG-(Pro-Hyp-Gly)7-Tyr (2 wt%) and PBS buffer (89.95 wt%). Each gel-construct was prepared in 100 μL cell- macromer solution and photopolymerized as described previously. The construct was transferred to a well of 12-well culture plate containing 2 ml of culture medium. The medium was composed of 10 mM HEPES (Gibco, Carlsbad, California), 0.1 mM NEAA (Gibco, Carlsbad, California), 0.4 mM proline (Sigma), 50 mg/L Vitamin C (Sigma), 10% FBS, and 1% penicillin-streptomycin in high glucose DMEM. Constructs were cultured at 37°C in 5% CO2 atmosphere and medium was replaced every 2-3 days.
Cell viability test
The viability of hydrogel encapsulated cells was determined after 2 weeks of culture. The medium was discarded and the hydrogel matrices were washed twice with phosphate
buffer solution (PBS, Gibco, Carlsbad, California). Cell viability was assessed based on the integrity of cellular membrane using Live/Dead Viability/Cytotoxicity Kit (Molecular Probes, Eugene, OR) that contains calcein-AM ("Live") dye and ethidium homodimer-1 ("Dead") dye. Dye solution was made with 0.5 μL of calcein-AM dye and 2 μL of ethidium homodimer-1 dye in 1 mL DMEM. A slice of the cell containing matrix was incubated in 500 μL of the "Live/Dead" dye solution for 30 minutes. Fluorescence microscopy was performed using a fluorescein optical filter (485 ± 10 nm) for calcein-AM and a rhodamine optical filter (530 ± 12.5 nm) for ethidium homodimer-1.
Histology and immunohistochemistry
After two weeks of culture, cell containing and control matrices were fixed overnight in 10% formalin solution and stored in 70% ethanol. The fixed cell containing matrix was embedded in paraffin, sectioned and stained with Safranin-O/fast green or with Masson's trichrome stain. Acellular controls of the CMP/PEODA hydro gel were also stained following the same procedure to measure any background signals. Immunohistochemistry was performed using rabbit polyclonal antibody to collagen type II (Research Diagnostics) and a Histostain-SP kit (Zymed).
Water content and biochemical assays
Water content of the cell-encapsulated hydrogels was calculated by the following equation:
Water content (%) = [(Ww - Wd) / Ww] x 100 ( 1 ) where Ww is wet weight of the hydro gel after one day equilibration in water, and Wd, dry weight of the hydrogel.
Cell containing and control matrices were digested with Papain overnight. The digested samples were used for both DNA and glucosaminoglycan (GAG) measurements. Hoechst 33258 dye from Molecular Probes (Eugene, OR) was used for the DNA assay47. The solution (0.1 μg/ml) was prepared in 1 x TNE buffer (10 mM Tris, 1 mM EDTA, 0.2 M NaCl, pH 7.4). Calf Thymus DNA standards were prepared with 0 to 100 μg/ml DNA. Papain-digested samples (30 or 60 μL) or standards were mixed with the prepared dye solution. DNA content was measured with a fluorometer (365 nm excitation and 458 nm emission) and calculated from the calf thymus DNA standard curve. The GAG was
measured using the dimethylmethlene blue (DMMB) dye48. A standard curve was created with chondroitin sulfate C (shark cartilage extract, Sigma). Absorbance was measured at 525 run on a UV-Vis spectrophotometer. Collagen assays were also performed as described above. Collagen contents in the acellular CMP hydrogels were also measured for the purpose of background subtraction. GAG and collagen contents from the biochemical assays were normalized by the DNA content. The value is presented as mean ± standard deviation. Statistical significance was determined by unpaired Student t test and set as/? < 0.05.
Other Embodiments
From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.
The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
All patents and publications mentioned in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.
References
1. Leikina, et al., (2002) Proc. Natl. Acad. Sci. 99:1314-1318.
2. Holmgren, et al., "(1998) Nature 392:666-667.
3. Goodman, et al., (1998) Biopolymers 47:127-142.
4. Stetefeld, et al., (2003) Structure (Camb) 11 (3):339-46.
5. Holmgren, et al., (1999) Chem Biol. 6:63-70.
6. Frank, et al., (2001) J. MoI. Biol. 308:1081-1089.
7. Frank, et al., (2003) The Journal of Biological Chemistry 278(10):7747-7750.
8. Koide, et al., (2005) Bioorganic & Medicinal Chemistry Letters 15:5230-5233.
9. Huynh, et al., (1999) Nat. Biotechnol. 17:1083-1086.
10. O'Connor, et al., (2000) J. Neurosci. Methods 102:187-195.
11. Myles, ET AL., (2000) J. Biomater. Sci. Polym. Ed. 11 :69-86.
12. Huang, et al.,(2001) J. Biomater. Sci. Polym. Ed. 12:979-993.
13. Koide, et al., (2005) Bioorganic & Medicinal Chemistry Letters 15:5230-5233.
14. Winblade, et al., (2002) J. Biomed. Mater. Res. 59:618-631.
15. Groll, et al., (2005) Biomacromolecules 6:956-962.
16. Groll, et al., (2005) J. Biomed. Mater. Res. 74A:607-617
17. Wang, et al., (2005) J. Am. Chem. Soc. 127: 4130-4131.
18. Groll, et al., (2004) J. Am. Chem. Soc. 126: 4234-4239.
19. Pasut, et al., (2004) Expert Opin. Ther. Patents 14(6):859-894.
20. Ameringer, et al. (2005) Biomacromolecules 6:1819-1823.
21. Petersen, et al., (2002) Biomacromolecules 3:926-936.
22. Fitzgerald, et al., (2003) FEBS Lett., 552:91-94.
23. Olsen, (1997) Int. J. Biochem. Cell Biol. 29:555-558.
24. Kassner, et al., (2004) S. J. MoI. Biol. 339: 835-853.
25. Gelse, et al., (2003) Advanced Drug Delivery Reviews 55:1531-1546.
26. Harris, et al., (1997) ACS Symposium Series 680; Amer. Chem. Soc: San Francisco.
27. Bretscher, et al, (2001) R. T. J. Am. Chem. Soc. 123:777-778.
28. Peffer, et al., (1993) Proc. Natl. Acad. Sci. 90:10648-10652.
29. Miles, et al., (2001) J. Micron 32:325-332.
30. Nimni, (1998) M. E. Collagen; CRC Press: Boca Raton.
31. Birk, et al., (1988) J. Cell. Biol. 106:999-1008.
32. Feng, et al., (1996) Biopolymers 39:859-872.
33. Bretscher, et al., (2001) J. Am. Chem. Soc. 123:777-778.
34. Grabar, et al., (1995) J. Anal. Chem. 67: 735-743.
35. Bella, et al., (1994) Science 266:75-81.
36. Levy, et al. (2004) J. Am. Chem. Soc. 126:10076-10084.
37. Williams, et al. (1978) J. Biol. Chem. 253:6578-6585.
38. Miles, et al. (1999) Biophys. J. 76:3243-3252.
39. Leikina, et al., (2002) S. Proc. Nat. Acad. Sci. 99:1314-1318.
40. Cruz., et al., (2001) J. Vase. Surg. 34:724-729.
41. Grabar, et al., (1995) J. Anal.Chem. 67:735-743.
42. Wang, et al., (2005) J. Am. Chem. Soc. 127:4130-4131.
43. Levy, et al., (2004) J. Am. Chem. Soc. 126:10076-10084
44. Hern, et al., (1998) J Biomed Mater Res 39:266.
45. Neuman, et al., (1950) J Biol Chem 184:299.
46. Woessner, (1961) Arch Biochem Biophys 93:440.
47. Kim, et al., (1988) Anal Biochem 174:168.
48. Melrose, et al. (1988) Anal Biochem 170:293.
49. Liu, et al., (1997) Proc. Natl. Acad. Sci. U.S.A. 94:1852-1856.
50. Bossavy, et al., (1999) Arterioscler Thromb Vase. Biol. 19:1348-1353.
Claims
1. A method for modifying collagen, the method comprising contacting collagen with a collagen mimetic peptide, under conditions that provide for a physical interaction between the collagen and the collagen mimetic peptide.
2. The method of claim 1, wherein the collagen mimetic peptide comprises a Z-[X-Y-GIy]n repeat unit, wherein Z is any amino acid, X is proline or modified proline, Y is proline or modified proline, and n is an integer between 1 and 20.
3. The method of claim 2, wherein the modified proline is 4-hydroxyproline and 4- fluoro proline.
4. The method of claim 1, wherein the collagen mimetic peptide comprises (ProHypGly)x, (ProProGly)x ,or (ProFlpGly)x, where Hyp is hydroxyl proline, FIp is 4-fluoro proline, and x is any integer between 1 and 30.
5. The method of claim 1, wherein the collagen mimetic peptide comprises at least 10 amino acids.
6. The method of claim 5, wherein the collagen mimetic peptide comprises at least 20 amino acids.
7. The method of claim 6, wherein the collagen mimetic peptide comprises between 25 and 30 amino acids.
8. The method of claim 1, wherein the collagen mimetic peptide is conjugated to an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
9. The method of claim 8, wherein the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
10. The method of claim 8, wherein the cell adhesion molecules is selected from the group consisting of a cadherin, fibronectin, integrin, laminin, and selectin.
11. The method of claim 8, wherein the contrast agent is a gadolinium complex, gadodiamide derivative, ferric ammonium citrate, or mangafodipar trisodium.
12. The method of claim 8, wherein the wherein the detectable label is selected from the group consisting of a colloidal particle, an enzyme, an electron-dense reagent, a fluorescent dye, a hapten, an immunogen, a magnetic bead, and a radiolabel.
13. The method of claim 8, wherein the growth factor promotes an activity selected from the group consisting of angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, cell survival.
14. The method of claim 8, wherein the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, and platelet-derived growth factor, transforming growth factor β and bone morphogenic protein.
15. The method of claim 8, wherein the component of the extracellular matrix is selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin; proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and aggrecan.
16. The method of claim 8, wherein the polymer is selected from the group consisting of collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2- hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol.
17. The method of claim 8, wherein the PEG is selected from the group consisting of a star shaped PEG, a multi-armed PEG, a graft linear PEG, PEG2ooo, and PEG5Oo0.
18. The method of claim 8, wherein the small molecule is selected from the group consisting of anti-thrombotics, anti-atherosclerosis agents, and cartilage repair agents.
19. The method of claim 18, wherein the anti-thrombotic is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP, Tenectaplase-CMP, Lanoteplase- CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab-CMP
Tirofiban-CMP, Epitfibatide-CMP, Tifacogin-CMP.
20. The method of claim 8, wherein the anti-atherosclerosis agent is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP, Tenectaplase-CMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab-CMP, Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP.
21. The method of claim 8, wherein the cartilage repair agent is selected from the group consisting of glucosamine sulfate, chondroitin sulfate, hyaluronic acid.
22. The method of claim 8, wherein the collagen mimetic peptide binds a collagen.
23. The method of claim 22, wherein the collagen mimetic peptide binds to a collagen selected from the group consisting of type 1-29 collagen.
24. The method of claim 23, wherein the collagen mimetic peptide binds to type I, II, III, rv ix, x, or xi.
25. A modified collagen made by the process of any one of claims 1-25.
26. A collagen mimetic peptide conjugate, wherein the conjugate is selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
27. The collagen mimetic peptide conjugate of claim 26, wherein the collagen mimetic peptide comprises a
Z-[X-Y-GIy]n repeat unit, wherein Z is any amino acid, X is proline or modified proline, Y is proline or modified proline, and n is an integer between 1 and 20.
28. The collagen mimetic peptide conjugate of claim 26, wherein the modified proline is 4-hydroxyproline, or 4-fluoro proline.
29. The method of claim 1, wherein the collagen mimetic peptide comprises (ProHypGly)χ, (ProProGly)x ,or (ProFlpGly)x, where Hyp is hydroxyl proline, FIp is 4-fluoro proline, and x is any integer between 1 and 30.
30. The collagen mimetic peptide conjugate of claim 26, wherein the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
31. The collagen mimetic peptide conjugate of claim 26, wherein the cell adhesion molecules is selected from the group consisting of a cadherin, fibronectin, integrin, laminin, and selectin.
32. The collagen mimetic peptide conjugate of claim 26, wherein the a contrast agent is a gadolinium complex, gadodiamide derivative, ferric ammonium citrate, or mangafodipar trisodium.
33. The collagen mimetic peptide conjugate of claim 26, wherein the detectable label is selected from the group consisting of a colloidal particle, an enzyme, an electron-dense reagent, a fluorescent dye, a hapten, an immunogen, a magnetic bead, and a radiolabel.
34. The collagen mimetic peptide conjugate of claim 26, wherein the growth factor promotes an activity selected from the group consisting of angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, and cell survival.
35. The collagen mimetic peptide conjugate of claim 26, wherein the angiogenic factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, and platelet-derived growth factor, transforming growth factor β and bone morphogenic protein
36. The collagen mimetic peptide conjugate of claim 26, wherein the component of the extracellular matrix is selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin; proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and aggrecan.
37. The collagen mimetic peptide conjugate of claim 26, wherein the polymer is selected from the group consisting of collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2-hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol.
38. The collagen mimetic peptide conjugate of claim 26, wherein the PEG is selected from the group consisting of a star shaped PEG, a multi-armed PEG, a graft linear PEG.
39. The collagen mimetic peptide conjugate of claim 26, wherein the small molecule is selected from the group consisting of anti-thrombotics, anti-atherosclerosis agents, and cartilage repair agents.
40. The collagen mimetic peptide conjugate of claim 26, wherein the anti-thrombotic is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP Tenectaplase-CMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab- CMP
Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP.
41. The collagen mimetic peptide conjugate of claim 26, wherein the anti-atherosclerosis agent is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP Tenectaplase-CMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab- CMP
Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP.
42. The collagen mimetic peptide conjugate of claim 26, wherein the cartilage repair agent is selected from the group consisting of chondroitin sulfate,
43. The collagen mimetic peptide conjugate of any one of claims 26-42, wherein the peptide comprises an amino acid sequence selected from the group consisting of:
Gly3-(ProHypGly)6,
Gly3-(ProHypGly)7,
Gly3-(ProHypGly)8,
Gly3-(ProHypGly)9
(ProHypGly)6-Tyr
(ProHypGly)7-Tyr
(ProHypGly)8-Tyr
Cys-(Pro-Hyp-Gly)3,
Cys-(Pro-Hyp-Gly)5, and
Cys-(Pro-Hyp-Gly)7.
44. The collagen mimetic peptide conjugate of any one of claims 26-43, wherein the peptide comprises: carboxyfluorescein-Gly3-(Pro-Hyp-Gly)6 carboxyfluorescein-Gly3-lys-(Pro-Hyp-Gly) g
PEG2000-Gly3-(Pro-Hyp-Gly)7
Methoxy PEG2000-GIy3-(PrO-HyP-GIy)7
(Pro-Hyp-Gly)8-Gly3-PEG50oo-OH
[AcGly-Gly2-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG
[CF-Gly3-Lys-Gly3-(Pro-Hyp-Gly)8]4-star shaped PEG
AcGIy-GIy2-LyS-GIy3-(PrO-HyP-GIy)8,
FL-PEG2000-GIy3-(PrO-HyP-GIy)7, and
5 carboxyfluorescein -Gly3-(Pro-Hyp-Gly)8-Gly3-PEG5000-OH.
45. The collagen mimetic peptide conjugate of claim 26, wherein the detectable label is 5- carboxy-fluorescein.
46. The collagen mimetic peptide conjugate of claim 26, wherein the collagen mimetic peptide binds to a collagen selected from the group consisting of collagen type 1-29.
47. The collagen mimetic peptide conjugate of claim 46, wherein the collagen mimetic peptide binds to type I, II, III, IV, IX, X, and XI collagen.
48. The collagen mimetic peptide conjugate of claim 26, wherein the contrast reagent is a gadolinium complex, gadodiamide derivative, ferric ammonium citrate, or mangafodipar trisodium.
49. A collagen mimetic peptide comprising any one of the following amino acid sequences:
Glyn-(ProHypGly)n',
(ProHypGly) n>-Tyrn
Cysn-(Pro-Hyp-Gly) n. wherein n is an integer between 1 and 5, and n' is any integer between 1 and 15, and the peptide further comprises a modifier selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, an anti-inflammatory, a component of the extracellular matrix, a polymer, PEG, and a small molecule.
50. The collagen mimetic peptide of claim 49, wherein the peptide has a melting transition temperature between 5°C and 95°C.
51. The collagen mimetic peptide of claim 49, wherein the peptide has a melting transition temperature between 10°C and 80°C.
52. The collagen mimetic peptide of claim 49, wherein the peptide has a melting transition temperature between 15°C and 40°C.
53. The collagen mimetic peptide of claim 49, wherein the peptide has a melting transition temperature between 2O0C and 37°C.
54. The collagen mimetic peptide of claim 49, wherein n' is 5, 6, 7, or 8.
55. The collagen mimetic peptide of claim 49, wherein collagen mimetic peptide comprises a conjugate selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, a polymer, PEG, and a small molecule.
56. A modified collagen comprising a CMP mimetic peptide conjugate of any one of claims 26-55.
57. A method of modifying the adhesiveness of a composition, the method comprising contacting the composition with a CMP conjugate.
58. The method of claim 57, wherein the composition comprises collagen.
59. The method of claim 57, wherein the collagen is present in a three-dimensional matrix or in a collagen film.
60. The method of claim 57, wherein the collagen is modified in a micropattern.
61. The method of claim 57, wherein the CMP conjugate is a poly(ethyleneglycol)- CMP conjugate.
62. The method of claim 57, wherein the modification increases or decreases adhesiveness.
63. A nanoparticle comprising a collagen mimetic peptide fixed to the nanoparticle.
64. The nanoparticle of claim 63, wherein the collagen mimetic peptide comprises the following sequence:
Cysn-(Pro-Hyp-Gly)n., wherein n is any integer between 1 and 5, and n' is any integer between 1 and 10.
65. The nanoparticle of claim 63, wherein n is 1 and n' is 3.
66. The nanoparticle of claim 63, wherein the collagen mimetic peptide is fixed to the surface of the nanoparticle.
67. The nanoparticle of claim 63, wherein the nanoparticle is between 5 and 20 nm in diameter.
68. The nanoparticle of claim 63, wherein the nanoparticle is between 10 and 15 nm in diameter.
69. The nanoparticle of claim 63, wherein the nanoparticle comprises AU.
70. The nanoparticle of claim 63, wherein the collagen mimetic peptide has a melting transition temperature between 5°C and 950C.
71. The nanoparticle of claim 63, wherein the collagen mimetic peptide has a melting transition temperature between 10°C and 80°C.
72. The nanoparticle of claim 63, wherein the collagen mimetic peptide has a melting transition temperature between 15°C and 40°C.
73. The nanoparticle of claim 63, wherein the collagen mimetic peptide has a melting transition temperature between 20°C and 37°C.
74. The nanoparticle of claim 63, wherein n' is 5, 6, 7, or 8.
75. The nanoparticle of claim 63, wherein the collagen mimetic peptide comprises a conjugate selected from the group consisting of an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, an anti-inflammatory, a component of the extracellular matrix, a polymer, PEG, and a small molecule.
76. A transmission electron microscopy marker comprising the nanoparticle of any one of claims 62-75.
77. The transmission electron microscopy marker of claim 76, wherein the nanoparticle comprises AU.
78. A diagnostic marker comprising a detectable CMP conjugate, wherein the marker binds collagen and detects a disease.
79. The diagnostic marker of claim 78, wherein CMP is conjugated to a nanoparticle, a detectable label, or a contrast reagent.
80. The diagnostic marker of claim 78, wherein the marker detects a disease characterized by disruption of collagen structure.
81. The diagnostic marker of claim 78, wherein the marker detects the disease by binding to a collagen selected from the group consisting of collagen type 1-type 29.
82. The diagnostic marker of claim 78, wherein collagen bound is type I, II, III, IV, IX, X, or XL
83. The diagnostic marker of claim 78, wherein the disease is selected from the group consisting of Ehlers-Danlos syndrome, osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymϋller.
84. The diagnostic marker of claim 78, wherein the marker is detectable using transmission electron microscopy.
85. A method for diagnosing a subject as having or having a propensity to develop a disease characterized by disruption of a collagen structure, the method comprising: a) contacting a patient sample with a detectable CMP-conjugate; b) detecting an alteration in a collagen structure present in the patient sample, wherein the alteration diagnoses the subject as having or having a propensity to develop a disease characterized by disruption of a collagen structure.
86. A method for diagnosing a subject as having or having a propensity to develop a thrombosis, the method comprising: a) contacting a blood vessel with a detectable CMP-conjugate; b) detecting an alteration present in the blood vessel, wherein the alteration diagnoses the subject as having or having a propensity to develop a thrombosis.
87. The method of claim 85 or 86, wherein the detectable CMP-conjugate binds a collagen selected from the group consisting of collagen type 1-type 29.
88. The method of claim 85 or 86, wherein the collagen bound is type I, II, III, IV, IX, X, or XI.
89. The method of claim 86, wherein the disease is selected from the group consisting of Ehlers-Danlos syndrome, Osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymϋller.
90. The method of claim 86, wherein the marker binds a collagen present in a thombosis or a vessel wall.
91. A diagnostic kit comprising a detectable CMP conjugate and directions for the use of the conjugate in the diagnosis of a disease characterized by a disruption in collagen structure.
92. The kit of claim 91, wherein the detectable CMP-conjugate binds a collagen selected from the group consisting of collagen type 1-type 29.
93. The kit of claim 91 , wherein the collagen bound is type I, II, III, IV, IX, X, or XI.
94. The kit of claim 93, wherein the disease is selected from the group consisting of Ehlers-Danlos syndrome, Osteogenesis imperfecta, achondrogenesis type 2, hypochondrogenesis, Kniest dysplasia, otospondylomegaepiphyseal dysplasia, spondyloepimetaphyseal dysplasia, Strudwick type, spondyloepiphyseal dysplasia congenita spondyloperipheral dysplasia, Stickler syndrome, and Weissenbacher-Zweymϋller.
95. A composition for repelling cell adhesion, the composition comprising a CMP- poly(ethylene glycol) conjugate.
96. The composition of claim 95, wherein the CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG2ooo-Gly3-(Pro-Hyp-Gly)7 or (Pro-Hyp-Gly)9-Gly3-PEG5oo0.
97. The composition of claim 95, wherein the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG or NHS activated star-shaped PEG.
98. The composition of claim 97, wherein the composition comprises star shaped PEG having the following formula:
99. The composition of claim 95, wherein the composition comprises AcGIy-GIy2-LyS- Gly3-(Pro-Hyp-Gly)8.
100. The composition of claim 95, wherein the CMP comprises -(Pro-Hyp-Gly)n', wherein n is any integer between 1 and 3, and n' is any integer between 1 and 10.
101. A matrix comprising a CMP-polymer conjugate, wherein the CMP-polymer conjugate alters the adhesive properties of the matrix.
102. .The matrix of claim 101, wherein the CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG2ooo-Gly3-(Pro-Hyp-Gly)7 or (Pro-Hyp-Gly)9-Gly3-PEG50o0.
103. The matrix of claim 101, wherein the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG.
104. The matrix of claim 101, wherein the composition comprises NHS activated star- shaped PEG.
106. The matrix of claim 101, wherein the composition comprises AcGIy-GIy2-LyS-GIy3- (Pro-Hyp-Gly)8.
107. The matrix of claim 101, further comprising a cell selected from the group consisting of chondrocytes, endothelial cells, dendritic cells, stem cells, multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, and osteoclasts.
108. The matrix of claim 101, wherein the CMP-poly(ethylene glycol) conjugate is present in a pattern.
109. The matrix of claim 101, wherein the CMP comprises -(Pro-Hyp-GlyV, wherein n is any integer between 1 and 3, and n' is any integer between 1 and 10.
110. A method for repelling cell adhesion on a composition, the method comprising fixing a CMP-PEG conjugate to a composition, wherein the CMP-PEG conjugate repels cell adhesion on the composition.
111. The method of claim 110, wherein the CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG200o-Gly3-(Pro-Hyp-Gly)7 or (Pro-Hyp-Gly)9-Gly3-PEG5oo0.
112. The method of claim 110, wherein the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG.
113. The method of claim 110, wherein the composition comprises NHS activated star- shaped PEG.
114. The method of claim 110, wherein the method repels adhesion of a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
115. A composition comprising a CMP-poly(ethylene glycol) conjugate that comprises a detectable marker.
116. The composition of claim 115, wherein the CMP-poly(ethylene glycol) conjugate comprises methoxy-PEG200o-Gly3-(Pro-Hyp-Gly)7 or (Pro-Hyp-Gly)9-Gly3-PEG50o0.
117. The composition of claim 115, wherein the CMP-poly(ethylene glycol) conjugate comprises grafted linear PEG.
118. The composition of claim 111, wherein the composition comprises NHS activated star-shaped PEG.
119. The composition of claim 111, wherein the composition comprises star shaped PEG having the following formula:
120. The composition of claim 111, wherein the composition comprises AcGIy-GIy2-LyS- Gly3-(Pro-Hyp-Gly)8.
121. A method of determining the presence of a CMP-poly(ethylene glycol) conjugate in a composition, the method comprising a) contacting a composition with a CMP-poly(ethylene glycol) conjugate comprising a detectable marker; and b) assaying presence or absence of binding of the CMP-poly(ethylene glycol) conjugate to the composition.
122. The method of claim 121, wherein the detecting quantifies the level of detectable marker.
123. The method of claim 117, wherein the detecting localizes the detectable marker in the composition.
124. A composition for crosslinking collagen, the composition comprising a CMP- poly(ethylene glycol) conjugate.
125. The composition of claim 124, wherein the CMP is conjugated to a multi-armed PEG compound.
126. The composition of claim 124, wherein the PEG comprises an amino group.
127. The composition of claim 124, wherein the PEG comprises a thiol group.
129. The composition of claim 124, wherein the composition comprises AcGIy-GIy2-LyS- Gly3-(Pro-Hyp-Gly)8.
130. A method for preventing or treating thrombosis in a subject, the method comprising contacting a blood vessel having or having a propensity to develop a thrombosis with a CMP- anti-thrombosis conjugate; wherein the contacting prevents or treats a thrombosis.
131. The method of claim 130, wherein the propensity to develop a thrombosis is related to angioplasty.
132. The method of claim 130, wherein the vessel is contacted with a hydrogel comprising a CMP-anti-thrombosis conjugate.
133. The method of claim 130, wherein the CMP-anti-thrombosis conjugate binds collagen present in the thrombosis.
134. The method of claim 130, wherein the CMP-anti-thrombosis conjugate degrades the thrombosis.
135. The method of claim 130, further comprising monitoring the efficacy of the method.
136. The method of claim 135, wherein efficacy is monitored by determining plasma level of β-thromboglobulin or thrombin-antithrombin complexes.
137. A diagnostic marker that detects a vessel having or having an increased propensity to develop a thrombosis relative to a control vessel, the marker comprising a detectable CMP conjugate that binds collagen.
138. The diagnostic marker of claim 137, wherein the marker detects the presence of a thrombosis in the vessel.
139. The diagnostic marker of claim 137, wherein marker binds collagen type III.
140. The diagnostic marker of claim 137, wherein the marker detects a vessel having a propensity to develop a thrombosis.
141. A diagnostic kit comprising the diagnostic marker of claim 133 and directions for the use of the conjugate in the diagnosis of a thromobosis or a propensity to develop a thrombosis.
142. An implantable, sustained release device comprising a CMP conjugate fixed to a collagen matrix.
143. The implantable, sustained release device of claim 142, wherein the conjugate is selected from the group consisting of an antibiotic, a growth factor, an anti-inflammatory, a component of the extracellular matrix, and a small molecule.
144. The implantable, sustained release device of claim 142, wherein the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
145. The implantable, sustained release device of claim 142, wherein the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, transforming growth factor β and bone morphogenic protein.
146. The implantable, sustained release device of claim 138, wherein the small molecule is selected from the group consisting of anti-thrombotics, anti-atherosclerosis agents, cartilage repair agent,
147. The implantable, sustained release device of claim 142, wherein the anti-thrombotic is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP Tenectaplase-CMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab-
CMP
Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP.
148. The implantable, sustained release device of claim 142, wherein the anti- atherosclerosis agent is selected from the group consisting of heparin-CMP, Hirudin-CMP, Saratin-CMP Tenectaplase-CMP, Lanoteplase-CMP, Monteplase-CMP, Pamiteplase-CMP, Abciximab-CMP, Tirofiban-CMP, Epitfibatide-CMP, and Tifacogin-CMP.
149. The implantable, sustained release device of claim 142, wherein the cartilage repair agent is selected from the group consisting of chondroitin sulfate, glucosamine, and hyaluronic acid.
150. The implantable, sustained release device of claim 142, wherein the antiinflammatory is selected from the group consisting of corticosteroids, and NSAIDS.
151. The implantable, sustained release device of claim 142, wherein the collagen matrix is a hydrogel.
152. The implantable, sustained release device of claim 142, wherein the collagen matrix is a pellet.
153. The implantable, sustained release device of claim 142, wherein the collagen matrix is a film.
154. A kit comprising an effective amount of an implantable, sustained release device of any one of claim 138-153, and directions for the use of the device in the treatment of a disease or disorder.
155. A hemostatic sponge comprising a collagen mimetic peptide and collagen.
156. The hemostatic sponge of claim 155, wherein the collagen mimetic peptide physically associates with the collagen.
157. The hemostatic sponge of claim 155, further comprising a natural or synthetic polymer.
158. The hemostatic sponge of claim 155, wherein the collagen mimetic peptide further comprises a conjugate selected from the group consisting of clotting agents, growth factors, and antibiotics.
159. The hemostatic sponge of claim 155, wherein the clotting agents is the group selected from the group consisting of thrombin and fibrin.
160. The hemostatic sponge of claim 155, wherein the growth factor promotes an activity selected from the group consisting of angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, cell survival
161. The hemostatic sponge of claim 155, wherein the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, transforming growth factor β and bone morphogenic protein.
162. The hemostatic sponge of claim 154, wherein the antibiotic is the group selected from the group consisting of penicillin, tetracycline, plectasin, and LAH4.
163. A corneal shield comprising a collagen mimetic peptide conjugate and a polymer.
164. The corneal shield of claim 163, wherein the CMP conjugate comprises an antibiotic, an anti-inflammatory, or a small molecule.
165. A wound healing device comprising a collagen mimetic peptide conjugate and a polymer.
166. The wound healing device of claim 165, wherein the CMP conjugate comprises an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti-inflammatory, and a small molecule.
167. The wound healing device of claim 165, wherein the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
168. The wound healing device of claim 165, wherein the cell adhesion molecule is selected from the group consisting of cadherin, fibronectin, integrin, laminin, and selectin.
169. The wound healing device of claim 165, wherein the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, transforming growth factor β and bone morphogenic protein.
170. The wound healing device of claim 165, is a component of the extracellular matrix selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin; proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and aggrecan.
171. The wound healing device of claim 165, wherein the small molecule is a cartilage repair agent.
172. The wound healing device of claim 165, wherein the anti-inflammatory is selected from the group consisting of corticosteroids, and NSAIDS.
173. The wound healing device of claim 165, the device is in the form of a plug, mesh, strip, suture, dressing, patch, threads, suture, or biological fastener.
174. The wound healing device of claim 165, further comprising a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
175. A kit comprising the wound healing device of any one of claims 160-174.
176. A matrix comprising a polymer in association with a collagen mimetic peptide, wherein the matrix promotes the survival, differentiation, or proliferation of a cell.
177. The matrix of claim 176, wherein the polymer is in a hydrogel.
178. The matrix of claim 176, wherein the polymer is biochemically inert.
179. The matrix of claim 176, wherein the polymer is photopolymerizable.
180. The matrix of claim 176, wherein the polymer is selected from the group consisting of collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2- hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol.
181. The matrix of claim 176, wherein the collagen mimetic peptide physically interacts with collagen.
182. The matrix of claim 176, wherein the physical interaction occurs by helical assembly or strand invasion.
183. The matrix of claim 176, wherein the collagen mimetic peptide acts as a cross-linking agent.
184. The matrix of claim 176, wherein the matrix is susceptible to proteolytic breakdown.
185. The matrix of claim 176, wherein the matrix further comprises an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
186. The matrix of claim 176, wherein the CMP is conjugated to an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an anti- inflammatory, a polymer, PEG, and a small molecule.
187. The matrix of claim 185 or 186, wherein the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
188. The matrix of claim 185 or 186, wherein the cell adhesion molecules is selected from the group consisting of a cadherin, fibronectin, integrin, laminin, and selectin.
189. The matrix of claim 185 or 186, wherein the growth factor promotes an activity selected from the group consisting of angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, cell survival.
190. The matrix of claim 189, wherein the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, transforming growth factor β and bone morphogenic protein.
191. The matrix of claim 185 or 186, wherein the component of the extracellular matrix is selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin; proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and aggrecan.
192. The matrix of claim 185 or 186, wherein the polymer is selected from the group consisting of collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2-hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol.
193. The matrix of claim 185 or 186, wherein the PEG is selected from the group consisting of a star shaped PEG, a multi-armed PEG, a graft linear PEG, PEG20O0, and
194. The matrix of claim 185 or 186, wherein the small molecule is selected from the group consisting of a cartilage repair agent, glucosamine, and hyaluronic acid.
195. The matrix of claim 185 or 186, wherein the matrix further comprises a cell selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastrointestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
196. A method for synthesizing a matrix, the method comprising contacting a collagen mimetic peptide to a polymer and cross-linking the polymer such that a molecular matrix is formed.
197. The method of claim 196, wherein the polymer is in a hydrogel.
198. The method of claim 196, wherein the polymer is biochemically inert.
199. The method of claim 196, wherein the polymer is photopolymerizable.
200. The method of claim 196, wherein the polymer is selected from the group consisting of poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2-hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol.
201. The method of claim 196, wherein the collagen mimetic peptide physically interacts with collagen.
202. The method of claim 196, wherein the physical interaction occurs by helical assembly or strand invasion
203. The method of claim 196, wherein the collagen mimetic peptide acts as a cross- linking agent.
204. A method for promoting cell survival or proliferation, comprising growing a cell in contact with a matrix comprising a polymer and a collagen mimetic peptide.
205. The method of claim 204, wherein the collagen mimetic peptide is capable of retaining a cell-secreted collagen.
206. The method of claim 204, wherein the matrix further comprises an antibiotic, a cell adhesion molecule, a contrast agent, a detectable label, a growth factor, a component of the extracellular matrix, an anti-inflammatory, a polymer, PEG, and a small molecule.
207. The method of claim 204, wherein the CMP is conjugated to an antibiotic, a cell adhesion molecule, a growth factor, a component of the extracellular matrix, an antiinflammatory, a polymer, PEG, and a small molecule.
208. The method of claim 206 or 207, wherein the antibiotic is selected from the group consisting of penicillin, tetracycline, plectasin, LAH4.
209. The method of claim 206 or 207, wherein the cell adhesion molecules is selected from the group consisting of a cadherin, fibronectin, integrin, laminin, and selectin.
210. The method of claim 206 or 207, wherein the growth factor promotes an activity selected from the group consisting of angiogenesis, cell growth, differentiation, proliferation, neurogenesis, osteogenesis, stem cell renewal, cell survival.
211. The method of claim 206 or 207, wherein the growth factor is selected from the group consisting of angiogenin, erythropoietin, vascular endothelial growth factor (VEGF), granulocyte/macrophage colony stimulating factor, macrophage- colony stimulating factor, platelet-derived endothelial cell growth factor, transforming growth factor β and bone morphogenic protein.
212. The method of claim 206 or 207, wherein the component of the extracellular matrix is selected from the group consisting of collagen, elastin, fibrillin, fibronectin, laminin; proteoglycans, hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, and aggrecan.
213. The method of claim 206 or 207, wherein the polymer is selected from the group consisting of collagen, poly(ethylene oxide) diacrylate (PEODA), poly(ethylene glycol), poly(2-hydroxyethyl methacrylate), polyacrylic alcohol, and polyvinyl alcohol.
214. The method of claim 206 or 207, wherein the PEG is selected from the group consisting of a star shaped PEG, a multi-armed PEG, a graft linear PEG, PEG200O, and PEG5000.
215. The method of claim 206 or 207, wherein the small molecule is selected from the group consisting of a cartilage repair agent, glucosamine, and hyaluronic acid.
216. The method of claim 213, wherein the polymer is in a hydrogel.
217. The method of claim 213, wherein the polymer is biochemically inert.
218. The method of claim 213, wherein the polymer is photopolymerizable.
219. The method of claim 213, wherein the cell is selected from the group consisting of endothelial cells, dendritic cells, stem cells or other multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, osteoclasts, and chondrocytes.
220. A method for replacing a damaged or absent tissue, the method comprising a) growing a cell in a matrix of any one of claim 170-188; and b) contacting a damaged tissue or site of an absent tissue with the cell and matrix of step (a), such that the cell and matrix replaces the damaged or absent tissue.
221. A method for or for tissue augmentation a) growing a cell in a matrix of any one of claim 176-214; and b) contacting a tissue that requires augmentation with the cell and matrix of step (a), such that the cell and matrix augments the tissue.
222. The method of claim 220 or 221, wherein the tissue is selected from the group consisting of muscle, cartilage, heart, bladder, brain, nervous tissue, glial tissue, esophagus, fallopian tube, heart, pancreas, intestines, gallbladder, kidney, liver, lung, ovaries, prostate, spinal cord, spleen, stomach, testes, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus, breast, skeletal muscle, skin, bone, and cartilage.
223. The method of claim 221 or 222, wherein the cell is selected from the group consisting of endothelial cells, dendritic cells, stem cells, multipotent progenitor cells, skin cells, liver cells, heart cells, kidney cells, pancreatic cells, lung cells, bladder cells, stomach cells, intestinal cells, cells of the urogenital tract, breast cells, skeletal muscle cells, skin cells, bone cells, cartilage cells, keratinocytes, hepatocytes, gastro-intestinal cells, epithelial cells, endothelial cells, mammary cells, skeletal muscle cells, smooth muscle cells, parenchymal cells, adipocytes, osteoclasts, and chondrocytes.
224. The method of claim 221 or 222, wherein the method is useful for cosmetic surgery.
225. The method of claim 221 or 222, wherein the method reconstructs a breast,
226. The method of claim 221 or 222, wherein the method reconstructs a face.
227. The method of claim 221 or 222, wherein the method reconstructs a body part after cancer surgery or trauma.
228. A method for promoting cartilage repair, the method comprising a) growing a chondrocyte in a matrix of any one of claim 170-188; and b) contacting cartilage with the chondrocyte and matrix of step (a), wherein the contact promotes cartilage repair.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/791,425 US8283414B2 (en) | 2004-11-23 | 2005-11-23 | Compositions comprising modified collagen and uses therefor |
US13/605,534 US8883964B2 (en) | 2004-11-23 | 2012-09-06 | Compositions comprising modified collagen and uses therefor |
US14/512,615 US20150111308A1 (en) | 2004-11-23 | 2014-10-13 | Compositions comprising modified collagen and uses therefor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63027104P | 2004-11-23 | 2004-11-23 | |
US60/630,271 | 2004-11-23 | ||
US72207905P | 2005-09-29 | 2005-09-29 | |
US60/722,079 | 2005-09-29 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/791,425 A-371-Of-International US8283414B2 (en) | 2004-11-23 | 2005-11-23 | Compositions comprising modified collagen and uses therefor |
US13/605,534 Division US8883964B2 (en) | 2004-11-23 | 2012-09-06 | Compositions comprising modified collagen and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007044026A2 true WO2007044026A2 (en) | 2007-04-19 |
WO2007044026A3 WO2007044026A3 (en) | 2008-12-31 |
Family
ID=37943236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/042813 WO2007044026A2 (en) | 2004-11-23 | 2005-11-23 | Compositions comprising modified collagen and uses therefore |
Country Status (2)
Country | Link |
---|---|
US (3) | US8283414B2 (en) |
WO (1) | WO2007044026A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048607A2 (en) * | 2006-10-16 | 2008-04-24 | Massachusetts Institute Of Technology | Collagen peptides as immune modulators |
WO2009140573A1 (en) | 2008-05-15 | 2009-11-19 | Purdue Research Foundation | Collagen peptide conjugates and uses therefor |
WO2010088469A2 (en) | 2009-01-30 | 2010-08-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof and hemostatic foam substrates |
EP2280720A2 (en) * | 2008-03-27 | 2011-02-09 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
US8076294B2 (en) | 2007-08-01 | 2011-12-13 | Advanced Technologies And Regenerative Medicine, Llc. | Collagen-related peptides and uses thereof |
US20130004478A1 (en) * | 2011-06-30 | 2013-01-03 | Yi-Lan Wang | Procoagulant Peptides and Their Derivatives and Uses Therefor |
US20130164220A1 (en) * | 2011-11-22 | 2013-06-27 | The Johns Hopkins University | Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use |
WO2013111759A1 (en) * | 2012-01-23 | 2013-08-01 | 学校法人早稲田大学 | Collagen-like peptide having stealth property and high urinary excretion property |
US8697193B2 (en) | 2008-05-22 | 2014-04-15 | Ethicon, Inc. | Process and apparatus for coating a porous substrate with a coating liquid |
CN104984410A (en) * | 2015-07-29 | 2015-10-21 | 陕西博与再生医学有限公司 | Controllable-degradation lacrimal passage suppository and preparation method thereof |
US9200039B2 (en) | 2013-03-15 | 2015-12-01 | Symic Ip, Llc | Extracellular matrix-binding synthetic peptidoglycans |
US9217016B2 (en) | 2011-05-24 | 2015-12-22 | Symic Ip, Llc | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use |
GB2540116A (en) * | 2015-04-14 | 2017-01-11 | Uab Ferentis | Novel peptide |
CN107530454A (en) * | 2015-01-30 | 2018-01-02 | 犹他大学研究基金会 | Dimerization collagen hybridizes peptide and application method |
WO2018187530A1 (en) | 2017-04-06 | 2018-10-11 | Sustain Holdings, Llc | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |
US10772931B2 (en) | 2014-04-25 | 2020-09-15 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
CN114199844A (en) * | 2021-12-09 | 2022-03-18 | 吉林大学 | Gold nanocluster and application thereof in preparation of alkaline phosphatase fluorescent probe |
US11529424B2 (en) | 2017-07-07 | 2022-12-20 | Symic Holdings, Inc. | Synthetic bioconjugates |
WO2023035719A1 (en) * | 2021-09-13 | 2023-03-16 | 熹微(苏州)生物医药科技有限公司 | Pegylated collagen-like protein, and preparation method therefor and application thereof |
US11648135B2 (en) | 2017-09-13 | 2023-05-16 | Boston Scientific Scimed, Inc. | Coated stent |
CN117797172A (en) * | 2024-02-28 | 2024-04-02 | 合肥启色生物科技有限公司 | Preparation method of anti-inflammatory, hemostatic and healing-promoting combination |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006292224B2 (en) | 2005-09-19 | 2013-08-01 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
JP2009523494A (en) * | 2006-01-12 | 2009-06-25 | ヒストジェニックス コーポレイション | Method for repair and reconstruction of broken ligaments or tendons and for treatment of ligament and tendon damage |
EP1996115B1 (en) * | 2006-03-07 | 2014-11-26 | Axle International | Bioactive scaffold for therapeutic and adhesion prevention applications |
US9248165B2 (en) * | 2008-11-05 | 2016-02-02 | Hancock-Jaffe Laboratories, Inc. | Composite containing collagen and elastin as a dermal expander and tissue filler |
US8148445B1 (en) * | 2009-01-14 | 2012-04-03 | Novartis Ag | Ophthalmic and otorhinolaryngological device materials containing a multi-arm PEG macromer |
JP5463531B2 (en) * | 2009-07-22 | 2014-04-09 | 国立大学法人 東京大学 | Polyion complex with PHD2 expression inhibitor |
FR2952306B1 (en) * | 2009-11-09 | 2012-03-30 | Creaspine | AQUEOUS COMPOSITION FOR THE TREATMENT OF LASER FIBROUS CONJUNCTIVE TISSUE REPAIR |
US20110294142A1 (en) * | 2010-05-27 | 2011-12-01 | Joydeep Lahiri | Multiply Fluorescently Labeled Calcium Phosphate-Protein Surfaces |
CA2801716A1 (en) | 2010-06-07 | 2011-12-15 | The Curators Of The University Of Missouri | Conjugated polymeric material and uses thereof |
EP2649095B1 (en) | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
JP6175055B2 (en) * | 2011-06-30 | 2017-08-02 | ジェネトン | Peptides having viral infection enhancing properties and uses thereof |
US10576037B2 (en) * | 2012-03-14 | 2020-03-03 | MAM Holdings of West Florida, L.L.C. | Compositions comprising placental collagen for use in wound healing |
US9949927B2 (en) * | 2012-04-10 | 2018-04-24 | The Regents Of The University Of California | Bis-polymer lipid-peptide conjugates and nanoparticles thereof |
US9644177B2 (en) * | 2012-07-12 | 2017-05-09 | Board Of Regents, The University Of Texas System | Extracellular matrix films and methods of making and using same |
WO2014160083A1 (en) | 2013-03-13 | 2014-10-02 | Applied Cardiovascular Solutions, Llc. | Methods, compositions, and devices for the occlusion of cavities and passageways |
US20140275751A1 (en) * | 2013-03-15 | 2014-09-18 | Abbott Medical Optics Inc. | Collagen-based ophthalmic interface for laser ophthalmic surgery |
JP2016520585A (en) * | 2013-05-09 | 2016-07-14 | シンガポール科学技術研究庁Agency for Science, Technology and Research | Modified collagen molecule |
US20150037434A1 (en) * | 2013-08-02 | 2015-02-05 | The Trustees Of Columbia University In The City Of New York | Biomaterials derived from tissue extracellular matrix |
EP3043835B1 (en) * | 2013-09-09 | 2020-08-12 | UAB Ferentis | Transparent hydrogel and method of making the same from functionalized natural polymers |
EP3057624B1 (en) * | 2013-10-14 | 2018-01-31 | UAB Ferentis | Regenerative prostheses as alternatives to donor corneas for transplantation |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US10359414B2 (en) * | 2015-03-09 | 2019-07-23 | The Regents Of The University Of Michigan | Frequency domain discrimination of tissue proteins |
WO2016149194A1 (en) | 2015-03-13 | 2016-09-22 | MAM Holdings of West Florida, L.L.C. | Collagen compositions and uses for biomaterial implants |
WO2016154070A1 (en) * | 2015-03-20 | 2016-09-29 | William Marsh Rice University | Hypothermic 3d bioprinting of living tissues supported by perfusable vasculature |
RU2669933C2 (en) * | 2015-12-07 | 2018-10-17 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Peptide medication from collagen for regeneration of skin tissue, method for its production and application |
SE539167C2 (en) * | 2015-12-22 | 2017-05-02 | Rafat Mehrdad | A composite collagen hydrogel material, an implantable ophthalmic device comprising such material and methods of producing the composite collagen hydrogel material and the implantable ophthalmic device |
WO2018106273A1 (en) * | 2016-12-06 | 2018-06-14 | University Of Utah Research Foundation | Collagen targeting nanofibers and nanosheets |
US20190167850A1 (en) | 2017-03-14 | 2019-06-06 | Unist(Ulsan National Institute Of Science And Technology) | Hydrogel patch |
US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
CN111295208B (en) * | 2017-10-20 | 2022-12-23 | 株式会社大塚制药工场 | Adhesion-preventing material |
US11732009B2 (en) | 2018-06-08 | 2023-08-22 | Glympse Bio, Inc. | Activity sensor with tunable analyte |
US11028425B2 (en) * | 2018-06-08 | 2021-06-08 | Glympse Bio, Inc. | Diagnosis and monitoring of liver disease |
KR20220031946A (en) * | 2019-04-22 | 2022-03-14 | 서스테인 홀딩스, 엘엘씨 | Collagen peptide-based pharmaceutical compositions and devices and methods for making and using same |
BR112022007717A2 (en) * | 2019-10-22 | 2022-07-12 | Massachusetts Inst Technology | BIOMATERIAL-BASED COMPOSITIONS TO DISPENSE MICROBES THAT PROMOTE PLANTS GROWTH |
CN111701073A (en) * | 2020-06-01 | 2020-09-25 | 天津大学 | Joint injection preparation based on collagen mimetic peptide modified hyaluronic acid and preparation method and application thereof |
EP4349850A1 (en) * | 2021-05-31 | 2024-04-10 | Opticell, Inc. | Cell culture supplement for producing stem cells, and method for producing stem cells |
WO2023060218A2 (en) * | 2021-10-07 | 2023-04-13 | 3Helix, Inc. | Biologically active collagen hybridizing peptides |
WO2023101678A1 (en) * | 2021-12-02 | 2023-06-08 | Oceanit Laboratories, Inc. | Method of preparation of biocompatible metal nanoparticles and applications thereof |
AU2022416566A1 (en) * | 2021-12-16 | 2024-06-27 | Ohio State Innovation Foundation | Single extracellular vesicle protein and rna assay via in-situ fluorescence microscopy in a uv micropattern array |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US7405037B2 (en) * | 2004-05-07 | 2008-07-29 | Lonza Walkersville, Inc. | Methods and tools for detecting collagen degradation |
-
2005
- 2005-11-23 US US11/791,425 patent/US8283414B2/en active Active
- 2005-11-23 WO PCT/US2005/042813 patent/WO2007044026A2/en active Application Filing
-
2012
- 2012-09-06 US US13/605,534 patent/US8883964B2/en active Active
-
2014
- 2014-10-13 US US14/512,615 patent/US20150111308A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
YU S.M. ET AL.: 'Exploitation of Collagen Mimetic Peptide as a Collagen Adhesive Biopolymer for Novel Biomaterials Development' MATERIALS RESEARCH SOCIETY SYMP. PROC. vol. EXS-1, 2004, pages 295 - 299 * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008048607A3 (en) * | 2006-10-16 | 2008-07-24 | Massachusetts Inst Technology | Collagen peptides as immune modulators |
WO2008048607A2 (en) * | 2006-10-16 | 2008-04-24 | Massachusetts Institute Of Technology | Collagen peptides as immune modulators |
US8076294B2 (en) | 2007-08-01 | 2011-12-13 | Advanced Technologies And Regenerative Medicine, Llc. | Collagen-related peptides and uses thereof |
US10689425B2 (en) | 2008-03-27 | 2020-06-23 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
AU2015230796B2 (en) * | 2008-03-27 | 2017-08-31 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
JP2011515499A (en) * | 2008-03-27 | 2011-05-19 | パーデュー・リサーチ・ファウンデーション | Collagen-binding synthetic peptidoglycan, preparation and use method |
EP2280720A4 (en) * | 2008-03-27 | 2013-01-09 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
EP2280720A2 (en) * | 2008-03-27 | 2011-02-09 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
US9512192B2 (en) | 2008-03-27 | 2016-12-06 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
JP2015134768A (en) * | 2008-03-27 | 2015-07-27 | パーデュー・リサーチ・ファウンデーションPurdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
AU2009228140B2 (en) * | 2008-03-27 | 2015-07-02 | Purdue Research Foundation | Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
WO2009140573A1 (en) | 2008-05-15 | 2009-11-19 | Purdue Research Foundation | Collagen peptide conjugates and uses therefor |
US8575311B2 (en) | 2008-05-15 | 2013-11-05 | Purdue Research Foundation | Collagen peptide conjugates and uses therefor |
US8991882B2 (en) | 2008-05-22 | 2015-03-31 | Ethicon, Inc. | Process and apparatus for coating a porous substrate with a coating liquid |
US8697193B2 (en) | 2008-05-22 | 2014-04-15 | Ethicon, Inc. | Process and apparatus for coating a porous substrate with a coating liquid |
WO2010088469A2 (en) | 2009-01-30 | 2010-08-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof and hemostatic foam substrates |
US9217016B2 (en) | 2011-05-24 | 2015-12-22 | Symic Ip, Llc | Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use |
US9149511B2 (en) * | 2011-06-30 | 2015-10-06 | Ethicon, Inc. | Procoagulant peptides and their derivatives and uses therefor |
CN103687631A (en) * | 2011-06-30 | 2014-03-26 | 伊西康公司 | Procoagulant peptides and their derivatives and uses therefor |
WO2013003045A3 (en) * | 2011-06-30 | 2013-04-25 | Ethicon, Inc. | Procoagulant peptides and their derivatives and uses therefor |
US20130004478A1 (en) * | 2011-06-30 | 2013-01-03 | Yi-Lan Wang | Procoagulant Peptides and Their Derivatives and Uses Therefor |
US9717820B2 (en) | 2011-06-30 | 2017-08-01 | Ethicon, Inc. | Procoagulant peptides and their derivatives and uses therefor |
US10426850B2 (en) * | 2011-11-22 | 2019-10-01 | The Johns Hopkins University | Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use |
US20130164220A1 (en) * | 2011-11-22 | 2013-06-27 | The Johns Hopkins University | Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use |
WO2013111759A1 (en) * | 2012-01-23 | 2013-08-01 | 学校法人早稲田大学 | Collagen-like peptide having stealth property and high urinary excretion property |
US9200039B2 (en) | 2013-03-15 | 2015-12-01 | Symic Ip, Llc | Extracellular matrix-binding synthetic peptidoglycans |
US9872887B2 (en) | 2013-03-15 | 2018-01-23 | Purdue Research Foundation | Extracellular matrix-binding synthetic peptidoglycans |
US10772931B2 (en) | 2014-04-25 | 2020-09-15 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
EP3250240A4 (en) * | 2015-01-30 | 2018-10-10 | University of Utah Research Foundation | Dimeric collagen hybridizing peptides and methods of using |
JP2021152004A (en) * | 2015-01-30 | 2021-09-30 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Dimeric collagen hybridizing peptides and methods of using |
US11684675B2 (en) | 2015-01-30 | 2023-06-27 | University Of Utah Research Foundation | Dimeric collagen hybridizing peptides and methods of using |
US10953104B2 (en) | 2015-01-30 | 2021-03-23 | University Of Utah Research Foundation | Dimeric collagen hybridizing peptides and methods of using |
JP2018508492A (en) * | 2015-01-30 | 2018-03-29 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Dimeric collagen hybridization peptides and methods of use |
CN107530454A (en) * | 2015-01-30 | 2018-01-02 | 犹他大学研究基金会 | Dimerization collagen hybridizes peptide and application method |
GB2540116A (en) * | 2015-04-14 | 2017-01-11 | Uab Ferentis | Novel peptide |
GB2540116B (en) * | 2015-04-14 | 2018-06-06 | Uab Ferentis | Collagen mimetic peptide |
CN104984410A (en) * | 2015-07-29 | 2015-10-21 | 陕西博与再生医学有限公司 | Controllable-degradation lacrimal passage suppository and preparation method thereof |
EP3606570A4 (en) * | 2017-04-06 | 2020-12-30 | Sustain Holdings, LLC | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |
WO2018187530A1 (en) | 2017-04-06 | 2018-10-11 | Sustain Holdings, Llc | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |
AU2020286248B2 (en) * | 2017-04-06 | 2023-01-19 | Sustain Holdings, Llc | Collagen Peptide-Based Medicament Compositions And Devices And Methods Of Production And Use Thereof |
US11529424B2 (en) | 2017-07-07 | 2022-12-20 | Symic Holdings, Inc. | Synthetic bioconjugates |
US11648135B2 (en) | 2017-09-13 | 2023-05-16 | Boston Scientific Scimed, Inc. | Coated stent |
WO2023035719A1 (en) * | 2021-09-13 | 2023-03-16 | 熹微(苏州)生物医药科技有限公司 | Pegylated collagen-like protein, and preparation method therefor and application thereof |
CN114199844A (en) * | 2021-12-09 | 2022-03-18 | 吉林大学 | Gold nanocluster and application thereof in preparation of alkaline phosphatase fluorescent probe |
CN114199844B (en) * | 2021-12-09 | 2024-02-09 | 吉林大学 | Gold nanocluster and application thereof in preparation of alkaline phosphatase fluorescent probe |
CN117797172A (en) * | 2024-02-28 | 2024-04-02 | 合肥启色生物科技有限公司 | Preparation method of anti-inflammatory, hemostatic and healing-promoting combination |
CN117797172B (en) * | 2024-02-28 | 2024-05-14 | 合肥启色生物科技有限公司 | Preparation method of anti-inflammatory, hemostatic and healing-promoting combination |
Also Published As
Publication number | Publication date |
---|---|
US8883964B2 (en) | 2014-11-11 |
WO2007044026A3 (en) | 2008-12-31 |
US20080287342A1 (en) | 2008-11-20 |
US20130116405A1 (en) | 2013-05-09 |
US8283414B2 (en) | 2012-10-09 |
US20150111308A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8883964B2 (en) | Compositions comprising modified collagen and uses therefor | |
Bai et al. | Biomimetic osteogenic peptide with mussel adhesion and osteoimmunomodulatory functions to ameliorate interfacial osseointegration under chronic inflammation | |
AU2018271341B2 (en) | Anti-thrombogenic grafts | |
Hachim et al. | Shifts in macrophage phenotype at the biomaterial interface via IL-4 eluting coatings are associated with improved implant integration | |
Yu et al. | Nanostructured mineral coatings stabilize proteins for therapeutic delivery | |
Jeon et al. | Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels | |
Vasconcelos et al. | Fibrinogen scaffolds with immunomodulatory properties promote in vivo bone regeneration | |
US8691946B2 (en) | Methods and compositions for soft tissue repair | |
AU2002367566B2 (en) | Interfacial biomaterials | |
JP5518066B2 (en) | Tissue scaffold derived from the pregastric extracellular matrix | |
CN108699522A (en) | Vessel extracellular matrix hydrogel | |
JP2003531685A (en) | Decellularized vascular prosthesis | |
US20090246249A1 (en) | Coating compositions having improved performance | |
Zheng et al. | Mussel-inspired triblock functional protein coating with endothelial cell selectivity for endothelialization | |
Luo et al. | Zwitterionic hydrogel-coated heart valves with improved endothelialization and anti-calcification properties | |
Liang et al. | Biomimetic-modified bioprosthetic heart valves with controlled release of glycyrrhizin acid mediated by the inflammatory microenvironment for anti-thrombotic, anti-inflammatory, and anti-calcification | |
Chokoza et al. | Tuning Tissue Ingrowth into Proangiogenic Hydrogels via Dual Modality Degradation | |
US8529951B1 (en) | Elastogenic cues and methods for using same | |
Grover et al. | Injectable hydrogels for cardiac tissue regeneration post-myocardial infarction | |
Costa et al. | Antimicrobial Pep-tides in the Battle against Orthopedic Implant-Related Infections: A Review. Pharmaceutics 2021, 13, 1918 | |
Hunt | Developing Enzyme-Sensitive Peptide-Polymer Conjugates for Cell-Mediated Scaffold Degradation | |
US20210054027A1 (en) | Catheter Injectable Cyclic Peptide Pro-Gelators for Myocardial Tissue Engineering | |
Kollar et al. | Biologic Scaffolds Composed of Extracellular Matrix as a Natural Material for Wound Healing | |
Zhang | Development of semi-synthetic tissue using decellularized intestine and aptamer-functionalized hydrogel | |
Hoshi | Engineering the Biomaterial Interface of Prosthetic Vascular Grafts for Improving Thromboresistance and Biocompatibility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 05858566 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11791425 Country of ref document: US |